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ABSTRACT 
Glioblastoma is a malignant form of brain cancer. This type of tumour is resistant to 
medical treatment and often yields a poor prognosis. It is important to understand the 
molecular basis of glioblastoma for developing new therapies. This study used U87 human 
glioblastoma cells for the investigation. The glioma cell line displayed the hallmarks of a 
tumour cell and corresponded on various cellular functions that are regulated by Rho family 
GTPases. This study intended to analyse the role of one member from this family - RhoE in 
U87 cells. RNA interference (RNAi) method was applied to knock down RhoE. The result 
showed that the loss of RhoE expression is associated with the decrease in cell cycle 
progression and increase apoptosis in U87 cells. Endogenous RhoE was found localised to the 
nucleus in U87 cells. RhoE is known can interact with serine/threonine kinases called ROCK1 
and PKC. The application of RNAi that knocks down ROCK1 has led to the stabilisation of 
RhoE expression in U87 cells. Y27632 was used to inhibit ROCK1 whereas Gӧ6976 blocked 
the function of PKC. Both pharmacological inhibitors prevent individual interaction with 
RhoE. The activation of novel PKC by PMA exhibit an increased the upper band of RhoE 
(29kD) and it remains more in the nucleus consistent with the active conventional PKC during 
ROCK1 inhibition. A co-immunoprecipitation (Co-IP) technique was used to pull down 
FLAG-RhoE from the transfected U87 cells with wild-type construct. As a result, the 
translocation of RhoE to the nucleus was facilitated by the interaction with importin  (Imp). 
A bioinformatics study on protein-protein interactions using DAVID on mass spectrometry 
data elucidated that RhoE could be indirectly bound to nuclear proteins. In conclusion, RhoE 
plays a pivotal role in regulating glioblastoma at the post-translational level.  
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CHAPTER 1  
INTRODUCTION AND LITERATURE REVIEW 
 
1.1 Research Background 
The origins of tumours are diverse and heterogeneous and almost all tumours have the 
ability to perform excessive proliferation compared to normal tissue. The imbalance between 
cell growth, differentiation and apoptosis could affect the net number of cells in the body, and 
the dysregulation of these processes extend a great risk of tumours (Ulrich et al. 2014). The 
cells in normal tissue proliferate to reproduce new and healthy two daughter cells. Extensive 
DNA damage in cell can occur during proliferation or cell division that result in apoptosis 
(Pecorino 2008). Thus, the starting point for the formation of all tumours is the anomaly in the 
regulation of cell proliferation and cell survival (Evan and Vousden 2001).  
The characterisation of the difference between normal cell and tumour cell phenotype 
is essential in monitoring cell proliferation and apoptosis (Pecorino 2008). It is crucial to 
study Rho GTPases since uncontrolled cell proliferation and suppression of apoptosis are 
central to tumours formation and both processes are dependent on the role of these small 
GTP-binding proteins (Cinti et al. 2003). These signalling proteins are important for various 
cellular processes such as cell cycle progression (Ras), dynamics of the cytoskeleton (Rho and 
Rac), membrane trafficking (Arf and Rab), and nucleocytoplasmic transport (Ran) (Williams 
and Rottner 2010). They are also implicated in multiple physiological processes, including 
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embryogenesis, reorganisation and maintenance of polarity, cell-cell adhesion and migration 
as well as differentiation of numerous cell types (Symons 2003). 
On the other hand, small GTPases are involved in numerous pathological human 
conditions, such as uncontrolled cell proliferation, metastasis or angiogenesis during tumour 
development, inflammation and vascular diseases, mental retardation and infections (William 
and Rottner 2010). It is not surprising that there is the involvements of small GTPases in the 
abnormality of pathological features as signalling proteins play the pivotal roles in numerous 
normal and developmentally regulated processes of living cells. As an example, Rho GTPase 
signalling in glioma cell could implicate invasion and tumour progression (Fortin Ensign et al. 
2013). One of the criticisms on the existed literature to date is the poor explanation on how 
small Rho GTPases regulate brain cancer (Liacini et al. 2014; Poch et al. 2007).  
Poch et al. (2007) demonstrated that RhoE has the ability to regulate cell proliferation 
in U87 cells in the two different stages of cell cycle. One of the limitations in their work is 
that they did not disclose a specific regulation for either G1/S phase due to the loss of RhoE or 
G2/M phase during the overexpression of RhoE. Their finding’s main weaknesses are the 
precise function of RhoE and the reason it switches between these two phases - G1/S or G2/M 
respectively. Moreover, it was observed that RhoE regulates apoptosis via promoting the 
expression of p53 target genes that inhibit membrane blebbing via antagonising the function 
of ROCK1 (Ongusaha et al. 2006). Therefore, this study intended to analyse the role for one 
of the members of Rho GTPases family - RhoE in glioma. Both findings will provide a 
significant framework in resolving intermediates and identifying pathways that are involved 
in both processes. It is assumed that, analysing the protein-protein interactions between RhoE 
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and potential tumour marker would be advantageous. This approach would reveal the 
mechanism and signalling pathway that are involved and used for exertive therapy.  
 
1.2 Glioma 
In general, glioma is a tumour of glial cell, which is a supportive cell that does not 
transmit impulse in the central nervous system (CNS). Glial cells comprised variety cell type 
in the brain including oligodendrocytes, astrocytes, ependymal cells, Schwann cells, microglia 
and satellite cells except neuronal cells. Approximately, 45 out of 100 (45%) of the primary 
brain tumours are gliomas. The incidence rate for new primary brain tumours that was 
diagnosed in the United Kingdom has reached 4 500 cases per year (NHS 2013). Brennan et 
al. (2013) reported that 2 to 3 per 100 000 population in the United States of America and 
European countries were diagnosed with brain tumour. It is known that, glioblastoma 
multiforme (GBM) is the most common and lethal primary brain tumours in adults (TCGA 
2008). Glioblastoma is associated with poor prognosis and the typical survival duration after 
diagnosis is less than two years (Holmberg et al. 2011).  
Brain tumours are classified based on glial cell growth efficiency. Pathologists had 
classified glioma into four groups, Grades 1 to 4 based on microscopic examination (NHS 
2013). Typically, the lower grade glioma is referred as slower growing brain tumour that is 
slightly similar to healthy cells. A higher grade of the glioma relies on the degree of 
phenotype abnormality and efficiency of the brain tumour formation (Soffietti et al. 2010).  
The first group is Grade 1, a benign glioma that is characterised by pilocytic 
astrocytoma with the slowest growing brain tumours. The second group is low-grade glioma 
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(LGG) that has multiple types of glioma, including astrocytoma, oligodendroglioma and 
oligoastrocytoma. Both Grade 3 and Grade 4 are malignant and the most aggressive form of 
glioma (CRUK 2013). These two malignant gliomas can be differentiated by their 
morphologies.  Grade 3 has distinct morphologies including anaplastic astrocytoma, 
anaplastic oligodendroglioma and anaplastic mixed oligoastrocytoma whereas Class 4 is an 
unspecified glioma or glioblastoma multiforme (GBM).  
Recently, it was found that GBM has multiple sub-types phenotypes that respond 
differently to aggressive therapies, making treatment extremely difficult and challenging 
(Kong et al. 2013; Verhaak et al. 2010). The sub-types include Proneural, Neural, Classical 
and Mesenchymal that are differentiated based on their gene signatures as well as somatic 
mutations and aberration of DNA copy number. As a result, the National Institute of Health 
under The Cancer Genome Atlas (TCGA) Research Network (2008) decided to select GBM 
as the first brain tumour to be sequenced as a part of their effort to map the genomes, instead 
of other types of cancer (Robbins et al. 2013). 
GBM is developed from the progenitors of star-shaped glial cells, called astrocytes 
that support nerve cells (Kong et al. 2013) and it developed primarily in the cerebral 
hemispheres that spread to other brain compartment, brainstem or spinal cord (NHS 2013). 
There is a high probability that each glioma could reoccur after surgery, even if it is 
completely removed. However, GBMs rarely metastasise outside the central nervous system 
(CNS). All gliomas have tentacle-like projections morphology that can directly invade nearby 
brain tissue (Li et al. 2007). Although low-grade astrocytoma is less harmful, it can spread to 
another region of the brain or spinal cord due to the lack of invasive barrier in the tissue 
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(Fortin Ensign 2013). Thus, recurrence after initial treatment is common, and the options of 
spreading to other brain sections or spinal cord is relatively high (Brennan et al. 2013). 
On the other hand, radiotherapy and chemotherapy are sometimes used to treat benign 
tumours which are similarly used in treating malignancies. The treatment for brain tumour is 
more complicated compared to other types of tumour from various parts of the human body. 
The key problem of this explanation is its lack of detail regarding why the treatment process 
is difficult, whereby benign tumour can cause severe symptoms and be deadly if it occurs in a 
significant part of the brain (Kunz et al. 2011). 
Figure 1 shows a glioblastoma lesion in the brain tissue and the defects in cell 
morphology. The appearance of deep blue-purple colour of nuclei is due to complex 
formation during staining of hematoxylin with nucleic acids; whereas eosin is pink and it non-
specifically stains proteins in the cytoplasm. These stains are commonly used in recognising 
various types of tissue and morphologic changes. In the pathology laboratory, hematoxylin is 
used to diagnose and determine between healthy cell type or cancer-type-specific patterns 
based on the condensation of heterochromatin (Fischer et al. 2008). 
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Figure 1: Immunohistochemistry (IHCC) of cells from the lesion tissue compared to the 
normal brain cells. (A) Glioblastoma showing extensive proliferation; (B) Normal brain 
tissue; (C) GBM cross section. Images are reproduced from College of American 
Pathologists (2011) and Sathornsumetee et al. (2007). 
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1.3  Small GTPases 
1.3.1  Rho GTPase Family 
1.3.1.1 Subfamily of Rho GTPase 
The Rho family of GTPases is a family of small signalling G proteins with low 
molecular weight (21-28 kD) and it is also a subfamily of the Ras superfamily. A 
phylogenetic analysis using bioinformatics tools demonstrated the classification for 20 
members of Rho proteins in mammals (Dellinger 2006). Although the Rho family is 
composed of 20 members, but only RhoA, Rac1 and Cdc42 were best characterised 
(McCormack et al. 2013). Figure 2 illustrates the Rho proteins that are structured into eight 
subgroups; (i) Rnd1, Rnd2, Rnd3/RhoE;  (ii) RhoA,  RhoB,  RhoC;   (iii) RhoD,  Rif;  (iv) 
Rac1,  Rac2,  Rac3, RhoG; (v) Cdc42, RhoQ/TC10, RhoJ/TCL, RhoV/Chp, RhoU/Wrch2; 
(vi) RhoH/TTF; (vii) RhoBTB1; and (viii) RhoBTB2/DBC-2. They are then distributed 
into four distinct clusters based on the expressed sequence tag (EST) databases for Rho 
GTPases using TBlastN or BlastP (v2.2.13) algorithms (Boureux et al. 2007). 
In a recent study, Saad et al. (2014) stipulated an advance evolutionary study on 
Ras superfamily and subfamily. The Ras superfamily consists of five major families 
including Ras, Rho, Arf, Ran and Rab. However, their work was restricted to Ras 
superfamily, as well as Rho and Rab subfamilies. These proteins in particular are involved 
in signal transduction pathway whereas Arf and Ran were poorly studied. The evolutionary 
of small GTPase and the signalling pathway that is involved in cancer and other 
developmental diseases can be exploited for a better drug design (Saad et al. 2014). Cook 
et al. (2014) also agreed on the fact that the abnormalities of Rho family small GTPases in 
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humans has a huge impact in cancer and other diseases as well as affecting cancer 
signalling pathway.  
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Figure 2: The Rho phylogeny of 20 members of Rho proteins and the presence of eight 
subgroups that are distributed into four distinct clusters using ClustalX Neighbour-Joining 
(NJ) and ProMaximum-Likelihood (ML). The numbers that appeared in primary and 
secondary branches show the bootstrap repetition of NJ values. This chart is reproduced 
from Boureux et al. (2007). 
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1.3.1.2 Regulators of Small GTPases 
The deformity of Ras homolog related to Rho family GTPases was recently 
identified as an indicator of cancer and other human diseases (Cook et al. 2014). In relation 
with the cancerous indication, Spiering and Hodgson (2011) explained that the function of 
Rho GTPases as molecular switches and they figured out the interaction via its 
downstream effector molecules. They have manipulated the work of Machacek et al.           
(2009) in examined the coordination of RhoGTPase during cell migration and 
rearrangement of the cytoskeleton. RhoA synchronises the leading edge by initiating the 
protrusion and retraction of the cell. At the end of the protrusion, Rac1 and Cdc42 block 
the advancement of cell edge by inhibiting the function of RhoA. One of the limitations for 
this explanation is its lack of clarification whether RhoE acts accordingly or against other 
Rho GTPase during cell migration. 
Each movement of the cell propagates the signal transduction in their activated 
GTP-bound state. The intrinsic phosphatase activity hydrolyses the GTP to GDP that turns 
the protein to become inactive. In this context, Cherfils and Zeghouf (2013) affirmed that 
the switch is positively controlled by guanine nucleotide exchange factors (GEFs) that 
catalyse the replacement of GDP by GTP besides being negatively regulated by GTPase 
activating proteins (GAPs) that facilitate the exchange of GDP to GTP via intrinsic activity 
of GTPase. In other words, Rho GTPases switches are respectively turned on and off by 
GEF and GAP. 
Fortin Ensign et al. (2013) have validated whether guanine nucleotide dissociation 
inhibitors proteins (GDIs) are important in regulating homoeostasis of the Rho GTPases by 
preventing protein degradation. The GTPases function as binary switches in cell signalling 
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that initially bind to GDP and localise in cytosol in an inactive form, and they are 
associated with membranes and converted into an active-GTP bound state in the place of 
effector target (Dermardirossian and Bokoch 2005).  
Figure 3 shows a comprehensive cycle of the Rho GTPase in which Rho GTPase 
shifts between inactive GDP-bound and active-GTP bound states. Typically, Rho proteins 
carry either farnesyl or geranylgeranyl lipid at their C-terminus and localise them to the 
cellular membranes (Cook et al. 2014). However, GDI shielding for the hydrophobic tails 
of the canonical Rho proteins allows diffusion into the cytosol and prevents the activated 
Rho-GTP anchoring to the membrane (Boulter et al. 2010).  
Cherfils and Zeghouf (2013) discovered the regulations of small GTPases using 
advanced mechanisms that are not dependent on GEF, GAP and GDI, and they are 
controlled by themselves. It is known that the GTPases in humans could deliver cellular 
signals and build up specific cell responses including rearrangement of autoinhibition, 
GTPase activating feedback loops, synchronise signalling between regulators and effectors 
and provide phosphorylation site for GDI. In addition, these small GTPase regulators 
(GEF, GAP and GDI) are vulnerable to biochemical aberrancy due to mutational diseases 
as well as bacterial infection that could invade the host regulatory system and intimidate 
the host cell (Cook et al. 2014; Lemichez and Aktories 2013). 
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Figure 3:  The Rho GTPase cycle. The cycling of Rho GTPase between inactive GDP-
bound and active-GTP bound states. Table 1 shows the examples of downstream effector 
of the Rho family. 
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1.3.1.3 Effector Molecules of Rho GTPases 
The Rho family members consisting of RhoA, Rac1 and Cdc42 are well 
characterised as the regulators of the actin cytoskeleton and they promote stress fibre 
formation, lamellipodia or filopodia. These regulators have specific interaction towards 
downstream effectors as listed in Table 1. Depending on particular signalling pathway 
involving RhoA, Rac1 or Cdc42, the downstream effector will correspond to a pertinent 
individual biological action (Arulanandam et al. 2010). Occasionally, Rho proteins interact 
with downstream effector molecules that are engaged to specific signalling cascades in 
coordinating various cellular processes, including cytoskeletal reorganization, vesicle 
trafficking, cell cycle progression, cell polarity, and transcription (Stengel and Zheng 
2011).  
The effector’s regulatory mechanisms are divided into catalytic and non-catalytic 
proteins. Bustelo et al. (2007) had discussed the multiple types of effector proteins such as 
p21 activated kinase protein (PAK), Rho-associated coiled-coil containing protein kinase 
(ROCK) and protein kinase N (PKN) that serve as catalytic proteins. The non-catalytic 
effector proteins function as an adaptor protein that include Diaphanous, Wiskott-Aldrich 
syndrome protein (Wasp) and Brain specific angiogenesis inhibitor 1-associated protein 2 
(Baiap2). Bustelo et al. (2007) emphasised that both class of proteins either catalytic or 
non-catalytic play a role as the effector for members of the Rho family, specifically for 
Cdc42. These effectors use distinct residues within switch I and switch II regions of the 
regulatory protein to identify the recognition site. Hence, the variant between residues is 
essential to make it visible, in creating docking between both proteins - Rho and 
downstream effector.  
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Stengel and Zheng (2011) suggested a number of catalytic proteins, particularly 
kinases that interact with Cdc42 such as p21 protein (Cdc42/Rac)-activated kinases 
(PAKs), mixed lineage kinases (MLKs) and Myotonic dystrophy protein kinase-like 
(MRCK). In addition, there are also other scaffolding proteins that are associated with 
Cdc42, including Partitioning Defective Protein 6 (Par6), Wiskott-Aldrich syndrome 
protein (WASP) and IQ motive containing GTPase-activating protein (IQGAP). Recently, 
Fortin Ensign et al. (2013) disclosed that the downstream effectors of RhoGTPase could 
promote invasiveness and glioma cell survival. As an example, Rac1 and Cdc42 share an 
overlapping set of downstream effectors such as signalling pathway via activation of PAK 
and MAPK during the process of cell migration. Table 1 described the comprehensive 
details about effector proteins for Rho family involving RhoA, Rac1 and Cdc42.  
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Table 1: List of Effector Proteins for Rho Family – RhoA, Rac1 and Cdc42 
Effector Type of protein Upstream 
GTPase 
Main Biological 
Action 
Reference  
Pard6, A, G Scaffold protein 
(Par6,,) 
Rac1, 
Cdc42 
Cell polarity, links 
GTPases and 
atypical PKCs 
 
Bustelo et al. 
(2007)  
IQGAP1, 2 RhoGAP and 
scaffold protein 
Rac1, 
Cdc42 
Regulator of the 
cytoskeleton, cell-
cell contacts and 
proliferation 
 
Fortin Ensign 
et al. (2013) 
c-Cbl 
 
Ubiquitin Ligase Cdc42 EGFR degradation Stengel and 
Zheng (2011) 
 
Cit 
 
Serine/threonine 
kinase  (Citron) 
 
 
RhoA 
 
Cytokinesis 
 
 
Bustelo et al. 
(2007) 
Pkn1,2 Serine/threonine 
kinase   (Prk) 
RhoA Vesicle recycling, 
cell cycle regulation, 
Pld1 activation 
 
Bustelo et al. 
(2007) 
ROCK 1, 2 Serine/threonine 
kinase (ROCK , 
β) 
RhoA Cytoskeleton, 
cytokinesis, 
blockage of cell 
contact inhibition 
 
Croft and 
Olson (2011) 
Pak1-7 Serine/threonine 
kinase 
Rac1, 
Cdc42 
Cytoskeletal 
organization, 
activation of kinase 
cascades 
 
Bastos et al.      
(2012) 
Map3K11 Serine/threonine 
(Mlk3) 
Rac1, 
Cdc42 
Activation in kinase 
cascades 
 
Bustelo et al. 
(2007) 
PrkcA Serine/threonine 
kinase (PKCα) 
RhoE 
RhoA, 
Rac1, 
Cdc42 
 
Signal transduction Sathornsumetee 
et al. (2007) 
Cdc42bpgA,B Serine/threonine 
kinase 
(MRCKα,β) 
Rac1, 
Cdc42 
Cytoskeletal 
regulation 
Bustelo et al. 
(2007) 
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Effector Type of protein Upstream 
GTPase 
Main Biological 
Action 
Reference  
Rps6kB1 Serine/threonine 
kinase    
(p70s6k, S6K1) 
 
Cdc42 Regulation of 
translation, cell 
cycle 
Bustelo et al. 
(2007) 
Map3K10 Serine/threonine 
kinase (Mlk2)  
Cdc42 Activation of kinase 
cascades 
 
Fortin Ensign 
et al. (2013) 
Map3K4 Serine/threonine 
kinase (Mekk4) 
Cdc42 Activation of Jnk 
route 
 
Fortin Ensign 
et al. (2013) 
Tnk2 Tyrosine kinase 
(Ack) 
Cdc42 Signal transduction, 
activation of GEFs 
 
Bustelo et al. 
(2007) 
 
Ppplr12A Regulatory 
subunit of 
phosphatase1 
RhoA Myosin light chain 
inactivation, 
cytoskeletal 
regulation 
 
Bustelo et al. 
(2007) 
Fml1 Formin-like 
molecule 
Rac1 Cytoskeletal 
organization, cell 
polarity and 
cytokinesis  
 
Bustelo et al. 
(2007)  
Fhod1 Formin-like 
molecule 
Rac1 Cytoskeletal and 
transcriptional 
regulation 
 
Bustelo et al. 
(2007) 
Cyfip1 Actin binding 
protein 
Rac1 Cytoskeletal 
organisation 
 
Bustelo et al. 
(2007) 
FlnA Actin binding 
protein 
RhoA, 
Rac1, 
Cdc42 
Cytoskeletal 
regulation, actin 
filament 
crosslinking 
 
Bustelo et al. 
(2007) 
TubA1 Tubulin Rac1 Integral component 
of microtubule 
 
Bustelo et al. 
(2007) 
Stat3 Transcriptional 
factor 
Rac1, 
Cdc42 
Transcription 
 
Arulanandam 
et al. (2010) 
 
Smurf2 E3 Ubiquitin 
protein ligase 2 
Rac1 Smad and RhoA 
ubiquitination, 
TGFβ receptor 
signalling 
 
Stengel and 
Zheng (2011) 
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1.3.2  The Role of Rho GTPases in Mammalian Cells 
1.3.2.1 Rho GTPases in Cell Cycle 
To date, cell cycle is closely associated with cancer cell motility and invasive 
properties (Kagawa et al. 2013). The Rho family GTPases - Rho, Rac and Cdc42 in 
particular, have important roles in regulating the cell cycle (David et al. 2012). The 
division of cells have four main phases including G1, S (DNA replication), G2 and M 
(mitosis) and they are almost all regulated by either Rho, Rac or Cdc42 (Hall 2005). In 
agreement with this fact, Hall (2009) explained that the function of Rho GTPase 
subfamilies is specifically based on the individual phases of the cell cycle, and Table 2 
shows their functions. Specifically, Rho plays a major role by controlling every phase and 
sub-phase of the checkpoints in cell cycle compared to Rac and Cdc42 (Hall 2009). 
Besides that, Rho GTPases are also involved in cell mitosis for the activation of Rho-
associated kinase (ROCK), where the effector of RhoA mediated the cortical retraction 
during mitotic cell rounding (Villalonga and Ridley 2006). 
Regarding the function of Rho in cell cycle, mitotic Rho regulatory pathway could 
directly affect cell proliferation (David et al. 2012). Moreover, mitotic kinases could also 
control the activity of phosphorylation and regulate cell cycle machinery including the 
processes of transcriptional activation, ubiquitylation and proteosomal degradation. David 
et al. (2012) summarised the examples of the mitotic kinases and their specific functions in 
regulating the cell cycle. Some of the kinases were picked up as they might be relevant in 
targeting Rho and the signalling pathways are also antagonising RhoE. Table 3 shows the 
list of mitotic kinases and the important functions in cell cycle that closely related to RhoE. 
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Table 2 : Contribution of Rho GTPases in cell cycle (Adapted from Hall 2009) 
Level of Cell 
Cycle 
Phases for Checkpoints in 
Cell Cycle 
Role of Rho GTPases Family 
 
G1 
 
Cell size 
 
Cyclin D1 transcription by 
Rho/Rac/Cdc42 
 
Levels of nutrients / growth 
factor 
 
Cyclin D1 mRNA translation by 
Rac 
 
DNA damage Cyclin D/CDK inhibitor p21/p27 
expression by Rho 
 
S S Phase entry Delay for problems in replication 
by Rho/Rac/Cdc42 
 
G2 Cell size DNA damage Assessment and G2/M progression 
by Rho/Rac 
 
M Prophase 
  
Cell rounding by Rho 
Centrosome position by Rho 
 
Prometaphase Kinetochore attachment by 
Cdc42/Rho 
 
Metaphase Asymmetric spindle positioning by 
Cdc42 
 
Anaphase - 
 
Telophase - 
 
Cytokinesis Contractile ring abscission by Rho 
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Table 3: Phosphorylation of Rho Signalling Proteins by Mitotic Kinases (Reproduced from 
David et al. 2012) 
Mitotic 
Kinases 
Target Residues of Rho Cell Cycle Machinery 
 
Cdk1 
 
Ect2 
 
Thr412 
 
Required for Ect/Plk-1 interaction 
Increases GEF activity 
Induces excessive membrane blebbing 
 
GEF-H1 Ser959 Inhibits GEF activity 
Dephosphorylation prior to cytokinesis 
 
p190 RhoGAP NR Downregulates GAP activity 
 
 
Plk-1 ROCK2 Thr967, Ser1099, 
Ser1133, Ser1374, 
Thr489 
 
Plk-1 dependent ROCK2 
phosphorylation activates ROCK2 
 
 
 
Aurora A GEF-H1 Ser885 Inhibits GEF activity 
Dephosphorylation prior to cytokinesis 
Allows interaction with 14-3-3 
 
 
Aurora B MacRacGAP Ser387 From telophase to cytokinesis 
Renders the GAP active on RhoA 
 
*NR : Not reported 
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According to the list of mitotic kinases in Table 3, Cdk1 is shown having critical 
function in phosphorylating Rho signalling protein including epithelial cell transforming 2 
(Ect2), Guanine nucleotide exchange factor-H1 (GEF-H1), and p190 RhoGAP. David et al. 
(2012) also denoted that there are various substrates that are phosphorylated by Cdk1 
including histones, nuclear lamins, proteins that interact with microtubules, condensation 
of chromosomes, nuclear envelope and spindle assembly. Regarding to the detail in Table 
2, both cell assessment and G2/M progression by Rho/Rac are essential to define cell size 
and DNA damage (Hall 2009). At this checkpoint, Cdk1 activation occurs during the 
transition phase to allow cell progression into mitotic phase. Beforehand, Cdk1 has to be 
initially executed by Cdc25 phosphatase via dephosphorylation at residue threonine 14 
(Thr14) and tyrosine 15 (Tyr15) to enable its function (David et al. 2012).  
Cytokinesis is coordinated on each cell cycle during late mitosis. Su et al. (2003) 
have examined multiple phenotypes within cells when p190 Rho GAP was overexpressed. 
It was observed that the increased level of exogenous p190 RhoGAP expression has led to 
the formation of multinucleation in the nuclear region, abnormal positioning of cleavage 
furrow specification site, unequal daughter cell partitioning and faulty furrow contraction. 
Besides that, endogenous p190 RhoGAP – a Rho family GTPase-activating protein, 
basically regulates cell proliferation, as well as having a close link to the completion of 
cytokinesis and generating viable cell progeny (Su et al. 2003).  
In summary, cell cycle is mainly regulated by Rho GTPases in G1 progression and 
M phases. The extracellular matrix (ECM) acts as elicit signals via integrins and actin 
cytoskeleton during the progression of cells from G1 entering S-Phase. Rho GTPases also 
control both assembly and disassembly of actin filament and these processes are necessary 
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for microtubule and actin filament reorganisation during mitosis. This study is interested to 
further investigate cell cycle by focusing on RhoE representing Rho GTPases. It is hoped 
that this effort would disclose more detailed explanations in characterising the role of Rho 
GTPase in cell cycle. 
 
1.3.2.2 Rho GTPases in Apoptosis 
The common characteristics of apoptosis are cell shrinkage, membrane blebbing 
and budding, chromatin condensation, and precise fragmentation at the end that led to cell 
disposal (Wickman et al. 2013). The subfamily of Rho GTPases that is listed in Section 
1.3.1.1 commonly acts as molecular switches in intracellular signal transduction pathways. 
Cinti et al. (2003) affirmed that one of the promising therapeutic targets in eliminating 
cancer cells is targeting components of pro-survival signal transduction pathways which 
involve Ras superfamily such as Ras, Rho, Arf/Sar, Ran, and Rab. It is known that this 
signalling pathway may contribute to intrinsic or inducible drug resistance. For instance, 
small molecule inhibitors of phosphoinositide-3-kinase (PI3K) kinase/Akt and 
farnesyltransferases are necessary in the activity of Ras that could induce apoptosis 
(Leverrier and Ridley 2001). It is advantageous to block this pathway as it is non-
carcinogenic to the normal cell besides annihilating the tumour.  
Moreover, Coleman and Olson (2002) discussed that Rac1 and Cdc42 signalling 
pathway could encourage cell survival. Both of these Rho GTPases interact with p21 
activated kinase protein (PAK) in enabling phosphorylation of BCL2-associated antagonist 
of cell death (Bad). Besides that, it was found that Rho GTPases including RhoA, Rac1 
and Cdc42 could activate the transcription factor; whereas necrosis factor-kappa B (NF-
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B) could block apoptosis (Perona et al. 1997). Effective activation of NF-B by Rho 
GTPases has the ability to induce translocation of this transcription factor into the nucleus. 
As a result, cell survival is maintained by DNA transcription and cytokine production by 
NF-B (Perona et al. 1997).  
On the other hand, the signalling downstream of Rho GTPases has contributed to 
actin reorganisation. As an example, cleavage of Cdc42 and Rac1 lead to the termination 
of downstream signalling. During apoptosis, Cdc42 and Rac1 eliminate actin filament, 
followed by ROCK1 that promotes actin-myosin II contractility. As a result, Cdc42 and 
Rac1 are cleaved at the end of the apoptotic process. For clearer description, Coleman and 
Olson (2002) agreed with Croft and Olson (2011) on a proposed mechanism of ROCK 
activation which is shown in Figure 4. This figure explains the loss of autoinhibition by 
Rho binding and caspase cleavage that led to ROCK activation. It was found that activated 
ROCK1 could aid the contraction and membrane blebbing during the late execution phase 
of apoptosis (Samuel and Olson 2010). 
Section 1.3.2.1 previously described that Rho GTPases interact with multiple 
functions in cell cycle. However, aberrant yield from the cell cycle has to be eliminated 
and this has made apoptosis an important mechanism in demolishing insignificant revenue. 
It was found that Rho GTPases - Rac1 and Cdc42 in particular regulate apoptotic cell 
uptake. An earlier research by Leverrier and Ridley (2001) demonstrated that the signalling 
pathways in regulating apoptotic cell phagocytosis and fragment crystallisable gamma 
receptor (FcR)-mediated phagocytosis share a common requirement for Rho GTPases 
including Rac1 and Cdc42, excluding Rho. 
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Figure 4: Activated Rho binding to ROCK or caspase cleavage in response to genotoxic 
stress to activate the kinase (Adapted from Coleman and Olson 2002; Croft and Olson 
2011). 
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Recently, Ohgushi et al. (2010) demonstrated that apoptotic cell uptake requires 
Rho. They claimed that the inhibition of endogenous Rho GTPases has blocked apoptosis 
and cell phagocytosis. This blockage occurs in a dose-dependent manner where apoptosis 
is dependent on the type of kinase inhibitors that are being used for that particular 
experiment. Regarding this argument, they clarified that Rac1 and Cdc42 were not only 
required during apoptosis as well as cell phagocytosis but these processes were enhanced 
via Rho depletion (Ohgushi et al. 2010).  
 
1.3.2.3 Rho GTPases in Cancer 
It was observed that tumour cells display uncontrolled proliferation, altered 
interactions with neighbouring cells and the surrounding ECM, as well as enhanced 
migratory properties. Senoo and Iijima (2013) reported that the proteins of the Rho GTPase 
family play important roles in regulating various uncontrolled processes in the cancer cells 
in vitro as well as in humans. Karlsson et al. (2009) also presumed that there is the 
involvement of proteins that regulate Rho GTPases and other effectors of Rho GTPases. 
For example, the differentiation between GDP-GTP bound forms of Rho requires the 
recognition of conformational changes by downstream effector proteins (Riento et al. 
2003). As a family of 20 small G proteins, Rho GTPases regulate the cytoskeleton and 
other cellular functions, including cell cycle, cell polarity and cell migration. Figure 5 
shows a diagram of Rho GTPase and the major function in tumour that is relevant at 
cellular and molecular level. 
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Figure 5: Rho GTPases and major function in tumour that is relevant at cellular and 
molecular level. (Adapted from Karlsson et al. 2009; Senoo and Iijima 2013). 
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Figure 5 shows that Rho GTPases regulate different cellular processes and they are 
important for tumour growth and progression in vitro. This study focused on the role of 
one member of this family, RhoE, which has the ability to regulate apoptosis and cell cycle 
in human cells. The summarised processes show the importance of Rho GTPases in cancer 
development. For example, Rac1 and RhoA promote G1-S transition by increasing the 
amount of cyclin D1 in cell cycle. On the other hand, for an experimental study that uses 
fibroblast, RhoE inhibits the cell cycle progression, upstream of the pRB checkpoint by 
blocking the expression of cyclin D1 at the posttranslational level when it binds to GTP 
(Poch et al. 2007). In addition, RhoE inhibits vincristine-induced apoptosis by reducing 
expression of BCL2-associated X protein (Bax) and promotes tumour cell survival albeit 
RhoA and RhoC by inducing the upregulation of Bax that led to apoptosis (Karlsson et al. 
2009). 
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1.3.3 Small GTPase in Nucleocytoplasmic Transport 
The most important molecular processes are transcription and translation that 
require an exchange between the cytoplasm and the nucleus. The exchange process 
predominantly occurs through large protein channel in the nuclear envelope (NE), which is 
particularly across the nuclear pore complex (NPC) (Kodiha and Stochaj 2012). However, 
the aberrant activity during DNA transcription in the nucleus can occur at a particular point 
due to the presence of excessive transcription factors. At that point, nuclear trafficking via 
NPC, could affect nuclear protein transport. This potential abnormality happens when 
uncontrolled protein is trafficking whilst the transportation of the translated protein 
traverses the NPC. The post-translational modification via phosphorylation at serine and 
threonine, as well as tyrosine, may direct the translocation of protein to the nucleus 
(Mihlan et al. 2013).  
In general, NPC is spanned for the means of either passive or active. 
Macromolecules exchange throughout NPC is restricted and sometimes dependent on 
nucleocytoplasmic machinery (Mingot et al. 2004)  and commonly mediated by 
karyopherins (KPNs), which is the nuclear transport protein. KPN is a family of transport 
receptors that bind to their cargoes via recognition of nuclear localisation signal (NLS) for 
nuclear import or nuclear export signal (NES) during formation of transportation cargo 
complex. This recognition process enables transient interaction between KPN with the 
NPC component.  
The import-export mechanisms are predominant nucleocytoplasmic machinery that 
regulates protein transport between the cytoplasm and the nucleus. Ran GTPase (Ras-
related nuclear protein) controls the interaction of karyopherin (KPN) with their cargoes 
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during nucleocytoplasmic transports (Sorokin et al. 2007). In addition, Bilokapic and 
Schwartz (2012) clarified that nuclear transport receptors (NTR) mediate the transport of 
proteins between the nucleus and the cytoplasm; similar function with KPN, the importin 
and exportin, but so-called with an alternative name. They also revealed a detailed 
description regarding NPC structure, NLS and NES, as well as the model of classic Ran-
dependent transport (Bilokapic and Schwartz 2012). 
Figure 6 shows an example of nucleocytoplasmic transport model and it suggests 
that the GTP hydrolysis by Ran in the cytosol facilitates the function of nuclear 
transporters (NTR/KPN) to traverse the NPC. This model is reproduced from Alberts et al. 
(2008) in explaining the recognition of NLS on a larger size protein that is mediated by 
either importin alpha subunit (Imp) or importin alpha and beta heterodimer (Imp/) or 
by using importin beta (Imp) alone or one of its many homologues (Alberts et al. 2008).  
For the principle, Chang et al. (2013) suggested that the NLS residue has to be 
recognised by the adaptor molecule of import receptor, which is Imp (Chang et al. 2013). 
Then, this cargo is linked to the carrier molecule or intermediate that is called importin-
beta (Imp). The complex of cargo protein (RhoE-Imp-Imp) translocates into the 
nucleus by crossing the nuclear pore within the nuclear envelope (Marfori et al. 2011). 
Besides that, the Impβ subunit mediates the docking of complex at the NPC, followed by 
translocation to the nucleoplasm. This model is also accepted by Xu et al. (2012) that 
established a similar conception for transient interaction which is specific for cargo 
delivery by nuclear transporter (NTR/KPN) (Xu et al. 2012).  
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Figure 6: Nuclear transporters (importin and exportin) through nuclear pore complex 
(NPC) and facilitated via GTP hydrolysis by Ran. The blue arrows show different 
localisation of Ran-GTP in the nucleus and Ran-GDP in the cytosol (Adapted from Alberts 
et al. 2008). 
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The cycles between Ran-GTP associates importin in the nucleus and Ran-GDP 
dissociates exportin in the cytosol are designated for cargo delivery across the NPC. 
However, the directionality of the transport process is maintained by the establishment of a 
Ran gradient (blue arrows, in Figure 6), whereby Ran-GDP is predominantly found in the 
cytoplasm and Ran-GTP is located in the nucleus. The transport process is sustained 
through the actions of the cytoplasmic Ran GTPase-activating protein (Ran-GAP), and the 
chromatin-bound Ran GDP-GTP exchange factor (Ran-GEF), respectively. In addition, 
Figure 6 also indicates the dissociation of the complex inside the nucleus, which is affected 
by the binding of guanine nucleotide-binding protein Ran in its GTP-bound form (Ran-
GTP) to Imp, thereby displacing Imp. After the dissociation is completed, the importins 
are cycled back to the cytoplasm and they are ready for another round of import (black 
arrow in Figure 6).  
Moore (1998) affirmed that nuclear carriers for most proteins depend on 
transporters of Imp group. Family members of Imp interact with their cargo directly or 
through an adaptor protein. In addition, phosphorylation and other post-translational 
modifications can also change the transport of individual cargos (Moore 1998). Nuclear 
export occurs in an analogous fashion, in which the proteins inside the nucleus containing 
a nuclear export signal (NES) are recognised by exportins, followed by a complex 
formation with Ran-GTP. In the cytoplasm, the hydrolysis of Ran-GTP to Ran-GDP 
dissociates the complex. In addition, a critical function of small G protein-Ran which is a 
member of RAS oncogene family can be indicated by Ran Binding Protein 2 (RanBP2) 
based on the work carried out by (Hamada et al. 2011).  The process of GTP binding 
nuclear protein is essential to capture the recycling Ran GTP–importin- complexes at the 
cytoplasm to allow adequate recognition for NLS-mediated cargo import. Furthermore, 
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RanBP2 or also known as Nup358, is the major component of cytoplasmic filaments for 
nuclear pore complex (NPC). It is known that RanBP2 is essential in sustaining cell 
viability and providing strong evidence that the apoptosis of cell is associated with 
transport defects rather than mitotic failure (Hamada et al. 2011).  
Usually, the permeability of NPC is selective and dependent on cell trafficking 
properties in controlling composition of macromolecules that are transported between the 
nucleus and the cytoplasm (Mingot et al. 2004).  In this case, the small molecules are 
effectively transported via passive diffusion but the object exceeding 45kD and it has to be 
transported through facilitated mean. The conventional nuclear import for larger proteins 
requires recognition from nuclear localisation signal (NLS). Poon and Jans (2005) also 
clarified on how NLS with larger size protein can be recognised. The short sequence of 
basic amino acids either alone (monopartite) or separated by a linker region of 10–12 
amino acids (bipartite), that are located in the cargo protein, should be visible and detected 
by the members of the importin superfamily (Poon and Jans 2005).  
Overall, proteins that are lower than 45 kD should be able to efficiently diffuse 
across the nuclear envelope including RhoE (27-29 kD). Hence, there is still the 
requirement of transient interaction with NTR/KPN if RhoE is bound to its interacting 
protein partners and formed complexes that are larger than 45 kD. Moreover, there is a 
recent development in the field of nucleocytoplasmic transport that importin and Ran-
dependent transport are not the only mechanisms that enter the nucleus. As an alternative, 
pathways that are independent of transporter molecules, RanGTPase, or energy are 
essential (Kodiha and Stochaj 2012). Thus, retention or accumulation of RhoE proteins in 
the nucleus offers a flip side of investigation for nucleocytoplasmic transport.  
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1.4 RhoE/Rnd3 
1.4.1 Definition, Structure and Characteristics of RhoE 
RhoE is predominantly a membrane-associated protein that has several synonyms 
such as Rho8, Rnd3 as well as Rho family GTPase 3. Besides that, RhoE is a small GTP-
binding protein that belongs to the Ras Superfamily (Riou et al. 2013). This signalling 
protein is also a member of the Rnd subfamily. In general, Rnd proteins are unique, and 
they are originally identified by making the cells round up when expressed. To date, three 
Rnd proteins were identified including Rnd1, Rnd2 and Rnd3/RhoE (Cao and Buck 2011).  
Komander et al. (2008) stated that RhoE is not stimulated by the conventional shift 
of GTP-binding configuration like other Rho family members. Although this protein is a 
small G-protein that belongs to the member of Rnd family for Rho GTPases, RhoE 
exhibits unusual properties through undetectable GTPase activity, and it does not bind to 
GDP. For instance, like other small G-proteins, RhoE binds to GTP, unlike other G-
proteins, RhoE does not hydrolyse GTP to GDP (Fiegen et al. 2002).   
The molecular structure of RhoE is visualised using the three-dimensional 
individual proteins - PyMOL Molecular Visualisation. To date, the data available in PDB 
Europe (http://www.ebi.ac.uk/pdbe) provides four ID codes that are related to the well- 
established RhoE crystallisation work including 4BG6 (RhoE and interaction with 14-3-3 
for prenyl and phosphorylation motif), 2V55 (RhoE and interaction with ROCK1 for 
multi-site phosphorylation), 1M7B (RhoE and its functional implication in human), and 
1GWN (homodimer and core domain for constitutively activated RhoE). The code of 
1M7B is portrayed in the following figure that mimics the character of RhoE in human. 
Figure 7 shows the high-resolution structure of RhoE image.  
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Figure 7: The high-resolution structure of RhoE in human (pdb: 1M7B) was visualised in 
PyMOL Molecular Visualisation and it was retrieved in a PNG file format. RhoE consists 
of six (6) -sheet strands (five parallel, one antiparallel) that are surrounded by five (5) -
helices connected by a loop and an insert helix. 
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Referring to the 3D image that visualises the folding structure of RhoE, Figure 8 
shows a linear amino acid sequence of RhoE. This protein has a unique GTP binding site 
in the GTP coordination where additional water molecule contacts invariant Ala179 of the 
177CSAL-motive and the carbonyl oxygen of the base, which are structurally different than 
RhoA. Additional stabilisation of RhoE by Asp103 is at the Lys136 of the 135CKSD-motive, 
whereas in RhoA is at the Ser85 (Garavini et al. 2002). 
Fiegen et al. (2002) mentioned that RhoE looks quite similar to RhoA in terms of 
sequence homology. Although the proteins share conserved regions and RhoE reproduces 
the essential structural features of RhoA that bind to the regulators or effectors, RhoE is 
differently regulated. RhoE does not utilise GDI, GAP and GEF, which regulate the 
activity of the most of small GTPases (Fiegen et al. 2002).  
Foster et al. (1996) had initially disclosed that RhoE proteins are unable to 
hydrolyse GTP and they are resistant to GAP activity. In addition, RhoE is resistant to 
RhoGAP activity because due to the absence of a catalytically competent glutamine; Ser81 
and the stearic clash of the arginine finger (RhoGAP) with Ser32 (Guasch et al. 1998). As a 
consequence, the G-domain of RhoE is also completely unable to hydrolyse GTP in the 
absence or the presence of RhoGAP (Foster et al. 1996). Furthermore, Fiegen et al. (2002) 
also found that the alterations of four amino acids - Ser32 and Gln33 (P-loop region), Ser79 
and Ser81 (Switch II region) are responsible for the RhoE GTPase deficiency (Fiegen et al. 
2002).  
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  IQEFCPNTKM LLVGCKSDLR TDVSTLVELS NHRQTPVSYD QGANMAKQIG AATYIE CSAL 
         Lys136               Ala179 
         190        200        210        220        230        240  
  QSENSVRDIF HVATLACVNK TNKNVKRNKS QRATKRISHM PSRPELSAVA TDLRKDKAKS  
  
        244 
  CTVM  
                        
Figure 8: The sequence of RhoE protein established in FASTA format (UniProt, 2011), 
RhoE is structurally different than RhoA due to the different coordination of GTP for GTP 
binding site that allows contact between additional water molecule to invariant Ala179 of 
the 177CSAL-motive as well as carbonyl oxygen of the base. Additional stabilisation of 
RhoE by Asp103 is at the Lys136 of the 135CKSD-motive whereas RhoA is at the Ser85. 
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1.4.2 Function of RhoE 
1.4.2.1 RhoE in Reorganisation of Actin and Stress Fibre 
RhoE involves in the reorganisation of actin cytoskeleton and loss of stress fibres 
followed by the decreased of contractility in various cell types (Riou et al. 2010). 
Normally, RhoE effect antagonises RhoA/ROCK1 mediated actomyosin contractility. 
Consequently, RhoE activity affects cell migration, contraction of the smooth muscle and 
neurite extension (Pacary et al. 2011).  For instance, the dynamics of actin cytoskeleton in 
vertebrate is crucial in maintaining cell shape, enabling cell motility, as well as regulating 
cell cycle progression and mitosis (David et al. 2012). Thus, RhoE is a critical regulator 
that controls cell dynamic as it induces cell rounding.  
Besides that, Gottesbühren et al. (2012) revealed that RhoE induces the increase in 
stress fibres and paxillin-containing focal adhesion. This effect was found to be non-
canonical as it is solely applied to endothelial cells (EC) in blood vessels and not for other 
cell type. Moreover, an experimental study using murine cerebral cortex demonstrated that 
p190 RhoGAP and PlexinB2 to be competing for RhoE binding (Azzarelli et al. 2014). In 
principle, RhoE function antagonises RhoA but the existence of PlexinB2 in the cerebral 
cortex inhibits the function of RhoE and physical interaction with other proteins. Hence, 
RhoA activity is elevated. In this context, both physical and functional interaction between 
RhoE and PlexinB2 receptor enable the stimulation of RhoA activity during the migration 
of cortical neurons (Jie et al. 2015).  
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1.4.2.2 RhoE and Cell Cycle Progression 
RhoE has an important role in the regulation of cell cycle. Lonjedo et al. (2013) 
investigated the RhoE expression level during cell proliferation and mechanisms for the 
regulation of cell cycle. They affirmed that RhoE is immediately accumulated when cells 
are entering the G1 phase, particularly during inhibition of cell-cell contact and when 
exiting the cell cycle. They also found that RhoE is rapidly degraded during the G1/S 
transition that is dependent on Akt (also known as protein kinase B/PKB) (Lonjedo et al. 
2013).  
Akt plays an important role in controlling both growth and neurotrophic factors; 
thus, commonly suppressing neuronal cell death. It is important to considering the Akt 
pathway in neuronal progression, as the role of RhoE is relevant in regulating the 
proliferation activity of the brain tumour cells. Glioma is also classified as the tumour of 
CNS and it is closely related with the abnormality of neuronal cells. Thus, the degradation 
of RhoE dependent on Akt pathway during the G1/S transition may reveal an explanation 
on how RhoE deregulates the cell cycle systems and promotes uncontrolled proliferation of 
the glioblastoma.  
In addition, Poch et al. (2007) explained that RhoE level will decrease immediately 
at the G1/S transition and prolong towards the end of the cell cycle in several cell types. 
Besides that, RhoE also regulates cell cycle in normal cell type (Villalonga et al. 2004). 
They also revealed that RhoE inhibits cell cycle progression at G1 phase in NIH3T3 cells. 
Nevertheless, the overexpression of RhoE could lead to the accumulation of cells in G2. 
The presence of RhoE inhibits cell proliferation, particularly via the deactivation of 
extracellular signal-regulated kinase (ERK) pathway (Poch et al. 2007).  
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Riou et al. (2010) also explained that the mechanism of cell cell cycle progression 
is regulated by RhoE via suppressing translation of the cell cycle regulators, which are 
cyclin D1 and c-Myc. For instance, the recognition of 5’ cap mRNA of cyclin D1 and c-
Myc by eukaryotic translation initiation factor 4E (eIF4E) is necessary to promote the 
translation of these genes before proceeding to G1 phase. However, the function of eIF4E 
is dependent on the phosphorylation status of translational regulator, 4EBP1 that is 
specifically phosphorylated by the protein kinase, mTOR (Villalonga et al. 2009). Most 
importantly, the phosphorylation of 4EBP1 by mTOR is also essential in promoting cell 
growth. Besides that, RhoE enables dephosphorylation of 4EBP1 via activation of protein 
phosphatase 2A (PP2A). Hence, RhoE promotes the binding between eIF4E to 4EBP1 and 
indirectly disrupt the cell cycle progression at G1 phase. Figure 9 shows the schematic 
diagram of RhoE action in regulating the cell cycle progression. 
Retinoblastoma tumour suppressor (pRB) has been studied as an attenuator of cell 
cycle progression through the interaction with E2F family of the transcription factors 
(McCabe et al. 2005). It was observed that cyclin D1 and its kinase partners, CDK4 and 
CDK6 consistently decreased in the presence of RhoE. The cell cycle regulators are 
required for the S-phase entry to mediate the phosphorylation of pocket proteins including 
retinoblastoma (pRb) (Kolupaeva and Janssens 2013). In general, the key function of 
pocket protein is to modulate E2F-regulated genes during the progression of cell cycle. The 
deactivation of E2F transcription factors could attenuate cyclin D1 and block the cell cycle 
progression (Cobrinik 2005). Consequently, the overexpression of RhoE leads to cell cycle 
arrest at the G1 phase. Figure 10 shows the particular points that RhoE would interfere in 
the cell cycle progression of a normal cell type. 
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Figure 9: The schematic diagram on the regulation of cell cycle progression by RhoE. 
Phosphatase PP2A dephosphorylates 4EBP1. The presence of RhoE deactivates the 
extracellular signal-regulated kinase (ERK) pathway. Sequentially, eIF4A blocks protein 
kinase; mamalian target of rapamycin (mTOR) from phosphorylating 4EBP1, as well as 
ruling out its binding to 4EBP1. RhoE reduces 4EBP1 phosphorylation and prevents eIF4E 
from inducing the translations of genes that are required for cell cycle progression and stop 
at G1 phase (Adapted from Riou et al. 2010).  
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Figure 10: RhoE regulates the cell cycle progression in normal cell type by blocking the 
cell cycle progression at either G1/S or G2/M phases. Cyclin D1 and its kinase partners, 
CDK4 and CDK6, are consistently decrease in the presence of RhoE. The cell cycle 
regulator, Cyclin D1, in associating either CDK4 or CDK6 is required for the S-phase 
entry to mediate the phosphorylation of pocket proteins (e.g.: retinoblastoma, pRb). The 
presence of RhoE also attenuates E2F transcription factors and sequentially prevents the 
translational activity of CDKs. However, information regarding the rest of cell cycle 
regulators (Cyclin A and E that associate with CDK2 or Cyclin B that associates with 
CDK1) that are relevant to RhoE is quite limited. (Adapted from Kolupaeva and Janssens 
2012). 
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1.4.2.3 RhoE in Cell Differentiation 
Occasionally, the healthy cells stop dividing and they are no longer preceded into 
the cell cycle. Instead, the cells undergo differentiation. Riou et al. (2010) reported that 
RhoE is transiently up-regulated during keratinocyte differentiation. Corresponding to the 
higher expression of RhoE, the cells will exit from the cell cycle. In contrast, when RhoE 
is down-regulated, hyperproliferation of cells was observed (Liebig et al. 2009). Similarly, 
Ryan et al. (2012) also investigated a similar study and discovered the function of RhoE in 
controlling epithelial cell polarity and differentiation of keratinocytes. They also 
discovered that the knockdown of RhoE could induce hyperproliferation and 
overexpression of RhoE in increasing differentiation, which is indicated by the 
stratification layers of keratinocytes (Ryan et al. 2012).  
 
1.4.3 Regulation of RhoE 
1.4.3.1 Regulation of RhoE at Transcriptional Level 
It was discovered that RhoE is not regulated by GTP hydrolysis, but instead the 
regulation of this protein is at multiple stages, including the transcription activity in the 
nucleus. A few evidence showed that it was activated at the level of transcription by 
diverse stimulants (Riou et al. 2010). Besides that, Chen et al. (2011) had carried out an 
experiment that used the inhibitor of histone deacetylation, Trichostatin A (TSA). This 
pharmaceutical product particularly blocks histone deacetylases (HDAC) by intercepting 
the elimination of acetyl groups from histones as well as modifying the functional gene 
synthesis. As a result, this modification promotes the accessibility of transcription factors 
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entering the DNA molecules inside chromatin. They revealed that acetylation of histone 
could elevate the activity of RhoE promoter, as well as RhoE mRNA and protein 
expression level (Chen et al. 2011). In contrast, they also discovered that DNA methylation 
has no effect on RhoE promoter based on the treatment with 5’-Aza-2’-deoxycitidine (5-
Aza-dC), which is a DNA methylation inhibitor. There is yet a study that reveals the effect 
of RhoE expression on other cell types. These two different kinds of promoter inhibitor -  
HDAC and 5-Aza-dC were only applied in gastric cancer cells.  
Besides, amino-terminal enhancer of split (AES) also enhances the activity of RhoE 
promoter. Although AES does not have a DNA binding site, it could regulate the 
transcriptional activity via interaction with transcriptional factors. Xia et al. (2013) 
investigated the expression level of RhoE when AES was knockdown via RNA 
interference. The results showed that mRNA of RhoE, as well as protein level, were down-
regulated in MDA-MB-231 and HepG2, two types of cancer cell lines when AES is 
depleted. The overexpress AES had significantly increases the activity of RhoE promoter 
(Xia et al. 2013).  
On the other hand, Pacary et al. (2011) discovered that RhoE is a direct 
transcriptional target of Ascl1, which is the proneural factor. Ascl1 is required for 
neurogenesis and proper neuronal migration in the embryonic cortex.The manipulation of 
the gene expression using microarrays indicated that RhoE was significantly down-
regulated in the embryonic cortex of mutant embryos when Ascl1 was depleted and up-
regulated in the ventral telencephalon of embryos that were overexpressing Ascl1. These 
results showed that Ascl1 regulates RhoE expression in the embryonic mice cortex by the 
direct regulation of E1 enhancer region and also other elements in the RhoE locus.  
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1.4.3.2 Regulation of RhoE via Phosphorylation for Stabilisation 
RhoE is a multifunctional protein where localisation and actions are commonly 
regulated by phosphorylation (Riento et al. 2005a). One of the most important aspects of 
RhoE regulation via phosphorylation is its interaction with ROCK1. Fiegen et al. (2002) 
discovered that -helix of RhoE is profound with hydrophobic residues. There was also 
comparison being made with other small G-proteins such as the interaction between -5 
and ROCK1 -G helix which was completely hydrophobic. As previously mentioned in 
Section 1.4.1, the specific sites of RhoE that interacts with ROCK1 do not exist in Rnd1 
and Rnd2, which led to disabling the specific interaction with ROCK1. Therefore, RhoE is 
designed as a substrate for ROCK1.  
The stable localisation of RhoE protein is increased via ROCK1 phosphorylation. 
Riento et al. (2003) stated that ROCK1 serine/threonine protein kinase promotes the 
formation of actin stress fibres and integrin-based focal adhesion by integrating the 
function of RhoA. The phosphorylation of RhoE by ROCK1 on multiple N and C termini 
has led to the stabilisation of RhoE. As a result, this modification reduces the stress fibre 
assembly, which contradicts to the function of RhoA (Riento et al. 2005a). Moreover, 
ROCK1 is also known to phosphorylate RhoE at seven sites (Riento et al. 2005b). Figure 
11 shows the schematic diagram for the seven domains of phosphorylation on RhoE. These 
seven domain sequences are located in the N- and C-termini regions of RhoE, outside the 
core GTP-binding site. Amongst all seven phosphorylation sites, only S240 is modified by 
farnesylation and this phenomenon will be further discussed in Section 1.4.3.4. This site is 
adjacently located at the C-terminal cysteine.  
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Figure 11: The schematic diagram shows the seven phosphorylation sites on RhoE. 
ROCK1 phosphorylates one site on threonine (Thr214) and six sites on serine residues (Ser7, 
Ser11, Ser210, Ser218, Ser222, Ser240) that are located in the N- and C-termini regions, outside 
the core-GTP-binding domain in RhoE. (Adapted from Riento et al. 2005b; Riou et al. 
2013). 
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RhoE interacts with ROCK1 through binding at the kinase domain (Sebti and Der 
2003). Komander et al. (2008) conducted crystal diffraction analysis and revealed that 
RhoE interacts with ROCK1, specifically at the C-lobe of -G helix domains. In particular, 
this area is adjacent to the catalytic site of ROCK1 that is located at N and C termini, but 
far from RhoE effector region (Komander et al. 2008). Moreover, the same working group 
showed that a high-resolution structure of RhoE in complex with ROCK1 kinase domain 
was found as a diverse phosphorylation site. Figure 12 shows the overview of ROCK1: 
RhoE complex. 
Riento et al. (2005a) demonstrated that the phosphorylation status of ROCK1 by 
RhoE could promote the function of RhoE in regulating the cell cycle progression. When 
stress fibres are disassembled, phosphorylated RhoE can be seen. Simultaneously, the 
dephosphorylation of RhoE is also reciprocated with the formation of stress fibres. 
Although RhoE activity is regulated by ROCK1 phosphorylation, a study by Riento and 
co-workers (2005b) discovered that unphosphorylated RhoE is not involved in the 
reorganisation of actin filaments. Moreover, Riento et al. (2003) also priorly claimed that 
RhoE interaction with ROCK1 is essential in the process of cell migration.  
Despite that disruption of ROCK1-RhoE interface eliminates RhoE 
phosphorylation, but it still maintaining disassembly of actin stress fibres. The defect at 
RhoE effector region causes the loss of stress fibres and disorganisation of actin 
cytoskeleton. As a result, RhoE forces the dysfunctional of ROCK1 specifically by 
blocking its interaction with effector region (Komander et al. 2008).  
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Figure 12: The high-resolution structure of RhoE in complex with the ROCK1 kinase 
domain. The structure of dimerisation domain between RhoE-ROCK1 and ROCK1-RhoE 
is visualised by Protein Data Bank (pdb: 2V55) using - PyMOL Molecular Visualisation 
and that can be retrieved in PNG file format. Each subunit of the ROCK1 dimer binds with 
one molecule of RhoE. 
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In brief, Komander et al. (2008) summarised the crystal diffraction work in Table 4. 
The list differentiates the interaction between RhoE and ROCK1 by means of ROCK1 
residues that are exposed to RhoE interfacing RhoE residues interacted with ROCK1. In 
principle, the part of a feedback loop in RhoA signalling is regulated by ROCK1 
phosphorylation of RhoE (Komander et al. 2008). RhoE antagonistically reacts with RhoA 
by inducing the loss of stress fibre formation, specifically at a part that binds to RhoA 
downstream kinase Rho-associated kinase (ROCK1) that resulted in the formation of a 
complex phosphorylated RhoE. This antagonist action prevents ROCK1 activation and 
inhibits downstream signalling (Loirand et al. 2006). Figure 13 shows a diagram for the 
flow of interaction between ROCK1 and RhoE.  
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Table 4: Interaction between RhoE and ROCK1 (Adapted from Komander et al. 2008) 
 
Residue of ROCK1 exposed to RhoE 
 
Residue of RhoE interacted with ROCK1 
 
G helix (Val284, Tyr287, Met291) 
EF helix (Leu246)  
additional contact: 
(Gln249 - amide side chain) 
5 helix (Val192 and Leu195) 
additional contacts:  
(His191 - imidazole side chain) 
(Arg187- guanidium side chain) 
 
 
G helix (Ser288) 
 
6 strand (Thr173) 
G helix (Asn292 - amide side chain 
at C terminus) 
 
4 strand (Tyr159 – hydroxyl group of side 
chain at the N terminus)  
 
 
EF/F loop (Gln249 – amide side chain; 
and Ala234 - amide main chain) 
 
2/3 loop (Asp67 – side chain) 
EF/F loop (Gln249)  - conformational 
shift 
2/3 loop (Asp67) 
5 helix (His191) 
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Figure 13: A diagram for the flow of interaction between ROCK1 and RhoE. (A) 
Molecular structure of ROCK1 comprised a sequence of kinase domain that is located at 
the amino terminus of the protein, followed by a coiled-coil region containing the Rho 
Binding Domain (RBD) and a Plextrin Homology domain (PH) with a cysteine-rich 
domain (CRD). (B) ROCK1 is activated when it interacts with RhoA bound GTP. (C) 
ROCK1 is inactivated when it interacts with RhoE, particularly when C-terminus of 
ROCK binds to the N-terminal region of the kinase, forming autoinhibitory loop. (Adapted 
from Loirand et al. 2006; Chen et al. 2010; Tu et al. 2011). 
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1.4.3.3 RhoE Is Not Regulated by ROCK2 
ROCK1 and ROCK2 are two ROCK isoforms found in humans. ROCKs are not 
identical to other protein kinases, and they are usually differentiated by the serine or 
threonine kinase domains. The N- and C-termini extension segments are both required for 
the catalytic activity. The N-terminal enables the combination of two ROCK kinase 
domains to form homodimers. The formation of ROCK dimer via homophilic interactions 
occurs at the coiled-coil domains. However, the conformation of the coiled-coil domain in 
ROCK is not permanent whereby the amino acids could be replaced or conserved between 
ROCK1 and ROCK2 (Morgan-Fisher et al. 2013).   
The properties of kinase domain have also led to the formation of autoinhibitory 
loops. Furthermore, the inactivation of kinase activity occurs when it binds to the C-
terminal Rho Binding Domain (RBD) and Plextrin Homology (PH). Recent research by 
Chuang et al. (2012) revealed that autophosphorylation of ROCK2 is at Ser1366. The 
specific site of phosphorylation is subjected to the activation status of the kinase      
(Chuang et al. 2012).  Nevertheless, there is yet to be any cited literature on the statement 
that autophosphorylation at this site corresponds to the kinase activity status. Thus, more 
studies should be done to identify the effect of phosphorylation, particularly on protein 
targeting or protein-protein interactions.  
One critic is not enough to explain on ROCK2 regarding the reason that RhoE is 
not meant to be its substrate. As mentioned in Section 1.4.3.2, residue G helix (Ser288) of 
ROCK1 allows the interaction of 6-strand (Thr173) of RhoE. Although, ROCK1 and 
ROCK2 are both reflecting amino acid Serine, they are subjected to activate their kinase 
domain. However, the reasons given on why RhoE is not designated as a downstream 
effector for ROCK2 is questionable. 
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1.4.3.4 Regulation of RhoE via Farnesylation to Induce Translocation 
Signal transduction can be amplified by membrane association to allow protein-
protein interaction (Tamanoi et al. 2001). For instance, the post-translational modification 
of RhoE by prenylation can activate the membrane function of this protein (Foster et al. 
1996). Prenylation is required in cycling the localisation of RhoE between cytoplasm and 
plasma membrane. Besides that, Riou et al. (2010) also reported that Rho protein, RhoE in 
particular can be prenylated with the addition of 15-carbon farnesyl group at C-terminus. 
Other Rho proteins such as RhoA, Rac1 and Cdc42 are prenylated with the addition of 20 
carbon of geranylgeranyl isoprenoid group. The prenylation process utilises a precursor of 
either geranylgeranyl or farnesyl isoprenoid, and the hydrophobic molecule is added to a 
cysteine to anchor and attach them to the membrane (Visvikis et al. 2010).  
During prenylation, geranylgeranylation (GG) and farnesylation are similar 
processes that occur in Ras superfamily protein, but both of them are specifically for Rab 
and Ras only. RhoE in particular contains the sequence of CTVM at the C-terminal, thus 
making it vulnerable to lipid modification. RhoE is unlike other Rho protein in lipid 
modification by GG, instead by the farnesylation because it has methionine at the carboxy-
terminal box, which is similar with Ras protein (Foster et al. 1996).  
14-3-3 is a scaffold protein that specifically binds to serine/threonine kinases 
(Linch et al. 2014). The function of 14-3-3 as an adapter which might change the 
configuration of other proteins or mask a part of the physical features of the binding 
partners before initiate various signalling cascades in cells. For example, Riou et al. (2013) 
have successfully used the novel farnesylation protein hybrid mode III/IV 14-3-3 binding 
to RhoE. The mode III is defined as 14-3-3 binds to N terminal residue of RhoE, whereas 
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mode IV is defined when C terminal of RhoE binds to two isoprenyl units. This hybrid 
mode can be manipulated to engage the C-terminal farnesyl group synchronously with the 
adjacent phosphorylated serine residues that are characterised in RhoE. Figure 14 shows 
the visualisation on 3D of 14-3-3 hybrid binding to RhoE. 
In brief, Figure 14 shows the high-resolution structure of the interaction at prenyl-
phosphorylation motif. The farnesylated peptide (KDKAK) is located upstream to the 
residues 232-241 of the CAAX box of RhoE, anchored by 14-3-3 at residue Cys241. Linch 
et al. (2014) stated that the disposition of RhoE from cytoplasm to the membrane requires 
farnesylation of isoprenoid protein, 14-3-3. However, RhoE prenylation process is 
dependent on dual phosphorylation, by PKC (Ser210) and ROCK1 (Ser240 and Ser218) 
dependent (Linch et al. 2014).  
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Figure 14: The high-resolution structure of 14-3-3 (pdb: 4BG6) interaction with prenyl-
phosphorylation motif that upstream to the residues 232-241 of the CAAX box. Crystal 
structure of 14-3-3 (zeta/delta) indicated by homodimers of blue helixes. The farnesylated 
peptide (olive stick – KDKAK) bound to each 14-3-3 monomer at Cys241 and anchor 
residue that is indicated by red stick. The homodimers of 14-3-3 at diagonal position are 
visualised to expose the farnesylated peptide in RhoE.  
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Figure 15 shows a proposed mechanism during RhoE farnesylation that requires 
phosphorylation by ROCK1 and PKC. 14-3-3 inhibits RhoE-induced cell rounding by 
translocating this protein from the plasma membrane to the cytosol and it is facilitated via 
phosphorylation of RhoE at Ser218 and Ser240 by ROCK1 and Ser210 by protein kinase C 
(PKC). Riou et al. (2013) stated that Ser240 is a consensus site with PKC and the position of 
this amino acid is upstream to the CAAX prenylation motif at C-terminal hypervariable 
membrane-targeting domain of RhoE. 
Madigan (2008) has investigated the modulation of PKC by using bryostatin-1, 
phorbol myristate acetate (PMA) and ionomycin that caused the loss of RhoE from the 
plasma membrane. In contrast, RhoE was found to be enriched in the cytosol and internal 
membranes when PKC was activated. Subsequently, Madigan et al. (2009) suggested that 
PKC agonist enables phosphorylation of RhoE to direct intracellular localisation. ROCK1 
and PKC are both members of AGC kinase family that require dual phosphorylation and 
they are responsible for C-terminal site modification (Flynn et al. 2000). Overall, the 
complex formation of RhoE protein to the farnesyl group from 14-3-3 besides the 
additional phosphate from PKC and ROCK1 could influence RhoE function in the plasma 
membrane.  
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Figure 15: The interaction of RhoE with ROCK1 and PKC and post-translational 
modification via farnesylation. 14-3-3 inhibits RhoE-induced cell rounding by 
translocating it from the plasma membrane to the cytosol and facilitated via 
phosphorylation of RhoE at Ser218 and Ser240 by ROCK1 and Ser210 by protein kinase C 
(PKC). (Adapted from Riou et al. 2013). 
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1.4.3.5 Regulation of RhoE via Ubiquitination to Promote Proteosomal Degradation 
Lonjedo et al. (2013) have identified a region between amino acids 231 and 240 of 
RhoE as the S-phase kinase-Associated Protein 2 (Skp2), E3 Ubiquitin Protein Ligase 
(Skp2-interacting domain) and Lys235 for the substrate of ubiquitylation. They proposed the 
mechanism by investigating which proteasomal degradation of RhoE by Skp2 that 
regulates its protein levels to control cellular proliferation. 
In principle, proteosomal degradation of RhoE requires the interaction with Skp2 at 
C-terminal domain and ubiquitylation of Lys235. Due to the RhoE mutant lacking of C-
terminal domain, it becomes more stable when compared to wild-type protein. The mutated 
residues of either Lys45 or Lys235 increase the half-life of RhoE. Based on these findings, 
these residues are modified under specific conditions or responsed to different stimuli. 
Besides that, it was discovered that the half-life of RhoE is shorter than other Rho proteins. 
Thus, proteasomal degradation by ubiquitination is involved in regulating the level 
expression of RhoE (Lonjedo et al. 2013). 
 
1.4.4 RhoE in Cancer 
During the overexpression of several members in Rho family of GTPases, it was 
observed that their upstream regulators or downstream effectors cause various 
malignancies, including pancreatic, breast, brain and prostate cancer. The negative 
regulation of p190 RhoGAP has the ability to negatively control the tumour growth, 
transformation, metastasis, invasion and angiogenesis, suggesting that Rho protein may 
function as a tumour suppressor in vivo (Vega and Ridley 2008). Prolonged inactivation of 
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Rho can result in apoptosis; however, reports are contrary regarding which apoptotic 
signalling pathways are activated. Furthermore, the cell transformation status was not 
clearly defined during the activation of signalling pathway (Ludwig and Parsons 2011).  
Vega and Ridley (2008) reported that RhoE has multiple effects on cancer cell 
proliferation of either inhibiting of cell cycle via Ras-induce transformation or enhancing 
cancer progression by acting as a pro-survival factor induced by p53 depending genotoxic 
stress. Similarly, a recent report by Pacary et al. (2011) inferred that RhoE involved in 
neuronal tumour formation. However, the study did not completely examine the exact role 
of RhoE in inducing neurite outgrowth during the migration of neurones. An extended 
study by Peris et al. (2012) revealed the role of RhoE in neuronal polarisation by 
examining neurite and axon outgrowth. It was discovered that down-regulation of RhoE 
could lead to neuronal alterations and activate the signalling pathway of RhoA/ROCK1 
/LIMK/Cofilin (Peris et al. 2012). 
RhoE has an important role regarding cancer by regulating apoptosis and the 
function of this protein is to antagonise p190 RhoGAP (Poch et al. 2007). Ludwig and 
Parsons (2011) demonstrated that p190 RhoGAP levels can regulate the apoptotic response 
in breast cancer cell lines with docetaxel, which is a chemotherapy drug for breast cancer 
that uses the regulation of Rho. They suggested that p190 RhoGAP is also a regulator of 
apoptosis. The formation of intermediates for apoptosis such as multinucleation and 
dendritic phenotypes suggested that this process is mediated by p190 RhoGAP and its 
downstream effectors, including caspases. In addition, they also affirmed that elevated 
levels of p190 RhoGAP can sensitise breast cancer cells to docetaxel-induced apoptosis, 
which functions as a tumour suppressor. Since RhoE function is antagonising p190 
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RhoGAP, RhoE-deactivated cell death may function as a tumour enhancer. Thus, the 
depletion of RhoE could assist apoptosis, and it can be manipulated for cytoskeletal-based 
chemotherapeutics. 
Ma et al. (2013) found a suppress profiling of RhoE that is closely related to 
tumourigenesis and metastasis of hepatocellular carcinoma cells (HCC). They observed 
that the decreased expression of RhoE in patients with hepatic tumours is significantly 
correlated with short survival after diagnosis. Moreover, a liver graft transplant model had 
demonstrated that RhoE depletion promotes local invasion of cancerous cells in the hepatic 
tissue of a nude mice in vivo. The immunity-inhibited mice exhibit the increase of 
angiogenesis including invasive tumour front (ITF) and formation of a large amount of 
draining veins in the liver. 
 
1.5 The Aim of This Project  
Peris et al. (2012) demonstrated that RhoE protein signature is consistent with the 
development of neuron. The knockdown of RhoE has led to suppressing both neurite and 
axon outgrowth as well as delaying the process of impulse transmission between neurons. 
RhoE depletion also induces neuronal alterations which involves in the activation of 
signalling pathway of RhoA/ROCK1 /LIMK/Cofilin. Regarding the work by Peris and co-
workers (2012), it can be suggested that the examination for the role of RhoE can be 
extrapolated. This research should consider examining the function of RhoE in U87 human 
glioblastoma cell since this glioma cell line is derived from a stage IV tumour of CNS that 
is closely related to neurons. 
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Soulet et al. (2010) conducted preliminary studies using the chick chorioallantoic 
membrane (CAM) model in vivo.  They implanted U87 cells into the CAM and mRNA 
samples, which are prepared at regular intervals after the implantation and the samples are 
analysed using microarrays. The result from the bioinformatics analysis of microarray data 
from U87 cells implicates nuclear RhoE in tumour development. Subsequently, Falciani 
and collaborators (2011) found that a number of nuclear RhoE interacting proteins are up-
regulated 2-3 days after implantation (result unpublished). 
The U87 human glioblastoma cell line is manipulated to study the function and 
regulation of RhoE in vitro for cell cycle and apoptosis, which is highly beneficial due to 
its ability to express RhoE at a consistent level. This is a collaboration work with Prof. 
Falciani and S. Durant from Molecular Angiogenesis Group at the IBR, School of 
Medicine, College of Medical and Dental Sciences, University of Birmingham, United 
Kingdom. Ryan (2010) has conducted an experiment using 293T cells that were generated 
preliminary data from the mass spectrometry analysis (result unpublished). The researcher 
has identified several novel protein partners in the nucleus that could potentially interact 
with RhoE including MCM3, MCM5, SSRPI, ORC3L and CAF1. 
The rationale of investigating the nuclear RhoE interacting proteins for this project 
is to understand the mechanism and signalling pathway that are involved at the molecular 
level during the formation and development of brain tumour particularly glioma. By 
referring to the work done by Soulet et al. (2010) and the preliminary result by Ryan 
(2010), I intended to extend the research to determine the role of RhoE in regulating 
glioblastoma.  
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I will use the U87 human glioblastoma cell line in vitro for this research. The 
following are the individual aims of the experiments:  
Aim 1:  Analyse the role of RhoE in cell proliferation and apoptosis 
Aim 2:  Investigate whether the localisation of RhoE to the nucleus is dependent on  
                        serine/threonine kinases 
Aim 3:  Identify a novel RhoE interacting protein partners in the nucleus  
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CHAPTER 2 
MATERIALS AND METHODS 
 
2.1 Materials 
2.1.1 General Laboratory Reagents 
Cisplatin (cis-DDP or cis-diamminedichloroplatinum (II)) was supplied by 
Calbiochem, (Catalogue No. 232120). Y27632 was produced by GlaxoSmithKline under the 
license from Welfide Corporation. Gӧ6976 was supplied by Cell Signalling (Catalogue No: 
12060). Phorbol myristate acetate (PMA) was obtained from Merk Millipore (Catalogue No: 
52440). Other salts were obtained from either Fischer Scientific or Sigma Aldrich or other 
suppliers that are stated in the text. This study has used acids that were analytical grade and 
they were supplied by Fischer Scientific whereas all bases were supplied by Sigma Aldrich. 
Besides that, all solvents were analytical grade and they were purchased from Fisher 
Scientific, except acetonitrile that was provided by Scientific Laboratory Supplies with HPLC 
grade. 
 
2.1.2 Media and Other Reagents for Cell Culture  
Dulbecco Modified Eagle Medium (DMEM), Trypsin-EDTA (1X) and Optimem were 
purchased from Gibco (Life Technologies) whereas Eagle's Minimum Essential Medium 
(EMEM) was obtained from Lonza (BioWhittaker). 
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2.1.3 DNA Constructs 
The overexpression vectors containing wild-type (WT) mouse RhoE and empty vector 
(EV) control, (pCMV5 RhoE Flag and pCMV5 EV Flag) and five (5) mutant constructs 
(pCMV5 Flag RhoEV56Y, pCMV5 Flag RhoE T173R/V192R, pCMV5 Flag RhoE F57Y, pCMV5 
Flag RhoE Y60A, pCMV5 Flag RhoE V192R) were received courtesy of Professor Ridley 
(King’s College London) (Komander et al. 2008). Both recombinant RhoE wild-type 
(RhoEWT) and RhoE point mutants were expressed as FLAG-tagged fusion proteins in E. coli. 
Recombinant FLAG was used as a control. Komander et al. (2008) generated all these 
constructs using the mutagenesis kit and they were cloned into the pCMV5 FLAG vector to 
produce FLAG epitope-tagged proteins. The wild-type and empty vector constructs were 
confirmed by DNA sequencing (Appendix 1 and Appendix 2). 
 
2.1.4 Primers 
Primers for real-time polymerase chain reaction (RT-PCR) targeted for RhoE 
sequence were designed according to personal discussion with Dr Sue Brewer (Brewer 2011). 
The appropriate primer was determined according to the nearest promoter adjacent to the 
multiple cloning sites (MCS). The gene of interest (RhoE) is usually inserted into the MCS of 
the vector via recombinant technology.  
Riento et al. (2003) supported this presumption when they generated expression vector 
encoding FLAG-RhoE by inserting full-length mouse cDNA between EcoRI and HindIII sites 
of pCMV5-FLAG.  A plasmid vector - pCMV5 was used in this experiment. The description 
of mammalian expression vector was adapted from Chubet and Brizzard (1996) and Figure 16 
shows the prediction of RhoE construct as well as the nearest primers. For the transient 
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transfection experiment, two primers were selected which are CMV_fwd_primer and 
pCEP_fwd_primer as these primers are mapped adjacent to the MCS, that notably starts at 
EcoRI. These primers were then purchased from AltaBioscience, University of Birmingham, 
United Kingdom. Table 5 shows the details of these primers. 
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Figure 16: The map of the mammalian expression vector-pCMV5 that was predicted to have 
RhoE construct in between EcoRI and HindIII (highlighted in blue). The position of the 
nearest primers namely CMV_fwd_primer and pCEP_fwd_primer are highlighted in yellow. 
These primers are mapped adjacent to the multiple cloning sites (MCS) (Adapted from 
Brewer 2011; Chubet and Brizzard 1996; Riento et al. 2003). 
  
 
CMV_innearly promoter 
SnaB1 674 
CMV_fwd_primer 
CMV_promoter 
Sac1_902 
pCEP_fwd_primer 
EcoRI 920 
BgIII 926 
 
Acc651 932 
KpnI 936 
MluI 938 
ClaI 945 
HindIII 950 
SbfI 966 
PstI 966 
SalI 968 
AccI 969 
XbaI 974 
BamHI 980 
XmaI 984 
SmaI 986 
 
pCMV5 
4657bp 
pBR322_origin 
 
   Pc1I 2379 
ScaI 3751 
Ampicilin 
 
AmpR_promoter 
PsiI 4548 
f1_origin 
NaeI 4317 
 
 
NgoMIV 4315 
lacZ_a 
lacZ_a  
M13_pUC_fwd_primer 
M13_forward20_primer 
        BsrGI 277 
             SpeI 333                                  
       
                         
CAG_enhancer 
                   Nde1 568 
 
hGH_PA_terminator 
AgeI 1532 
pBABE_3_primer                                              
SV40_enhancer 
SV40_promoter 
SV40_origin  
             SV40pro_F_primer 
        StuI 1950 
        AvrII 1951 
        XhoI 1973 
        T7_promoter 
M13_reverse_primer 
M13_pUC_rev-primer 
lac_promoter 
ORF 
Multiple cloning 
sites  
2716 
3492 
3492 
3880 
4268 4656 
2328 
1940 
1552 
1164 
776 
388 
2328 
3104 
3880 
Possible 
location for 
insertion of the 
recombinant 
RhoE construct 
(FLAG-tagged 
-RhoE) 
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Table 5: Primers for RT-PCR of RhoE Sequence   
Primer 
 
Sequence Tm (C) 
 
pCMV 
 
 pCMV Forward:  
5´d[CGCAAATGGGCGGTAGGCGTG]3´ 
 
72.2 
 
pCEP 
 
pCEP Forward:  
5´d[AGAGCTCGTTTAGTGAACCG]3´ 
 
54.8 
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2.1.5 Antibodies 
Antibodies used in this study are listed in Table 6. 
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Table 6: List of antibodies used in immunoblotting (IB) and immunocytochemistry (ICC) 
Type of 
antibody 
Titre of antibody Species Company 
provider 
Storage 
 IB ICC    
 
a) Primary antibody 
RhoE 500 100 Mouse Upstate, 
Millipore 
 
-20C 
ROCK1 1000 100 Rabbit Santa Cruz 
Biotechnology 
 
4C 
Full Length 
Caspase 3 
 
1000 N/A Rabbit Cell Signalling -20C 
Cleaved Caspase 
3 
 
1000 N/A Rabbit Cell  Signalling -20C 
Full Length 
Caspase 9 
 
1000 N/A Rabbit Cell Signalling -20C 
Cleaved Caspase 
9 
 
1000 N/A Rabbit Cell Signalling -20C 
α-Tubulin 5000 N/A Mouse Sigma (T6199) -20C 
 
Actin Alexa-594-
conjugated 
Phalloidin 
 
N/A 1000 Fungi Molecular 
Probes 
 
-20C 
GAPDH 1000 N/A Rabbit Santa Cruz 
Biotechnology 
 
4C 
Lamin 1000 N/A Mouse Santa Cruz 
Biotechnology 
 
4C 
SSRPI 500 100 Mouse Abcam 4C 
 
MCM3 1000 100 Rabbit Abcam 4C 
 
MCM5 1000 200 Rabbit Abcam 4C 
 
CAF1 1000 100 Mouse Abcam 4C 
 
Anti-FLAG 1000 100 Mouse Sigma Aldrich -20C 
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Type of 
antibody 
Titre of antibody 
 
IB               ICC 
Species Company 
provider 
 
Storage 
 
b) Secondary antibody 
Anti-Mouse – 
HRP 
 
10 000 N/A Sheep Fischer scientific 4C 
Anti-Rabbit – 
HRP 
 
10 000 N/A Goat Fischer scientific 4C 
Anti-Mouse – 
IgG biotinylated 
 
10 000 N/A Sheep Amersham  
GE Healthcare 
4C 
Anti-Rabbit – 
IgG biotinylated 
 
10 000 N/A Donkey Amersham 
GE Healthcare 
4C 
Anti-Mouse – 
link 680nm 
 
20 000 N/A Goat Odyssey -20C 
Anti-Rabbit – 
link 800nm 
 
20 000 N/A Goat Odyssey -20C 
Anti-Mouse 
FITC - Alexa  
Fluor 488nm 
 
N/A 200 Goat Molecular 
Probes 
4C 
Anti-Rabbit 
FITC - Alexa 
Fluor 488nm 
 
N/A 200 Goat Molecular 
Probes  
4C 
 
c) Tertiary (Fluorescence Label) 
Streptavidin, 
DyLightTM 800 
 
Conjugated 
40 000 N/A N/A ThermoScientific 4C 
ECL  1:1 N/A N/A ThermoSientific 4C 
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2.2 Methods 
2.2.1  General Laboratory Procedure 
2.2.1.1 Cell Culture 
U87 human glioblastoma cell line was received courtesy of Sarah Durant (Professor 
Roy Bicknell’s Lab, Institute for Biomedical Research (IBR), School of Medicine, College of 
Medical and Dental Sciences, University of Birmingham) and it was cultured in Dulbecco’s 
Modified Eagles Medium (DMEM) (Gibco Cat. No. 41966) supplemented with 100units/ml 
penicillin, 100 µg/ml streptomycin (Gibco) and 10% (v/v) of foetal bovine serum (FBS) 
(Lonza, BioWhittaker). The dish or flask was pre-coated with 0.1% (v/v) animal gelatine 
before the culturing process. COS7 and 293T cell lines were received courtesy of Jenson Lim 
(Professor Robin May’s Lab, Biosciences, University of Birmingham) and Sylwia Krawczyk 
(Professor John Heath’s Lab, Biosciences, University of Birmingham), respectively. The cells 
were cultured in Dulbecco’s Modified Eagles Medium in a similar way to the U87 cells but 
without pre-coated with gelatine. HaCaTs, the immortalised keratinocyte cell lines were 
grown in Dulbecco’s Modified Eagles Medium (DMEM) (Gibco Cat. No. 41966) 
supplemented with 100 units/ml penicillin, 100 µg/ml streptomycin (Gibco) and 5% (v/v) of 
FBS. Glioma cell line 11 and cell line 21 were received courtesy from the late Dr Carina 
Helberg (in memorial of School of Biosciences, University of Birmingham). The cells were 
cultured in Eagle's Minimum Essential Medium (EMEM) (Lonza) supplemented with 100 
units/ml penicillin, 100 µg/ml streptomycin (Gibco) and 10% (v/v) of FBS. All the cell types 
were maintained at 37C in a humidified 5% CO2 atmosphere. The cells were passaged when 
they reached approximately 5 x 106 cells in 1 ml aliquot and the small passage stocks were 
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stored in liquid nitrogen with 10% (v/v) dimethylsulphoxide (DMSO) preservative in FBS  
(Thompson 2009). 
 
2.2.1.2 Cell Lysis 
All cells were washed with PBS, and trypsinised and they were harvested in cold PBS. 
The cells were then pooled in a Falcon tube and centrifuged at 500 g for 5 min at room 
temperature. After that, the cells were lysed for 5 min in ice using RSB + 0.5% NP40 lysis 
buffer containing a final concentration of 10 mM Tris base pH 7.4, 5 mM MgCl2, 10 mM 
KCl, protease inhibitors mix (Complete Mini, Roche Diagnostics) and phosphatase inhibitors 
cocktail (ThermoScientific). Both nuclear and cytoplasmic fractions were prepared by 
centrifugation 500 g for 5 min at 4C. Whole cell lysates and supernatants (cytoplasmic 
fraction) were mixed with 6 X SDS sample buffer, whereas pellets (nuclear fraction) were 
mixed with 2 X SDS sample buffer (100 mM Tris, pH 6.8, 1 % Bromophenol blue, 10 % 
glycerol, 2 % SDS, 20 mM DTT). All fractions were then sonicated for 15 sec for three times 
and boiled at 95 °C for 5 min. All samples were stored at -20 C (Lal et al. 2005). 
                                                                      
2.2.1.3 Purification of Plasmid DNA 
This study used DNA constructs (see Section 2.1.3) that were purified using QiaFilter 
Plasmid Maxi Kit (Qiagen Cat.No. 12262). 5 ml of LB (Luria Bertani broth) containing the 
appropriate selection was inoculated with E. coli transformed with the plasmid of interest and 
grown for 8 h at 37 C. This culture was then diluted into 500 ml of LB (McMullan 2002), 
containing the appropriate selection and was grown for another 16-18 h at 37C. The bacteria 
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were harvested by centrifugation at 2350 g for 15 min at 4C and maxipreps were performed 
according to the manufacturer’s instructions. The purified DNA plasmids were stored at -20 
C (McMullan 2002). 
 
2.2.1.4 Quantification of DNA Concentration 
The concentration of DNA was purified by maxipreps (see Section 2.2.1.3) and it was 
determined by measuring the absorbance of the DNA solution diluted in distilled water at 260 
nm. An optical density unit represents 50 µg/ml of DNA (McMullan 2002). 
 
2.2.1.5 Western Blotting  
Equal amount of protein (20-25 µL) were resolved on 10 – 12.5% (v/v) SDS-PAGE 
gels for 1 h 20 min at 250V, 25mA, 100W at room temperature. Then, gels were transferred to 
PVDF (Immobilon-P, Millipore, Billerica, MA, USA) using a mini trans-blot apparatus 
(MiniProtean II, Bio-Rad) for 1 h 15 min at 100 V, 400 mA, 25 W at 4 C (Colyer 1999). 
 
2.2.1.6  Immunoblotting 
The protocols used for immunoblotting were variable depending on types of protein to 
be detected and imaging system available during that particular time. Table 7 briefly describes 
the individual protocol.  
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Table 7: Immunoblotting protocols 
Protocol X-Ograph Odyssey Odyssey 
(biotinylation)  
 
a) Blocking system 
Blocking Buffer/ 
Solvent 
5% skimmed milk in 
TBST 
Absolute Methanol  
2 min followed by 
air dry 
 
5% skimmed milk in 
TBST 
Total time consumed 
for blocking 
 
1 h, RT 12 min, RT 1 h, RT 
b) Primary antibody    
Buffer used for 
antibody dilution 
5% skimmed milk in 
TBST 
Odyssey blocking 
buffer diluted (1:1) 
with cold PBS (1X)  
 
5% skimmed milk in 
TBST 
Incubation time and 
condition 
 
Overnight, 4C Overnight, 4C Overnight, 4C 
Washing buffer TBST PBST TBST  
and washing step 3 x 10 min each 4 x 5 min each 3 x 10 min each 
 
Total time consumed 
for washing 
 
 
 
30 min 
 
20 min 
 
30 min 
c) Secondary antibody 
Buffer used for 
antibody dilution 
5% skimmed milk in 
TBST 
Odyssey blocking 
buffer diluted (1:1) 
with cold PBS (1X) 
 
5% skimmed milk in 
TBST 
Incubation time and 
condition 
1 h, RT 1 h, RT 1 h, RT 
 
Washing buffer 
       
 and 
 
 
TBST 
 
PBST, final wash 
PBST was replaced 
with PBS 
 
TBST (1st wash) 
TBS (2nd and 3rd 
wash) 
washing step 3 x 10 min each 4 x 5 min each 
(membrane to be 
kept in the dark) 
 
3 x 10 min each 
Total time consumed 
for washing 
 
30 min 20 min 30 min 
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Protocol X-Ograph Odyssey Odyssey 
(biotinylation)  
 
d)Tertiary (Fluorescence label) 
Reagent 
 
 
Super signal ECL/ 
normal ECL 
 
IRDye 
 
 
Dylight 
Streptavidine 
 
Time exposure to 
fluorescence label 
 
5-30 sec N/A 30 min – 1 h 
Buffer used for 
fluorescence label 
dilution 
 
N/A N/A TBS 
Washing buffer N/A N/A TBS 
 
Washing step N/A N/A 3 x 10 min each 
 
Total time consumed 
for washing 
 
N/A N/A 30 min 
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2.2.1.7  Image Scanning 
The blots were processed by the exposure of medical X-ray film (Scientific Lab 
Suppliers Ltd), which was then developed using an X-Ograph (Colyer 1999). Alternatively, 
the immunodetection of proteins in blots can also be spotted by scanning the PVDF 
membranes onto an Odyssey infrared imaging system (LI-COR Biosciences) at two different 
wavelength of 700 nm and 800 nm, with 2.5 gains of exposure under red channel (680 nm) 
and 5.5 gains of exposure under green channel (800 nm) at 169 µm resolution.  
 
2.2.1.8 Densitometry Analysis 
The quantification of density (intensity) of bands on Western blot was carried out 
using Java-based image processing software, Image J.  
 
2.2.1.9 Preparation of Glass Cover Slips for Cell Culture 
The glass coverslips were treated for 5 min in concentrated nitric acid at room 
temperature. The nitric acid was then diluted with tap water, and the cover slips were washed 
in overflowing water for 30 min. Next, the coverslips were washed in pure methanol for three 
times, and they were left to evaporate at room temperature for overnight in a sterile condition. 
The coverslips were dried by incubation at 140 C for at least 4 h before being used 
(Robertson 2004). 
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2.2.1.10 Fixation of U87 Human Glioblastoma Cell Lines on Coverslips 
The cells were cultured on pre-coated coverslips with 0.1 % (w/v) gelatine from 
animal skin for 48 h. The coverslips that were previously prepared (Section 2.2.1.9) were 
rinsed three times with PBS and fixed with 4 % paraformaldehyde (PFA) pH 7.4 for 10 min at 
room temperature (Thompson 2009).  
 
2.2.1.11 Permeabilisation 
The coverslips were permeabilised using cold 0.1% (v/v) Triton X-100 in PBS for 5 
min at room temperature after PFA fixation. This step is essential for the accessibility of 
antibody into the cells in detecting the protein. These include intracellular proteins and 
transmembrane proteins with epitopes that are located in the cytoplasmic region. 
 
2.2.1.12 Immunofluorescence Staining 
Immunofluorescence staining was performed as described previously but with some 
modifications (Ryan, 2010). The cells were washed three times with PBS, and the coverslips 
were incubated with primary antibody diluted in PBS, about an hour at room temperature. 
Next, the coverslips were washed three times in PBS and incubated with the relevant 
secondary antibodies (Alexa 488nm conjugated antimouse or antirabbit) diluted in PBS, about 
an hour at room temperature. The coverslips were rinsed with PBS contained 0.1% (v/v) 
Tween-20 for 10 min followed by nuclear staining using Hoechst 33342 or DAPI at 1:10 000 
dilution in PBS Tween-20. Later, the coverslips were extensively washed with PBS and 
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rinsed with distilled water to prevent crystallisation (Ryan, 2010). Finally, the coverslips were 
mounted using Mowiol (Robertson 2004) and the immunostained cells were visualised using 
a Nikon Eclipse Ti microscope that is equipped with Hamamatsu ORCA-R2 camera model 
C10600-10B. The images were captured and processed using NIS-Elements BR 3.22.00 (710) 
software (Nikon, Japan).  
 
2.2.1.13 Immunofluorescence Staining for FLAG and Confocal Microscopy 
According to Ryan (2010), immunofluorescence staining for FLAG was modified 
from Sections 2.2.1.11 and 2.2.1.12 by performing a blocking step to reduce non-specific 
antibody binding. After fixation (see Section 2.2.1.10) cells were incubated with 50 mM 
NH4Cl diluted in PBS for 10 min at room temperature, the process is followed by 
permeabilisation (see Section 2.2.1.11). Then, the cells were washed three times in PBS, for 
about 5 min each at room temperature. The coverslips were incubated with 10% (v/v) heat-
inactivated normal goat serum (HINGS) and 5 % (w/v) bovine serum albumin (BSA) in PBS 
for 1 h at 37 C to prevent non-specific binding (Ryan 2010). The anti-FLAG primary 
antibody was diluted in blocking buffer at 1:1 000 and the coverslips were incubated for 2 h at 
37 C. Then, the coverslips were rinsed with PBS contained 0.1 % (v/v) Tween-20 for 10 min, 
followed by nuclear staining of using either Hoechst 33342 or Sytox Red 633 (Molecular 
Probes, Invitrogen) at 1:10 000 dilution in PBS Tween-20. The rest of the protocol is similar 
with the descriptions mentioned in Section 2.2.1.12. 
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2.2.2 Experimental Design 
2.2.2.1 RNAi Transfection for Knocking Down RhoE 
The method that is used to knockdown RhoE is RNA interference (RNAi) by gene 
silencing. Transfection via small interfering RNA (siRNA) was conducted in the 
concentration of 9 pmol oligo per 300 000 cells in 35 mm of p6 well tissue culture dish. Two 
siRhoE oligos were used to deplete RhoE from U87 cells, which are the oligo A, 5’-
TAGTAGAGCTCTCCAATCA-3’ and the oligo B, 5’-CAAACAGATTGGAGCAGCT-3’. 
The sustainability of the knocked down in U87 cell line was investigated after the transfection 
with siRNA oligos. The protein samples were prepared on a daily basis for four days to 
determine the effectiveness of RhoE knockdown in U87 cell over time. 
Figure 17 (A) and (B) show the knocked down effectiveness  when using RhoE oligo 
A and RhoE oligo B. The non-silencing control was used as a control oligo at the same time. 
Both figures, show that RhoE was totally depleted on day 1 (24 h), and the depletion was 
prolonged until  day 4 (96 h) in knock down RhoE conditions. The knockdown was consistent 
for both oligos.  
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      24h                48h                72h                 96h 
                        __________  __________  __________   __________  
 
 
 
          
          
 
                       24h                48h                72h                 96h 
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Figure 17: Knock down RhoE of U87 cells using oligo RhoE A (A) and oligo RhoE B (B) in 
comparison with control oligo (non-silencing control) over time. The depletion of RhoE was 
prolonged until at least 96 h. 
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2.2.2.2 Bromodeoxyuridine (BrdU) Uptake 
The entry into S-phase was analysed by the incorporation of BrdU 
(Bromodeoxyuridine) that uses a BrdU labelling and detection kit from Boehringer 
Mannheim (Cat. no. 1296732). The cells were grown on glass coverslips for 48 h and they 
were incubated with BrdU, before being diluted in normal growth medium, for 1 h under 
normal cell culture conditions. The media was not changed to prevent serum stimulation at the 
S-phase entry. Cells fixation with 70 % (v/v) ethanol was applied in 50 mM glycine pH 2 for 
20 min at -20 °C. BrdU incorporation was assessed by indirect immunofluorescence using a 
monoclonal antibody against BrdU. DAPI was used to label all nuclei at 1:10 000 dilution. 
The cells were visualised using a Nikon Eclipse Ti microscope that is equipped with a Nikon 
camera. The microscopic images of both BrdU positive cells and DAPI were taken before 
being overlapped for each field of view, with seven areas for each condition. For the statistical 
test, the minimum cells were 250 for each coverslip in triplicate for each set of experiment 
and conducted in three different batches (n = 3). The number of BrdU-positive cells was 
determined as the percentage (%) of S-phase entry cells for the total number of cells.  
 
2.2.2.3 Optimisation of Apoptosis Assay 
This study conducted an apoptosis experiment, using a similar approach by Darenfed 
et al. (2007). The siRNA RhoE oligos were used to perform the siRNA transfection to get the 
target gene knockdown for 96 h. The oligo B, 5’-CAAACAGATTGGAGCAGCT-3’ was 
introduced to U87 cells at the beginning of the experiment to enable transient transfection. 
This study has applied some modifications, particularly to the time frame of the treatment of 
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ROCK inhibitor (Y27632) to fit the U87 cells condition. In addition, cisplatin was also added 
within 96 h of RhoE knockdown, and this step was not applied in the previous study.  
The ROCK inhibitor (Y27632) was applied 48 h after the knockdown, followed by 
genotoxic stress that is induced by cisplatin after 78 h post-RhoE-depletion. The U87 cells 
were also prolonged and incubated with Y27632 by replenishing this compound at every 12 h 
intervals during cisplatin treatment to conserve ROCK1 inhibited phenotype. The treatment 
with cisplatin and Y27632 on U87 cells were accomplished at 96 h post-transfection. These 
cells were then harvested, and cell lysates were prepared for SDS-PAGE, before being 
transferred to PVDF membrane and subjected to immunoblotting.  
Figure 19 shows the experimental design. The flow chart shows the optimised 
apoptosis experiment and indicates the critical time point for the addition of the apoptotic 
inducer (cisplatin) and ROCK inhibitor (Y27632).  
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Figure 18: Schematic diagram of optimised apoptosis experiment indicating critical time for 
the addition (+) of apoptotic inducer (cisplatin) and ROCK inhibitor (Y-27632). 
U87 cell culture: 
siRNA transfection (t=0) 
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         RhoE knockdown (t=78) 
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(+) Cisplatin for genotoxic stress (t=0) 
 Sampling coverslips and lysates preparation  
RhoE knockdown (t=96) 
 Y27632 for ROCK1 inhibition (t=48) 
Cisplatin for genotoxic stress (t=18) 
Sampling coverslips and lysates preparation  
RhoE knockdown (t=48) 
ROCK1 inhibition (t=0) 
         RhoE knockdown (t=84) 
(+) Y27632 for ROCK1 inhibition (t=36) 
 Cisplatin for genotoxic stress (t=6) 
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2.2.2.4 Translocation of RhoE to the Nucleus by the Effect of Serine/Threonine Kinase 
The U87 cells expressing endogenous RhoE were cultured at 1.0 million units of cells 
per 100 mm tissue culture dishes for 24 h to obtain 50 % confluence level. Then, these cells 
were pre-treated with the pharmacological inhibitor of either Y27632 for ROCK1 or/and 
Gӧ6976 for PKC for up to 3 h. For control conditions, the U87 cells were only received the 
diluents, of either PBS or DMSO. Then, the translocation of RhoE following the inhibition of 
serine/threonine kinases (ROCK1 and PKC) was investigated via the activation of novel 
PKC by 15 min treatment with phorbol myristate acetate (PMA). Figure 19 shows the 
schematic diagram for the procedure of this experiment, including detailed descriptions of 
condition, 1 to 8 for each replicate.  
The U87 cells were treated with designated pharmacological compounds before being 
harvested, and the cell lysates were prepared for SDS-PAGE, transferred to PVDF membrane 
and subjected to immunoblotting. The semi-quantitative analysis was performed on the PVDF 
blot to determine RhoE intensity using Image J software. The full set of the experiment, 
including condition 1 to 8 were conducted in triplicates (n = 3). The significant difference 
between novel activation of PKC and inhibition of ROCK1 in translocating RhoE between 
cytoplasm and nucleus was determined with the statistical analysis, which is Student t-test (*) 
(p < 0.05). 
 
 
 
 84 
 
1 2 3 4 
 
(-) Y27632 (10µM) 
(-) Gӧ6976 (2.5µM) 
 
(+) Y27632 (10µM) 
(-) Gӧ6976 (2.5µM) 
 
(-) Y27632 (10µM) 
(+) Gӧ6976 (2.5µM) 
 
 
(+) Y27632 (10µM) 
(+) Gӧ6979 (2.5µM) 
 
5 6 7 8 
 
(-) Y27632 (10µM) 
(-) Gӧ6976 (2.5µM) 
 
 
(+) Y27632 (10µM) 
(-) Gӧ6976 (2.5µM) 
 
(-) Y27632 (10µM) 
(+) Gӧ6976 (2.5µM) 
 
 
(+) Y27632 (10µM) 
(+) Gӧ6979 (2.5µM) 
 
(Pre-treatment for 3 h) 
  
1 2 3 4 
 
(-) PMA (100 nM) 
 
(-) PMA (100 nM) 
 
(-) PMA (100 nM) 
 
(-) PMA (100 nM) 
 
5 6 7 8 
 
(+) PMA (100 nM) 
 
(+) PMA (100 nM) 
 
(+) PMA (100 nM) 
 
(+) PMA (100 nM) 
 
(Treatment for 10 min) 
Note:  
(-) Y27632 (10µM) is replaced by PBS 
(-) Gӧ6976 (2.5µM) is replaced by DMSO 
(-) PMA (100 nM) is also replaced by DMSO 
 
Figure 19: Schematic diagram for the procedure of investigating the translocation of RhoE to 
the nucleus using pharmacological compound - ROCK inhibitor (Y27632), PKC inhibitor 
(Gӧ6976) and novel PKC activator (PMA). The verification of the experiment was 
determined by the localisation of endogenous RhoE in U87 cells in the control condition.   
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2.2.2.5 Localisation of RhoE in U87 Cells via Export-import Mechanism 
The preparation for the isolation of the nuclear fraction from cytoplasm is to confirm 
the hypothesis for the existences of the Nuclear Export Signal (NES) in RhoE. Leptomycin B 
(LepB) – the NES inhibitor, was introduced into U87 cells for 6 h to allow inhibition of NES, 
which might lead to RhoE accumulation within the nuclear region. 1.0 million unit cells were 
cultured in 100 mm diameter of dishes for a series of concentration starting from 0.0 nM up to 
15.0 nM. The U87 cell was cultured for 24 h before being treated with LepB. Then, whole cell 
lysate, nuclear and cytoplasmic fractions of U87 cell were prepared 6 h post-LepB treatment. 
The samples underwent SDS-PAGE, transferred to PVDF membrane and subjected to 
immunoblotting. 
Besides that, the isolation of the nuclear fraction from cytoplasm was also prepared to 
investigate the existence of Nuclear Localisation Signal (NLS) in RhoE. Three (3) 150 mm 
diameter dishes were pre-coated with animal gelatine 0.1 % (w/v) to allow stratified and 
optimum growth of U87 cells before transfection. Each plate was assigned for the in vitro 
culture of 2.85 million units of U87 cells that were incubated overnight until they reached 60-
70% confluence and ready for transfection. RhoE wild-type (RhoEWT) and RhoE double 
mutants (RhoET173R/V192R) were transfected into U87 cells with FLAG-tagged RhoE epitope. 
The overexpression vector that contains empty vector (EV) is also applied for the control of 
experiment using mammalian expression vector, pCMV5 with FLAG-tagged. The serum-free 
medium was replaced with complete medium 8 h post transfection (Wallenstein et al. 2010). 
The nuclear and cytoplasmic fractions of the U87 cell were prepared 42 h post-transfection.  
FLAG-RhoE was pulled down from a combination of nuclear and cytoplasmic 
fractions of the transfected U87 cells. In order to perform this experiment, the cell fractions 
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from each transfected U87 cells were utilised in co-immunoprecipitation (Co-IP) to pull down 
RhoE and protein binding partners using FLAG antibody. Then, the Co-IP samples then 
underwent SDS-PAGE, transferred to PVDF membrane and subjected to immunoblotting. 
 
2.2.2.6 Transient Transfection of RhoE Constructs into U87 Cells 
The U87 human glioblastoma cells line were cultured in Dulbecco’s modified Eagle 
medium (GIBCO) containing [+] 4.5g/L D-Glucose and [+] L-Glutamine. This medium is 
also supplemented with 10 % (v/v) foetal bovine serum (FBS). The cells were left to grow in a 
humidified incubator with 5 % CO2 at 37 C for 24 h before transfection. Lipofectamine 
PLUS LTX Reagent was utilised according to the manufacturer’s instructions (Life 
Technologies, Invitrogen).  
The ratio of plasmid DNA to liposome is 2.5µg DNA: 5µL Lipofectamine LTX: 2.5 
µL PLUS Reagent were optimised using FLAG-tagged wild-type RhoE (RhoEWT) before 
proceeding with the actual experiment using another RhoE mutant plasmid. As a result,       
300 000 unit cells were consistently grown on the animal gelatine pre-coated coverslips, as 
well as in the six wells tissue culture plates  (p6 well) at the beginning of the transfection 
experiment. The serum-free medium was replaced with a complete medium after 8 h post 
transfection. 
After transfection, the cells were harvested for the preparation of whole cell lysate, 
nuclear and cytoplasmic fractions at 42-44 h post-transfection. The lysates and cell fraction 
were also prepared in similar manner as described in Section 2.2.1.2, followed by blot 
analysis (see Section 2.2.1.5 -2.2.1.8). The preparation of coverslips for FLAG staining      
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(see Section 2.2.1.13) was also conducted at the same time. Later, the quantity of transfected 
cells for each mutant is calculated for the percentage (%) of FLAG-RhoE expressed by 
dividing by the total number of cells. The experiment was conducted in triplicates (n = 3), 
where at least 250 cells were counted per coverslips, followed by statistical analysis. 
 
2.2.2.7 Immunoprecipitation Followed by Mass Spectrometry Analysis 
RhoE was immunoprecipitated from a nuclear extract of glioblastoma cells.  
According to Shimwell et al. ( 2009), the immunoprecipitated proteins can be separated by 1D 
SDS PAGE and protein bands stained with Coomassie blue. Protein bands can be excised 
from the gel and the proteins digested into peptides for identification (Newton et al. 2008). 
Using reverse HPLC coupled to an ion trap mass spectrometer, it is possible to identify 
peptides belonging to the proteins in an immunoprecipitated sample by comparing the 
recorded peptide fragmentation pattern with database of peptide in FASTA (Lodge et al. 
2007). Novel binding proteins that interact with RhoE are found by BLAST the sequence of 
peptides to the bioinformatics database.  
 
2.2.2.8 Bioinformatics Analysis on The List of Genes Found from RhoE Pulled-down 
Assay 
This study used Database for Annotation Visualisation and Integrated Discovery 
(DAVID), as well as Search Tool for the Retrieval of Interacting Genes (STRING) for this 
analysis. Both databases, DAVID and STRING facilitate the clustering for the abundance of 
the gene into a more comprehensive set of functional annotation tools. The biological 
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explanation from a huge genes list was initially interpreted by DAVID (Huang et al. 2008). 
Then, the biological processes at the cellular level and systematic characterisation were 
predicted by looking into protein-protein assemblies according to physical and functional 
interactions using STRING (Szklarczyk et al. 2015).  
Later, DAVID is also applied to disclose the list of interacting proteins that are essential in 
brain tumour development or implicates the diversity of glioma subtype for this research. The 
analysis of genes signature and profiling in identifying related biomarkers for particular 
diseases is done using DAVID tools (Huang et al. 2002). This application was also used for 
the intensive search of individual domain and motif of the specific protein. Besides that, 
DAVID could also confirm the determination for the functional group of gene by guiding the 
investigation with appropriate pieces of literature and adapting into the alternative gene 
description (Huang et al. 2009). 
 
2.3 Statistical analysis 
This study repeated all the experiments for at least three times (n = 3) except for 
certain individual experiments. The data were evaluated using appropriate statistical test 
depending on the variability of the samples and treatment. Welch Two Sample t-test was used 
for paired samples, ANOVA one-way for multiple samples followed by Tukey Kramer 
procedure and ANOVA two-factor with replication; whereas multiple comparisons were 
carried out using Tukey-HSD post-test for variety samples and multiple interactions. The 
differences were considered statistically significant if the p value is at least below than 0.05 or 
indicated by the asterisks:  (*) p < 0.05  or (**) p < 0.01  or (***) p < 0.001  or                  
(****) p < 0.0001 (Crawley 2005). 
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CHAPTER 3 
RHOE REGULATES CELL CYCLE AND APOPTOSIS                                                   
IN U87 HUMAN GLIOBLASTOMA CELLS  
 
3.1 Introduction 
Alteration of Rho GTPase signalling pathway often occurs in malignant growth and 
cancer development. It is known that the dysregulation of Rho proteins could promote 
uncontrolled cell proliferation, resistance to apoptotic stimuli, neovascularization or tumour 
cell motility, invasiveness and metastasis. David et al. (2012) suggested that the inhibition of 
Rho, Rac and Cdc42 could block cell cycle progression. However, it is important to question 
whether the restriction occurs during the transition from G1 to S-phase or G2 to M-phase on 
each cell type. The main limitation is the lack of explanation regarding how the cell 
proliferation in healthy cell lines and literally ill cells are affected by RhoE. 
Besides that, Rho proteins also regulate the furrow formation that takes part in the 
assembly of the actin-myosin network. A model was postulated by Su et al. (2003) that the 
initial positioning of the cleavage furrow during cytokinesis is partly specified by p190 
RhoGAP. They discovered that the overexpression of p190 RhoGAP could alter the cleavage 
furrow position and split it into unequal daughter cell, followed by uneven furrow contraction 
and formation of multiple nuclei. Moreover, phosphorylation of p190 RhoGAP is also 
dependent on the mitotic kinases, and Cdk1 is responsible to down-regulate the GAP activity. 
RhoE can also antagonise p190 RhoGAP; alternatively, this GAP protein could indirectly 
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increase the GTPase activity of RhoA. Consequently, the activated RhoA during the absence 
of RhoE may lead to the activation for the signalling pathway of 
RhoA/ROCK1/LIMK/Cofilin. As a result, the activated ROCK1 could aid the contraction and 
membrane blebbing during the late execution phase of apoptosis (Peris et al. 2012). 
Previous work by Ryan et al. (2012) discovered that the depletion of RhoE could lead 
to hyper proliferation of cells, suppress apoptosis and inhibit cell differentiation in 
keratinocytes. Several researchers also investigated similar case involving RhoE in cell cycle, 
apoptosis and differentiation. However, the impacts of protein are inconsistent. For instance, 
Peris et al. (2012) demonstrated the positive role of RhoE in regulating cell differentiation. In 
contrast, Poch et al. (2007) revealed the negative role of RhoE in regulating cell proliferation 
and apoptosis. In brief, it is confirmed that the role of RhoE is hugely relevant in cell 
proliferation and cell death.  
This chapter focuses on the role of RhoE in regulating the cell cycle and apoptosis in 
U87 human glioblastoma. This study is interested in investigating RhoE in the cell cycle and 
apoptosis using the endogenous RhoE in glioma cell lines in vitro, which is advantageous 
compared to the exogenous system. According to Poch and co-workers (2007), overexpress 
RhoE by transfecting adenovirus (Ad-RhoE) in U87 human glioblastoma cells can be 
manipulated for an extrapolation study. The endogenous RhoE might simulate the real 
condition of brain tumour as it has the ability to mimic the basal level of RhoE in GBM. 
 
 91 
 
3.2 Results 
3.2.1 RhoE Regulates the Cell Cycle of U87 Cells  
This experiment determined the evaluation of cell cycle by looking at the number of 
cells entering the synthesis-phase (S-phase). The cells were cultured in gelatine pre-coated 
coverslips in the 6 well tissue culture plates. 48 h post-RhoE knockdown, the cells were 
introduced with BrdU (Bromodeoxyuridine) for an hour. The U87 cells, which individually 
enter the S-phase were identified by the ability of the DNA of this glioma cell incorporating 
BrdU. The labelling is accurate as BrdU could incorporate into the chromatin of genomic 
DNA at only the S-phase whilst the cells are proliferating. Then, thymidine is replaced with 
BrdU and it is incorporated into the DNA of cycling cells during the labelling period. 
The U87 cells were stained with an anti-BrdU antibody and a green fluorescence 
secondary antibody to assess the number of cells in the S-Phase. The BrdU positive cells were 
detected by FITC under an epifluorescence microscope. The nucleus was stained with DAPI 
which gives the total number of U87 human glioblastoma cells for each area; whereas 
individual cell that have BrdU incorporated defined with green fluorescence represents the 
newly synthesised cellular DNA. Figure 20 shows the results. The presence of RhoE could 
maintain the number of cells entering the S-phase which is demonstrated by the control oligo 
using non-silencing control. In contrast, U87 cells with depleted RhoE showed the decrease in 
the number of cells entering the S-phase. 
Further analysis was done to evaluate the number of BrdU positive cells by 
determining the percentage of cells the entering S-phase (%) out of the total number of cells 
counted. Figure 21 shows the data regarding the loss of RhoE expression in U87 cells that 
could lead to the decrease in the number of cells entering the S-phase. Based on the 
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histogram, the ability of cells entering the S-phase is persistent at 35% in the control condition 
when RhoE is present. On the other hand, the U87 cells with RNAi-mediated depletion of 
RhoE; using both oligos, RhoE oligo A and RhoE oligo B, showed less than 20% cells 
entering the S-phase.  
The number of cells entering the S-phase was reduced about half (1/2) in the absence 
of RhoE. A statistical analysis was done (see Section 2.3) to check the significant difference 
between the presence of RhoE and RhoE depleted U87 cell. This experiment was conducted 
in triplicate (n = 3), where the minimal total cell numbers counted were 250 and the 
coverslips were prepared in triplicates for each experiment. The differences between control 
(Control Oligo) and RhoE knockdown conditions (RhoE oligo A and RhoE oligo B) were 
statistically significant (p < 0.05). 
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Figure 20: Less cell number entered S-phase indicated by the green fluorescence of BrdU in 
RhoE depleted U87 cells (RhoE oligos, A and B) compared to the cells with the presence of 
RhoE (Control oligo).  The cell nuclei were stained with DAPI where the same field is 
observed for BrdU uptake. The images represent the three separate experiments (n = 3). 
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Figure 21: The loss of RhoE expression in U87 cells has resulted in the decreased number of 
cells entering the S-phase. The percentage of U87 cells in S-phase was analysed and the mean 
values are presented. The error bars show the standard error of the mean (S.E.M) for each 
datasets of three separate experiments (n = 3), where 250 cells were counted in each of the 
three coverslips. The differences are significant between the silencing RhoE and control oligo 
(*) (p < 0.05). The statistical analysis was performed using ANOVA single factor.  
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3.2.2 RhoE Regulates Apoptosis in U87 Cells 
 A study on apoptosis during the depletion of endogenous RhoE was also conducted 
using U87 human glioblastoma cells. Although, many researchers used different drugs and 
analysis method, the experimental design in this study was modified and used an alternative 
apoptotic inducer; Cis-diamminedichloroplatinum (II) or cisplatin. This chemical has been 
widely used in cancer chemotherapy (Torigoe et al. 2005). This chemical compound was 
selected due to its potential activity to induce genotoxic stress against solid tumours such as 
ovary, testis, head, lung and neck (Kartalou and Essigmann 2001).  
A preliminary study was done on the effect of cisplatin, in stimulating genotoxic stress 
in U87 cells with the presence of RhoE, as well as during RhoE depletion. Prior to the 
treatment with cisplatin, the U87 cells were transiently transfected with siRNA oligos to 
generate RhoE-depleted U87 cells, and they were cultured for approximately 48 hour. A non-
silencing control was transfected into U87 cells as the control of the experiment. The whole 
cell lysates were prepared 16 hours after being treated with cisplatin at a constant 
concentration of 50 µM.  
Then, these lysates were separated by SDS-PAGE and immunoblotted with the 
antibodies against caspase 3, cleaved caspase 3 and RhoE, as well as -tubulin as a loading 
control. Figure 22 shows that RhoE depleted U87 cells are more sensitive towards cisplatin 
compared to U87 cells with the presence of RhoE. The results show that cleaved caspase 3 
was elicited at three (3) different molecular weights of 11, 15 and 17 kD in RhoE depleted 
U87 cells using RhoE oligo B. In contrast, the knockdown RhoE using RhoE oligo A was not 
successful based on the RhoE blot. This is because, RhoE bands still appear at 27 kD and 29 
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kD, and similar observation was also found in non-silencing control condition. Relatively, 
fewer cells died with the presence of RhoE. 
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Figure 22: Preliminary results on apoptosis show that RhoE depleted U87 cells are more 
sensitive to cisplatin. There is no result of RhoE blot for the condition without cisplatin due to 
shortage of sample. For the condition with cisplatin treatment, RhoE was almost entirely 
depleted using RhoE oligo B whereas RhoE oligo A reached approximately quarter 
knockdown. 
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Caspase 3 
Cleaved caspase 3 
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  b) RhoE blot 
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3.2.3 RhoE Regulates Apoptosis but Independent ROCK1 
Further investigation was done to determine whether the interaction between RhoE 
and ROCK1 is crucial during apoptosis. Y27632 [(1)-(R)-trans-4-(1-aminoethyl)-N-(4-
pyridyl) cyclohexane carboxamide dihydrochloride] is commonly used as a specific inhibitor 
of Rho-associated coiled-coil forming protein serine/threonine kinase (ROCK) family of 
protein kinases. This experiment also used Y27632 to investigate whether it inhibits the 
interaction of RhoE with the kinase domain of ROCK1. In principle, Y27632 inhibits ROCK1 
by competing with ATP and binds to the kinase, particularly at the catalytic site (Ishizaki et al. 
2000). Then, the Y27632 compound prevents ROCK1 from forming the autoinhibitory loop 
and disrupts the interaction with p190 RhoGAP. Thus, membrane blebbing is blocked and the 
cell is prevented from entering the apoptosis pathway. 
In this study, the occurrence of apoptosis was detected based on the intrinsic pathway 
where caspase 9 functions as an initiator for the caspase cascade; and caspase 3 for the 
execution phase of the caspase cascade. Figure 23 shows the results of immunoblot images for 
both caspases regarding the detection of apoptotic marker. As shown in Figure 23 (A) and 
(B), t=0 is defined as 48 h post-knockdown and it is the starting point in introducing Y27632; 
whereas t=48 is defined as 96 h post-knockdown and the end point for the treatment of 
Y27632. Cisplatin was added to the cells 78 h post-knockdown in between the starting point 
and end point to promote apoptosis. Y27632 compound was fixed at either 0 M or 5 M, 
and a series of cisplatin was used between 0 to 50 µM. The titration of both chemical 
compounds is labelled horizontally for caspase 9 and caspase 3 blots. Each lane represents the 
sample of the whole cell lysate that is accordingly loaded to the following titration series: 
0Y0C, 0Y25C, 0Y50C, 5Y0C, 5Y25C and 5Y50C. Y is Y27632 and C is cisplatin.  
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Figure 23 (A) shows the full length of caspase 9 and it was completely intact in both 
conditions of either NSiC or siRhoE at the beginning of the experiment (t=0). However, at the 
end of the experiment (t=48), siRhoE showed the loss of full length caspase 9 at 47 kD for 
each titration tested, excluding 5Y25C. The cleaved caspase 9 was elicited at 35 kD at every 
concentration tested in siRhoE. Consequently, the RhoE depleted U87 cells using RhoE oligo 
B did not show the inhibition effect of ROCK1 in preventing apoptosis, and the cells were 
dead as indicated by the formation of cleaved caspase 9. It was found that the full-length 
caspase 9 was intact and expressed more at each titration in NSiC.  
Parallel observation was found using caspase 3. Figure 23 (B) shows the full length of 
caspase 3, as well as cleaved caspase 3 indicating that apoptosis underwent the execution 
phase in siRhoE. The three different bands of 15, 17 and 19 kD appeared at each titration 
tested in siRhoE with 15 kD, showing the strongest signal compared to the other two cleaved 
caspase; which are 17 kD and 19 kD. Moreover, the half part of the full length caspase 3 still 
remained at 35 kD, showing that the execution pathway is still progressing during the time of 
sampling. Contrary to siRhoE, the cleaved caspase 3 was not detected in control condition 
(NSiC). The caspase 3 eventually remain intact even when there is more expression at 35 kD, 
which is consistent with the increased concentration of cisplatin with or without ROCK 
inhibitor.  
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Figure 23: The occurrence of apoptosis was detected based on the intrinsic pathway, where 
caspase 9 functions as the initiator of caspase cascade; and caspase 3 for the execution phase 
of caspase cascade.  
 (A): Apoptotic marker detection of the full length caspase 9 that remains intact at 47 kD in 
Control Oligo (NSiC), but entirely lost in RhoE depleted U87 cells (siRhoE) (except at 5µM 
Y27632/ 25 µM Cisplatin) and it was replaced with cleaved caspase 9 that was elicited at 35 
kD. This blot is a representative for this single experiment (n = 1). 
(B): Apoptotic marker detection of the full length caspase 3 that remains intact at 35 kD in 
NSiC, but partially degraded in siRhoE with the formation of cleaved caspase 3 that was 
elicited at 15 kD. However, there is an exception for siRhoE at 5 µM Y27632/ 25 µM 
Cisplatin, and the full length caspase 3 was quarter degraded with the formation of cleaved 
caspase 3 at three different molecular weight; which are 15, 17 and 19 kD. This blot is a 
representative for three separate experiments (n = 3). 
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Further analysis was conducted via densitometry using image J to quantify the loss of 
full length, as well as the formation of cleaved caspase 3. This study has also made a 
comparison between control (NSiC) and Rho depleted U87 cells (siRhoE). The semi-
quantitative analysis is essential to validate the presence of apoptotic marker, particularly 
caspase 3 as this is an indicator that the cells underwent late stage of apoptosis. Figure 24 (A) 
and (B) show the densitometry of full length and cleaved caspase 3 respectively, to observe 
the effect of RhoE in regulating apoptosis.  
The differences between control (NSiC) and RhoE knockdown conditions (siRhoE) 
were not statistically significant for the full length caspase 3 (ns) (p > 0.05); except during the 
titration of 0Y50C and 5Y50C (**) (0.001 < p < 0.01). RhoE depleted U87 cells was severely 
affected by cisplatin though in the presence of Y27632 for the titration 5Y50C if compared to 
5Y25C (**) (0.001 < p < 0.01).  In contrast, the cleaved caspase 3, siRhoE was significantly 
different from NSiC. ANOVA two factors with replication were performed in both datasets 
(NSiC and siRhoE). Then, multiple comparisons were carried out using Tukey-HSD post-test 
for increasing concentration of cisplatin in the U87 cell’s system. The effect of cisplatin was 
significant in siRhoE to induce apoptosis as indicated by the asterisks (****) p < 0.0001 (see 
the histogram in Figure 24 B).  Nevertheless, there were no significant differences between 
the conditions without or with Y27632 treatment in both the presence of RhoE or RhoE 
knockdown conditions (ns) (p > 0.05).  
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(B) Cleaved caspase 3  
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Figure 24: The densitometry analysis of late-stage apoptotic marker (execution pathway); the 
caspase 3 using Image J. (A) Semi-quantitative analysis to compare full-length caspase 3 
between siRhoE and NSiC when increasing the concentration of cisplatin with and without 
the presence of ROCK inhibitor, Y27632. There were no significant different for the full 
length caspase 3 (ns) (p > 0.05); except during the titration of 0Y50C and 5Y50C (**)      
(0.001 < p < 0.01). The siRhoE was severely affected by cisplatin though in the presence of 
Y27632 for the titration 5Y50C if compared to 5Y25C (**) (0.001 < p < 0.01).  (B) Semi-
quantitative analysis to compare cleaved caspase 3 between siRhoE and the NSiC when 
increasing the concentration of cisplatin with and without the presence of ROCK inhibitor, 
Y27632. The difference between NSiC and siRhoE as well as the increased concentration of 
cisplatin compared to without cisplatin were considered statistically significant for cleaved 
caspase 3 with (****) p < 0.0001. These data are representatives for three separate 
experiments (n = 3). 
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3.2.4 RhoE is Essential in Attenuating Genotoxic Stress in Glioma 
The previous section describes the end of apoptosis, which is manifested by the 
execution phase based on the detection of the apoptotic marker, including the loss of full-
length caspase 3 and formation of cleaved caspase 3. The previous experiment (see Section 
3.2.3) investigated apoptosis by using pharmacological approach that targeting either 
metabolite or intermediate compound during caspase cascades. However, the investigation 
was limited and only focused on the implication of signalling pathway at the intracellular 
level. Previous research did not explore the mechanisms that inhibit apoptotic machinery at 
the gene level. Hence, this section intended to understand the resistance mechanisms that 
prevent chromatin condensation. It is hoped that this experiment could explain how RhoE is 
relevant in regulating apoptosis at the molecular level, particularly in preventing DNA 
damage in glioma.  
Ryan (2010) reported that RhoE expression is induced by a number of apoptosis-
inducing stimuli, including camptothecin, cisplatin and UVB irradiation. In addition, the 
researcher also emphasised that RhoE is also a transcriptional target of tumour suppressor 
protein p53, which supposed to promote apoptosis, and induces RhoE transcription in 
response to DNA damage. This study also obtained a similar observation when the treatment 
of cisplatin led to enhance RhoE expression in U87 cells. However, increasing RhoE 
expression did not elevate apoptosis but a contrary result revealed when genotoxic stress was 
attenuated in control condition using non-silencing control oligo.  
Figure 25 showed that relatively cisplatin encourages more expression of RhoE but 
maintain cell survival in control condition. The siRhoE has relatively capable underwent 
apoptosis with or without cisplatin. The result exhibited in Figure 25 also suggested that 
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increased cisplatin concentration activates the caspase 3 cascade activity in knockdown RhoE 
condition; particularly at the concentration of 25 µM (the fifth lane). Consequently, the 
caspase 3 encourages cleaved of 160 kD endogenous ROCK1 protein into a 130 kD ROCK1 
fragment. The previous study by Jie et al. (2015) observed similar findings with this 
experiment by which they used gene knockout mouse as a model. They demonstrated that 
depletion of RhoE increased the activity of ROCK1 and its downstream effectors in mouse 
hearts. As a result, the mouse suffered from apoptotic cardiomyopathy and heart failure. 
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Figure 25: RhoE is essential in attenuating genotoxic stress in glioma. RhoE also reflects the 
stability of ROCK1 expression at 160 kD in control condition. Cisplatin could induce the 
expression of RhoE in U87 cells but it did not happen in RhoE knockdown condition. The 
ROCK1 blot in RhoE knockdown condition presented with smaller molecular weight at 
approximately 130 kD  that represents the  caspase-cleaved form of ROCK1. 
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Coleman and Olson (2002) characterised the apoptotic phenotype cells by the 
alteration cell morphologies, including shrinking cell, condensed chromatin, membrane 
blebbing and formation of apoptotic bodies. This section is about evaluation of chromatin 
condensation to confirm that RhoE depleted U87 cells underwent apoptosis. The condensed 
chromatin was visualised via microscope under DAPI fluorescence. The data was assessed by 
using colony counter application, which is a plug in software in Image J. The evaluation of 
cell damage is based on the percentage (%) of apoptotic cells over the total cell number. 
Figure 26 shows the percentage (%) of nuclear condensation over the total cell number based 
on the titration of both chemical compounds, Y27632 (Y) that was fixed at either 0 M or 5 
M, and a series of the cisplatin (C) used between 0, 25 and 50 µM.  
The basal level of apoptosis in the control experiment, which is (0Y0C), showed that 
RhoE depleted U87 cells (siRhoE) underwent apoptosis and could reach up to 56 % compared 
to the control U87 cell (NSiC) with the result of 11 %. Therefore, the apoptosis in siRhoE is 
five (5) fold more than NSiC for this titration. In comparison, the mean percentage of cells 
undergoing apoptosis without cisplatin with the presence of Y27632 (5Y0C) showed a 
decreasing trend where 46 % of the cells were apoptotic in the siRhoE condition and 2 % 
were apoptotic in NSiC. Thus, apoptosis in siRhoE is approximately 20 fold more than NSiC 
for this titration.  
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Figure 26: The evaluation of nuclear condensation in U87 cells with the presence of RhoE 
(NSiC) and in RhoE depleted U87 cells (siRhoE). The U87 cells were observed under DAPI 
fluorescence and the percentage (%) of condensed nuclei was calculated by counting the 
number of cells that appeared condensed at the nucleus, which is then divided by the total 
number of cells grown on coverslips. The difference between NSiC and siRhoE were 
considered statistically significant for condended nuclei, since (****) p < 0.0001. This data is 
representatives for three separate experiments (n = 3). 
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The next level of titration was 0Y25C. The cells in siRhoE condition achieved 65 % of 
apoptosis, compared to NSiC with the result of 13%. The apoptosis in siRhoE with the 
presence of ROCK inhibitor (5Y25C) was maintained at five (5) fold more than NSiC. 
However, there is a decreasing trend for the number of percentage, which is 50% in siRhoE 
compared to 10% in the NSiC. 
The final titration was 0Y50C, with the highest apoptosis percentage of 75 % in 
siRhoE condition, and there is a drastic increase until up to 30 % in NSiC.  The percentage of 
apoptosis in siRhoE is 2.5 fold more than NSiC. However, the addition of ROCK inhibitor, 
(5Y50C), has reduced the apoptosis percentage to 60 % whilst NSiC also decreases to 13 %.  
The results in this experiment supported the preliminary findings that were discussed 
in Section 3.2.2. The data from this experiment showed that RhoE plays a positive role in 
tumour development and becomes potential tumour enhancer. Apoptosis could occur with the 
absence of cisplatin when RhoE was depleted (siRhoE). In contrast to the observation in 
Section 3.2.3, the interaction between RhoE and the kinase domain of ROCK1 is important as 
indicated by the decreased percentage of condensed chromatin in the control cell (NSiC) 
(5Y25C, 5Y50C). However, the apoptotic cells were easily detached from the coverslips and 
increase the risk of cells being washed out during sampling and immunostaining. Overall, the 
importance of RhoE interaction with the kinase domain of ROCK1 during apoptosis is still 
ambiguous. 
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3.3 Discussion  
The results have proven that RhoE could regulate the cell cycle progression, as well as 
interfering with the regulation of apoptosis. However, this effect is not exclusive for the U87 
cell line. This effect can be seen in other cell types, including keratinocytes that is a typical 
healthy cell as well as other abnormal cell, such as human tumour-derived cell lines. Poch et 
al. (2007) found that overexpressed RhoE in U87 human glioblastoma cells showed the 
disorganisation of actin cytoskeleton, rounding of the cell body, and formation of long 
branches between adhered cells. Besides that, the role of RhoE in glioblastoma was found to 
be consistent with earlier studies by Bohmer et al. (1996). These researchers primarily 
disclosed that a proper assembly of actin cytoskeleton is essential to proceed beyond the G1 to 
S-phase checkpoint of the cell cycle (Bohmer et al. 1996).  
Then, Poch et al. (2007) evaluated the effect on cell cycle progression via depletion of 
endogenous RhoE from the U87 cell system. The previous work particularly assessed the 
overexpression of RhoE via the manipulation of the adenoviral system to transfect RhoE in 
U87 cells, and this methodology might resulted in altered gene expression. Besides that, the 
alteration might implicate numerous genes that regulate the signalling pathways during cell 
proliferation. The limitations of the previous system by RhoE overexpression are modified. 
Alternatively, the gene depletion methodology was used in this study as a different tool. As a 
result, this approach reduced the interference by other genes in regulating signalling pathway 
during cell cycle progression.  
Poch et al. (2007) also found that RhoE expression induces the decrease in 
phosphorylation of Rb and the expression of cyclin D1. It is assumed that other genes (Cdk1 
in association with of CDK4 or CDK6) might also be affected by RhoE overexpression during 
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the transfection, as well as altering the progression of the cell cycle. Coleman et al. (2004) 
also observed the effect of Cdk in cell proliferation. They suggested that cell cycle 
progression is controlled by the complexes formation of cyclins and cyclin-dependent kinases 
(Cdks). The association of cyclins to Cdks has led to phosphorylation of retinoblastoma (pRb) 
pocket proteins. As a consequence, the assembly of all these regulatory proteins promotes the 
advancement of the cell cycle and switches on the cell proliferation (Coleman et al. 2004). 
Lonjedo et al. (2013) had identified the potential involvement of RhoE in cell cycle 
regulation, in which RhoE and p27 levels decrease after the overexpression of F-box protein 
Skp2. They found that there is a region between amino acids 231 and 240 of RhoE that 
facilitates the cells when entering the S-phase, which are Skp2 and Skp2-interacting domain. 
Section 1.4.2.2 describes this phenomenon in detail. According to this finding, they proposed 
a mechanism in which Skp2 regulates its protein levels via proteasomal degradation of RhoE 
to control cellular proliferation (Lonjedo et al. 2013).  
Poch et al. (2007) found that RhoE plays a significant role in the apoptosis of U87 
human glioblastoma cells. They isolated the live and dead cell populations using flow 
cytometry method. The extracellular surface of apoptotic cells were tagged by fluorescence 
label using Annexin-V (A5), which is a protein that specifically interacts with lipid 
phosphatidylserine (PS) in the cell membrane. During cell sorting, the membrane integrity 
was measured and segregated by either A5 or propidium iodide (PI); or A5 and 7-Amino-
actinomycin D (7AAD) to differentiate between late apoptotic and necrotic cells. 
 A5 alone could only recognise early apoptotic cells. This approach was used to 
monitor whether RhoE-expressing U87 cells were dying by as a cause of apoptosis or 
necrosis. Besides that, investigations on other tumour cell lines were also conducted, and they 
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consistently observed apoptosis in the presence of RhoE (Poch et al. 2007). Nevertheless, the 
results in this study contradicted with Poch and coworkers (2007). The results in this study are 
similar with Ongusaha et al. (2006) and Boswell et al. (2007). Both studies also used siRNA 
to inhibit RhoE expression. Following the silencing of RhoE, they introduced apoptotic 
stimuli, and found RhoE depletion could increase the level of apoptosis (Boswell et al. 2007). 
In principle, cisplatin enters the cells and its chloride ligands are replaced by water 
molecules which in turn form a positively charged aqueous species that can react with 
nucleophilic sites on the intracellular macromolecules to form protein, RNA and DNA 
adducts (Torigoe et al. 2005). Due to the cytotoxic mode of action that formed these 
intermediates, these would activate several signal transduction pathways, including ATR, p53, 
p73 and MAPK (Siddik 2003).  
The presence of endogenous RhoE in U87 cells might accelerate the crosslink between 
adducts intermediate and intra strand. Subsequently, the communication or response for 
apoptosis activation is terminated. Some information on how RhoE regulates and which 
pathway involved remain unclear but the possible effect from the crosslinking could promote 
DNA replication and RNA transcription. As a result, the stimulation of S-phase entry of the 
cell cycle is activated. Thus, cell proliferation is prolonged in glioma cells, at the same time 
block the apoptosis. 
Another important aspect in monitoring apoptosis is to consider the p190 RhoGAP 
levels. This GTPase activating protein can regulate the apoptotic response in cancer cell line 
through its regulation of ROCK1 (Ludwig and Parsons 2011). The multinucleation and 
dendritic formation are two phenotypes that commonly appear within cells that are 
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undergoing apoptosis. They also confirmed that p190 RhoGAP could affect the downstream 
effectors of Rho, including caspases that have important role in mediating cell death.  
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CHAPTER 4 
LOCALISATION OF RHOE TO THE NUCLEUS OF U87 CELLS                                  
IS INDEPENDENT ROCK1 
4.1 Introduction 
RhoE is predominantly a membrane-associated protein and in particular this signalling 
protein localised to the Golgi membrane. In principle, intracellular localisation of RhoE 
requires a post-translational modification including farnesylation and prenylation activity. As 
described in Section 1.4.3.4, the process of geranylgeranylation (GG) is involved during 
farnesylation for shifting the localisation of RhoE between cytoplasm and plasma membrane. 
Previous work by Madigan (2008) has affirmed this principle and demonstrated that the 
stimulation of protein kinase C (PKC) enables the activation of electrophoretic mobility shift 
of RhoE to enable the enrichment at the internal membranes.  
Phosphorylation of RhoE is important in regulating either its localisation or stability. 
PKC and ROCK1 are two types of kinases that are well known in interacting with RhoE, 
and this was described in detail in Section 1.4.3.4. For instance, Riento et al. (2005) found 
seven sites of ROCK1phosphorylation of RhoE were identified in vitro, and from that finding 
Ser11 was phosphorylated in response to the extracellular stimuli. An extended study by Riou 
et al. (2013) found that both of these kinases shared similar phosphorylation site at Ser11 and 
Ser240 of the amino acids sequence of RhoE. 
One of the limitations with the available literature is that it does not explain the reason 
RhoE was found in the nucleus. Although all previous works indicated a specific interaction 
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between RhoE and both kinases; ROCK1 and PKC, but none of the literature revealed if 
these interactions are involved during the translocation RhoE to the nucleus. Therefore, this 
experiment is crucial to reveal new insight and determine the mechanism involved during the 
localisation of RhoE to the nucleus of U87 cells.  
The inadequate information about nuclear RhoE localisation was the main loophole in 
this study. The mechanism is essential to explain the preliminary finding (Ryan, 2010) as of 
the reason RhoE interacts with several proteins in nuclear processes such as MCM3, MCM5, 
SSRPI, CAF1 and ORC3L (Section 1.5). The mechanism by which RhoE shuttles across 
nuclear pore complex (NPC) of U87 cells is one of the main concerns in this study. The idea 
is to manipulate the knowledge on RhoE post-translational modification. For example, the 
process of phosphorylation that accompanied farnesylation via prenylation could possibly 
modulate the translocation of RhoE between nucleus and cytoplasm.  
RhoE is a small molecular weight protein that is either 27 or 29 kD. Therefore, in 
canonical situation, the interaction of RhoE with importin or exportin is speculated as none 
essential as it should be able to traverse alone between cytoplasm and nucleus across the NPC 
via passive diffusion. However, the engagement of integrin may regulate downstream 
signalling of RhoE by inducing the PKC-mediated phosphorylation and enlarging the 
protein size. Although the size of RhoE is less than 45 kD, the complex formation with other 
protein partners can possibly increase the size. Thus, it is possible to have an interaction with 
specific nucleocytoplasmic machinery. This chapter also includes the discussion on 
probability for the existence of either nuclear export signal (NES) or nuclear localisation 
signal (NLS) in RhoE. 
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4.2  Results 
4.2.1 The Localisation of Endogenous RhoE to the Nucleus of Glioblastoma 
Section 2.2.1.2 describes the cytoplasmic and nuclear fractions that were prepared and 
blotted for RhoE expression to analyse the localisation of RhoE. Figure 27 shows the results 
in which a clean separation of nuclear and cytoplasm based on expression of the nuclear lamin 
A/C and the absence of -tubulin in the nuclear fraction. RhoE was observed in every fraction 
including whole cell lysate, nuclear fraction and cytoplasm. This experiment revealed that 
RhoE is expressed in the nucleus and cytoplasm. Figure 27 shows the blots that represent the 
immunoblots of three (n = 3) separate experiments, in which the results of each replicate are 
identical.  
Following the western blotting, densitometry analysis was carried out using Image J 
software to evaluate the distribution of RhoE between nucleus and cytoplasm in U87 cell. 
Figure 28 shows the results. It was found that RhoE antibodies could recognise two distinct 
forms of RhoE at 27 kD and 29 kD. The higher molecular weight band is believed to 
represent the phosphorylated form of RhoE (Madigan et al. 2009). Therefore, the RhoE that is 
in the nucleus is probably predominantly phosphorylated.  
Riento et al. (2003) suggested the use of RNAi to knockdown the expression of RhoE 
to confirm both bands are indeed RhoE and no other members of the Rnd family. In 
agreement with this finding, RNAi knockdown of Rnd1 has no effect on the expression of 
these two bands (Ryan and Hotchin, unpublished). Figure 30 (Section 4.2.2) shows the loss of 
both bands, suggesting that both forms are RhoE. A higher molecular weight RhoE (29 kD) 
was equally distributed in both nuclear and cytoplasmic fractions. However, the lower 
molecular weight RhoE (27 kD) was mainly localised to the cytoplasm (p < 0.05).   
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Figure 27: Localisation of endogenous RhoE in U87 cells. U87 cells were lysed in a buffer 
containing Nonidet P-40. Nuclear and cytoplasmic fractions were prepared, separated by 
SDS-PAGE and immunoblotted with an antibody against RhoE. The effective isolation of 
nuclear and cytoplasmic fractions was confirmed using antibodies against Lamin A/C and -
tubulin respectively. These blots represent the results of three separate experiments (n = 3). 
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Figure 28: The relative distribution of endogenous RhoE in U87 cells. A semi-quantitative 
analysis was conducted using Image J to quantify the RhoE intensity for the blot in Figure 
4.1. It was also used to determine the distribution of the different forms of RhoE (27 kD and 
29 kD). A statistical analysis was done on paired datasets (29kD and 27 kD) of each fraction 
using Welch Two Sample t-test. These data represent results for the three separate 
experiments (n = 3), and the difference are significant with the p value is below than 0.05 (*) 
(p < 0.05). Error bars indicate the standard error of the mean (S.E.M) and they are shown 
alongside the histogram of each mean value. 
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Next, the localisation of RhoE in other cell lines was also investigated. This study 
used two different cell lines derived from gliomas, which are cell line 11 and cell line 21 
(Häǹgerstrand et al. 2011) and a normal human keratinocyte cell line (HaCaT). Figure 29 
shows the results of the study. In HaCaT, RhoE is mainly located in the cytoplasm, consistent 
with the data from other normal mammalian cell lines. However, RhoE was highly expressed 
in the nuclear fractions of U87 cells and cell line 11 suggesting a nuclear localisation of RhoE 
may be important in glioma. Interestingly, RhoE was not expressed in glioma cell line 21. A 
parallel study in the Hotchin lab observed differential expression of Rho GTPases (including 
RhoE) during progression of glioma (Clarke et al. 2015).  Thus, it is possible that a difference 
in expression of RhoE is a reflection of tumour subtype (Häǹgerstrand et al. 2011).  
The localisation of RhoE in the nucleus of U87 and glioma Type 11 cells suggests that 
RhoE may have a nuclear function during brain tumour progression. The nuclear functions 
may include regulating gene transcription, the replication of DNA and protein trafficking but 
further investigation is required to validate the presumption. Madigan et al. (2008) reported 
that other Rho subtypes are localised mainly to the cytoplasm. For instance, RhoA and RhoC 
are shown localised to the plasma membrane and the cytoplasm whereas RhoB is primarily 
found in the early endosomes. However, none of these cited literature emphasised on the fact 
that RhoE was found in the nucleus. 
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Figure 29: Localisation of RhoE in multiple types of cell lines. Each cell lines were lysed in a 
buffer containing Nonidet P-40. Then, nuclear and cytoplasmic fractions were prepared, 
separated by SDS-PAGE and immunoblotted with an antibody against RhoE. An effective 
isolation of nuclear and cytoplasmic fractions was confirmed using antibodies against Lamin 
A/C and -tubulin respectively. Glioma Type 11 and 21 are cell lines that represent brain 
tumour at Stage IV, whereas HaCaT represents normal cell type.  
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4.2.2 Confirmation of Endogenous RhoE Localisation to the Nucleus of U87 Cells 
The RNAi technique that specifically knockdown the expression of RhoE has used 
two different oligos; RhoE oligo A and RhoE oligo B. Prior to further used, each vial of oligo 
purchased was first validated as described in Section 2.2.2.1. The application of RNAi is 
convenient to confirm the expression of endogenous RhoE in the nucleus of U87 cells.      
Figure 30 shows that RhoE was expressed in the nucleus. The knockdown of RhoE using both 
oligos has led to the loss of RhoE in either the nucleus or cytoplasm.  
Subsequently, the localisation of RhoE to the nucleus was confirmed using 
epifluorescence microscopy via staining cells with an anti-RhoE/Rnd3 antibody. As seen in 
Figure 31 (A), panel (c), shows that RhoE was localised to both nucleus and cytoplasm of 
NSiC of the U87 cells. The microscopy images proving that RhoE’s appearance in both cell 
compartments were consistent with the western blot data.  
Panel (c) in Figure 31(B) and Figure 31 (C) demonstrate that the fluorescence of RhoE 
was not found in both compartments of U87 cells, in either nuclear or cytoplasmic region. The 
microscopy images that show RhoE’s disappearance using siRhoE found that U87 cells were 
successfully knocked down using both oligos, RhoE oligo A and RhoE oligo B.  
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Figure 30: The localisation of endogenous RhoE to the nucleus of U87 cells was confirmed 
using RNAi. U87 cells were knockdown for 48 h and cells were harvested from the 6 wells 
plate. U87 cells were lysed in buffer containing Nonidet P-40. Next, nuclear and cytoplasmic 
fractions were prepared, separated by SDS-PAGE and immunoblotted with an antibody 
against RhoE. An effective isolation of nuclear and cytoplasmic fractions was confirmed 
using antibodies against -tubulin. These blots represent the results of three (3) separate 
experiments (n = 3). 
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(A) Control  oligo 
 
 
(B) RhoE oligo A 
 
 
(C) RhoE oligo B 
Note:  
(a) Actin staining  (b) Nuclear staining  (c) Rnd3/RhoE staining  (d) Merged images 
 
 
Figure 31: Immunostaining of U87 cells (A) U87 cell of non-silencing control using control 
oligo, (B) RhoE depleted U87 cells using RhoE oligo A (C) RhoE depleted U87 cells using 
RhoE oligo B. U87 cells were cultured for 24h on coverslips and observed under 
epifluorescence microscope at 40 x magnification. (a) U87 cells staining for F-actin observed 
at 900 ms exposure under Texas Red isothiocyanate (TRITC) filter (b) U87 cells staining for 
nuclear observed at 100 ms exposure under DAPI filter (c) U87 cells staining for Rnd3/RhoE 
observed at 400 ms exposure under FITC filter (d) U87 cells’ merged image of three (3) 
different fluorescence filters (TRITC/DAPI/FITC). 
(a) (b) (c) 
(c) 
(a) 
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4.2.3  The Expression of RhoE in the Nucleus of U87 cells is ROCK1 Independent 
The knockdown of ROCK1 via RNA interference (RNAi) was applied using ROCK1 
oligo 6 (ROCK1 6) and ROCK1 oligo 7 (ROCK1 7) for 48 h to investigate the interaction of 
ROCK1 and RhoE in brain tumour development. At the same time, Control oligo (NSiC) was 
used as the control condition for U87 cell.  
After 48 h of incubation, the whole cell lysates were prepared for nuclear and 
cytoplasmic fractions (see Section 2.2.12). Following this, lysates were immunoblotted for 
ROCK1 to confirm knockdown and RhoE for identifying the effect on expression and 
localisation after disruption of ROCK1: RhoE interaction. The lysates were also 
immunoblotted for -tubulin as a loading control. Figure 32 shows the results. These blots 
represent four separate experiments (n = 4) in which the result for every replicate was 
consistent.  
As shown in Figure 32, the first three lanes on the left are for the whole cell lysates. 
Control oligo shows less expression of RhoE in the first lane when compared to ROCK1 
depleted U87 cell that is located in the second and third lanes. This observation is consistent 
with the other three lanes at the right side (cytoplasmic fraction), where more RhoE are 
expressed after ROCK1 is knocked down. However, nuclear RhoE appeared to be evenly 
expressed either when ROCK1 is presence or depleted from U87 cell. The individual 
expression of nuclear RhoE in ROCK1 depleted U87 cell and in the presence of ROCK1 are 
represented using three lanes in the middle, in which this observation is true for both oligos.  
A semi-quantitative analysis on the expression level of RhoE after ROCK1 
knockdown was carried out using Image J from four replicated experiments (n = 4). The 
results on densitometry analysis using image J for RhoE intensity after ROCK1 knockdown in 
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U87 cell are shown in Figure 33, where the intensity of RhoE for each fractions of nuclear (29 
kD) and cytoplasm (29kD and 27 kD) was determined.  
ROCK1 in U87 cell was depleted using oligos, ROCK1 oligo 6 and ROCK1 oligo 7 
for 48 h. The statistical analysis using Tukey Kramer procedure to one factor ANOVA 
showed that RhoE intensity in nuclear consistently increased when compared to the cytoplasm 
for the higher band. The differences between ROCK1 depleted U87 cells and the control oligo 
are statistically significant (p < 0.0001). 
The RhoE intensity was increased nearly to 2/3 fold (from 40 unit to 60 unit) in 
ROCK1 depleted U87 cell when compared to the control condition. Although more RhoE 
expression were observed in the U87 cell after ROCK1 depletion, more 29 kD form of RhoE 
was translocated to the nucleus, whereby increased the accumulation of 27 kD form of RhoE 
in the cytoplasm. Thus, the RhoE translocation from cytoplasm to the nucleus is not hindered 
even in the absence of ROCK1, indicating that the RhoE function is independent of ROCK1. 
Table 8 shows the exact ratio of each U87 cells condition. 
The proportion of nuclear RhoE (29 kD) to cytoplasm (29 kD) in ROCK1 depleted 
U87 cells shows a value of more than 2.00, which indicates the upper band of RhoE (29 kD) 
was mainly translocated to the nucleus. In contrast, the ratio of upper band nuclear RhoE     
(29 kD) over lower band of cytoplasmic RhoE (27 kD) is less than 0.7; this indicates that the 
lower band of RhoE (27 kD) was accumulated in cytoplasm of ROCK1 depleted U87 cells. 
The distribution of RhoE for both bands (29 kD and 27 kD) in control oligo was relatively 
equal by ratio ~ 1.00. 
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Figure 32: The localisation of RhoE to the nucleus is not regulated by ROCK1. U87 cells 
were lysed in a buffer containing Nonidet P-40. Next, nuclear and cytoplasmic fractions were 
prepared, separated by SDS-PAGE, and immunoblotted with an antibody against RhoE. The 
effective isolation of nuclear and cytoplasmic fractions was confirmed using antibodies 
against SSRPI and -tubulin, respectively. 
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Figure 33: The acceleration of 29 kD RhoE in the nuclear proportionate to 27 kD of RhoE in 
cytoplasms were observed in ROCK1 depleted U87 cells. The densitometry of RhoE using 
Image J in ROCK1 depleted U87 cells using both oligos were compared to the control 
condition. The intensity unit for nuclear and cytoplasmic RhoE from each condition is 
arbitrary and it was respectively normalised either to SSRPI or to -tubulin as the loading 
control. Error bars indicate standard error of the mean (S.E.M) of each data set according to 
U87 cells conditions. This study employed statistical analysis using Tukey Kramer procedure 
on one factor ANOVA for the whole dataset from four replicated independent experiments     
(n = 4) (p < 0.01). 
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Table 8: The data are the mean ratio that listed along with standard error of the mean (S.E.M) 
from four replicated independent experiment (n = 4). 
U87 cells 
condition 
Nuclear RhoE (29 kD)     
over cytoplasm (27 kD) 
Nuclear RhoE (29 kD)    
over cytoplasm (29 kD) 
Control oligo 1.076  0.075 1.412  0.081 
ROCK1 oligo 6 0.575  0.029 2.01  0.207 
ROCK1 oligo 7 0.623  0.068 2.468  0.306 
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4.2.4  ROCK1 Interaction is Not Solely Required for Nuclear Localisation of RhoE 
Other than immunoblot analysis, the RhoE protein localisation in U87 cell was also 
visualised under epifluorescence microscopy after applying immunofluorescence staining, 
which was previously described in Section 2.2.1.12. RhoE in the control condition (NSiC) 
and ROCK1 depleted U87 cell using ROCK1 oligo 7 (siROCK1) were stained using anti-
Rnd3/RhoE antibody. Figure 34 shows the results on microscopic images. The RhoE 
expression was represented using a green fluorescence of FITC in Figure 34 (A) and 34 (B) - 
panel (c).  
The microscopic image of U87 cells in siROCK1 shows that RhoE was expressed in 
both regions, which are nucleus and cytoplasm, and it was slightly more intense than the 
NSiC. Microscopic images only display a qualitative observation but comparison to the 
previous observation is still done (refer to Section 4.2.3; Figure 32) particularly on the RhoE 
blot of whole cell lysate and cytoplasm. Results on immunoblotting and immunostaining are 
consistent in terms of more RhoE is expressed in siROCK1 compared to NSiC. More 
expression of RhoE indicates that the absence of ROCK1 affected the stabilisation of RhoE in 
glioblastoma. However, the mechanism of RhoE stabilisation in siROCK1 is still unclear. 
This experiment also investigated the stress fibre formation demonstrated by F-actin 
staining. The depletion of ROCK1 has led to the loss of actin and stress fibre as shown in 
panel (a) of Figure 34 (B). In contrast, actin cytoskeleton was maintained in NSiC, as shown 
in panel (a) of Figure 34 (A). ROCK1 is antagonising the function of RhoE by inducing the 
loss of stress fibre from U87 cells. Data on stress fibre phenotype also demonstrated that 
ROCK1 was successfully depleted using siRNA oligo 7 via RNAi technique.  
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(A) NSiC 
 
 
(B) siROCK1 
 
Note:  
(b) Actin staining 
(c) Nuclear staining  
(d) Rnd3/RhoE staining  
(e) Merged images 
 
Figure 34: Immunostaining of U87 cells show the interaction of ROCK1 is not solely required 
for the RhoE localisation to the nucleus. (A) U87 cell of non-silencing control (NSiC) using 
control oligo, (B) ROCK1 depleted U87 cells (siROCK1) using ROCK1 oligo 7. U87 cells 
were cultured for 48h on coverslips and observed under epifluorescence microscope at 40 x 
magnification. (a) U87 cells staining for F-actin observed at 900 ms exposure under Texas 
Red iso-thiocyanate (TRITC) filter (b) U87 cells staining for nuclear observed  at 100 ms 
exposure under DAPI filter (c) U87 cells staining for RhoE observed at 400 ms exposure 
under FITC filter (d) Merged image of U87 cells at three different fluorescence filters 
(TRITC/DAPI/FITC). 
(a) (b) (c) (d) 
(a) (b) (c) (d) 50 µm 50 µm 50 µm 
50 µm 50 µm 50 µm 
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4.2.5  Localisation of RhoE to the Nucleus is Alternatively Dependent on PKC 
A previous study by Riento et al. (2003) observed that only ROCK1 binds to and 
phosphorylates RhoE efficiently, and that was the first evidence that showed ROCK1 has a 
specific target for RhoE. However, Chardin (2006) stated that inhibition of ROCK1 did not 
completely block RhoE phosphorylation. Instead, other kinases such as protein kinase C alpha 
(PKC) might be involve in this process particularly in phosphorylating Ser11.  
In agreement to Chardin (2006), the phosphorylation sites that were predicted in RhoE 
were conducted via NetPhos 2.0 Server (Technical University of Denmark, 2012). Results 
retrieved from this server indicate that RhoE is highly specific as a substrate of kinases. Based 
on the sequence position, more than twenty (> 20) phosphorylation sites were predicted in 
RhoE, in which fifteen sites for serine (Ser), and four sites each for both threonine (Thr) and 
tyrosine (Tyr), respectively. Appendix 3 shows the details on phosphorylated peptide 
sequences for each residue of amino acid (Ser, Thr and Tyr).  
Phosphorylation of RhoE by ROCK1 is primarily required in enabling the 
translocation of protein complexes, from cytosol to the plasma membrane (Madigan 2008). 
The similar hypothesis was presumed essential in translocating RhoE to other regions 
intracellularly, including to the nucleus. The treatment of U87 cells with selective 
serine/threonine inhibitors was probably relevant to validate this hypothesis. Therefore, 
Y27632 and Gö6976 were used in this experiment to inhibit ROCK1 and PKC in the U87 
cells, respectively.  
Y27632 is an ATP competitive inhibitor for ROCK1 and ROCK2 in vitro and the 
inhibition is specific for the catalytic site of both kinases (Yu et al. 2012). Meanwhile, 
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Gö6976 is an ATP competitive PKC inhibitor that is specific for Ca2+-dependent PKCα and 
PKCβ1 isozymes (Madigan et al. 2009). Post 24 h culture of U87 cells lines, they were treated 
with pharmacological inhibitors of either ROCK1 or/and PKC using Y27632 (10 µM) and 
Gӧ6976 (2.5 µM), respectively for 3 h. Following the 3 h inhibition of conventional ROCK1 
and PKC, the translocation of RhoE was investigated during the activation of PKC using 
PMA (100 nM) for 15 min. After the designated treatment was completed, U87 cells were 
lysed in a buffer containing Nonidet P-40. Then, nuclear and cytoplasmic fractions were 
prepared, separated by SDS-PAGE, and immunoblotted with an antibody against Rnd3/RhoE.  
The localisation of RhoE to the nucleus of U87 cells is shown in Figure 35. 
Accordingly, RhoE intensity was measured and the arbitrary result is shown in Figure 36. In 
Figure 35, the SSRPI blot was also detected at 92 kD, which is a loading control for nuclear 
RhoE. It represents the equal protein loaded for each sample from the nuclei. Meanwhile, -
tubulin was not found in any sample tested for nuclear fraction and this finding has proven 
that the separation of nuclei from cytoplasm was successful. 
The localisation of RhoE to the cytoplasm is shown in Figure 37. Again, RhoE 
intensity was measured and the arbitrary result is shown in Figure 38 (A) for 29 kD form of 
RhoE and Figure 38 (B) for 27 kD form of RhoE. There was also a clean separation of nuclear 
from cytoplasm, as SSRPI disappeared in cytoplasm. Then, -tubulin was also applied to 
cytoplasmic fraction where bands appeared vice-versa to the nuclei.  
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Figure 35: Localisation RhoE to the nucleus is alternatively dependent on PKC without the 
assistance of ROCK1. RhoE (29kD) almost completely lost from the nucleus by the 
stimulation of conventional PKC with or without RhoE interaction to ROCK1. A clean 
separation of the nuclear RhoE from the cytoplasm was confirmed based on the empty -
tubulin blot and the appearance of each individual band at the SSRPI blot. Y27632 used to 
inhibit the interaction of ROCK1 to RhoE, enabled individual interaction with PKC. Gӧ6976 
prevented the interaction of PKC to RhoE, allowed a sole interaction with ROCK1. 
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    Treatment of pharmacological inhibitor in the nuclear of U87 cells  
 
Figure 36: Histogram of nuclear RhoE intensity according to the treatment of 
pharmacological inhibitor in U87 cells. RhoE almost completely lost from the nucleus by the 
stimulation of conventional PKC with or without RhoE interaction to ROCK1. The 
activation of novel PKC by PMA exhibit an increased the upper band of RhoE (29kD) and it 
remains more in the nucleus consistent with the active conventional PKC during ROCK1 
inhibition. The intensity unit for nuclear RhoE (29 kD) from each condition was normalised 
to SSRPI as the nuclear loading control. The RhoE intensity was compared between U87 cells 
treated with pharmacological inhibitors, (+) Y27632 or/and (+) Gӧ6976 for 3 h (      ) and the 
activation of PKC with the addition of PMA in U87 cells (      ). The statistical analysis for 
two factor ANOVA with replication involving multiple comparisons uses Tukey’s HSD 
procedure to identify the difference within the whole datasets of three independent experiment 
(n = 3) (****) (p < 0.0001). 
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Figure 37: Immunoblot of cytoplasmic fraction of U87 cells post 24 h culture.  Cells were 
treated with pharmacological inhibitors either ROCK1 or/and PKC using Y27632 (10 µM) 
and Gӧ6976 (2.5 µM) for 3 h. Then, the activation of PKC was applied using PMA (100 nM) 
for 15 min. U87 cells were lysed in a buffer containing Nonidet P-40. Then, nuclear and 
cytoplasmic fractions were prepared, separated by SDS-PAGE and immunoblotted with an 
antibody against Rnd3/RhoE. -tubulin blot detected at 55 kD is a loading control for 
cytoplasm that represents equal protein loaded for each sample from the cytoplasmic fraction. 
A clean separation of the cytoplasm is shown from the empty SSRPI blot. 
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Treatment of pharmacological inhibitor in the cytoplasm of U87 cells 
(A) 
              
Treatment of pharmacological inhibitor in the cytoplasm of U87 cells 
(B) 
 
Figure 38: (A) Data presents the mean of cytoplasmic RhoE intensity as determined from 
triplicate experiment (n = 3) of western blotting of the cytoplasm. The intensity unit of 
cytoplasmic RhoE (29 and 27 kD) was normalised to -tubulin as the loading control. The 
RhoE intensity was compared between U87 cells treated with pharmacological inhibitors, (+) 
Y27632 or/and (+) Gӧ6976 for 3 h (      ) and the activation PKC with the addition of PMA in 
U87 cells (     ). A statistical analysis using two factor ANOVA with replication involving 
multiple comparisons usesTukey’s HSD procedure to identify the difference within the whole 
datasets of three independent experiment (n = 3). 
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A semi-quantitative analysis was conducted to evaluate the distribution of RhoE 
intracellularly. The statistical difference was to determine whether the treatment of ROCK 
and PKC inhibitor could affect the RhoE translocation. Figure 36 and Figure 38 (A) and (B), 
show the results on densitometry analysis for nuclear and cytoplasm. The intensity of RhoE 
upper band (29 kD) in the nuclei in Figure 36 was calculated by normalising the value of 
RhoE intensity from each condition (1 to 8, Section 2.2.2.4) to SSRPI. A similar method was 
used to determine the intensity of RhoE upper band (29 kD) and lower band (27kD) in the 
cytoplasm that are shown in Figure 38 (A) and (B). The cytoplasmic RhoE intensity from 
each condition (1 to 8, Section 2.2.2.4) was calculated by normalising the value to -tubulin.  
Figure 36 is implied to nuclear RhoE (29 kD), in which the differences for activation 
of novel PKC was found crucial to translocate RhoE out from the nucleus for the control and 
(+) Y27632.The difference is statistically significant (****) (p < 0.0001) (n = 3). Next, Figure 
38 (A) shows the upper band of RhoE (29 kD) in the cytoplasm. The difference for the 
activation of novel PKC was found unnecessary to translocate RhoE into the cytoplasm. The 
difference is not significant. Finally, Figure 38 (B) indicates the lower band of RhoE (27 kD) 
in the cytoplasm, and the activation of novel PKC was found not significant to translocate 
RhoE into the cytoplasm for the control and (+) Y27632; (+) Gӧ6976. The differences are not 
statistically significant for the control, and (+) Y27632; (+) Gӧ6976, respectively. Overall 
observation for this experiment (Figure 35-38) is to describe the details on the localisation of 
RhoE to the nucleus that is alternatively dependent on PKC instead of ROCK1.  
The first lane of the blot in Figure 35 had shown that endogenous RhoE localises to 
the nucleus of the U87 cell. Introducing 100 nM PMA to the cells activate the conventional 
PKC and promote loss of RhoE from the nucleus. Although the fifth lane of the same blot 
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showed that RhoE was invisible in the nuclear fraction, in Figure 37, the fifth lane has 
revealed more expression of RhoE in cytoplasms compared to the first lane of the same blot. 
Prior to the experiment, the phosphorylation status of RhoE was speculated due to interaction 
with either ROCK1 or PKC to alter the localisation of RhoE.  
Next, the second lane of the blot in Figure 35 indicated that the inhibition of ROCK1 
by adding 10 µM of Y27632 causes more expression of endogenous RhoE in the nucleus. 
However, the observation in the sixth lane of the same blot was against the second lane by 
which inhibition of ROCK1 followed by the activation of conventional PKC has led to a 
loss of RhoE from the nucleus. As compared to the sixth lane in Figure 37, more expression 
of RhoE was observed in cytoplasms. This result confirmed that PKC interaction with RhoE 
is essential to translocate RhoE between nucleus and cytoplasm even though without the 
assistance of ROCK1. 
Later, 2.5 µM Gӧ6976 was used to inhibit PKC in order to block its interaction with 
RhoE. The result shown in the third lane of the blot in Figure 35 has demonstrated that more 
expression of RhoE in the nucleus. In parallel, the seventh lane of the same blot also disclosed 
that the inhibition of conventional PKC followed by the activation of novel PKC in the 
presence of ROCK1 causes RhoE to accumulate in the nucleus. Consistently, the third and the 
seventh lane of the blot in Figure 37; both showed relatively similar expression of RhoE in 
cytoplasms. The effect of either conventional or novel PKC in regulating the localisation of 
RhoE in U87 cells demonstrated a consistent potential in both fractions, either nuclei or 
cytoplasm. 
Finally, the inhibition of ROCK1 and conventional PKC led to the accumulation of 
endogenous RhoE in the nucleus. The result is shown in the fourth lane of the blot in Figure 
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35. In contrast, result in the eighth lane of the same blot exhibited much loss of RhoE from 
the nucleus. The inhibition of ROCK1 and conventional PKC, followed by the activation of 
novel PKC enable the partial loss of RhoE from the nucleus. In parallel, the fourth lane of 
the blot in Figure 37 showed less 29 kD RhoE whereas the eighth lane of the same blot 
relatively showed more expression of both 29 kD and 27 kD RhoE in cytoplasms. In 
summary, this experiment confirmed that the localisation of RhoE to the nucleus is 
alternatively dependent on PKC without the assistance of ROCK1.  
 
4.2.6 Nucleocytoplasmic Transport is Essential for the Localisation of RhoE 
Nucleocytoplasmic shuttling process is a possible mechanism for the RhoE 
localisation to the nucleus. This transportation machinery is triggered by either the recognition 
of nuclear export signal (NES) or the nuclear localisation signal (NLS) by the exportin or 
importin, which was described Section 1.3.3. This hypothesis was presumed after considering 
that some of the translated proteins in the cytoplasm were assigned as the transcription factors 
and transported back to the nucleus. Both signals, either NES or NLS, are possibly important 
to enable the communication of RhoE with other interacting proteins partners. The 
communication is particularly important to enable the recognition of RhoE by the 
intermediator - nucleocytoplasmic transport receptor (NTR/KPN) for the localisation of RhoE 
intracellularly. However, the RhoE localisation to the nucleus that relies on the existence of 
NES and NLS has been poorly studied and needs validation.   
Prediction analysis on RhoE amino acids sequence was conducted to determine 
whether this protein consists of NES. An established FASTA format of RhoE protein 
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sequence was searched and copied from UniProtKB (see Section 1.4.1), then BLAST to the 
NetNES 1.1 server prediction programme: (http://www.cbs.dtu.dk/services/NetNES/). As a 
result, this prediction revealed a leucine rich region within point 68 to 75. There are eight 
amino acids in a sequence with the following prediction: TQRIEL73SL75. Appendix 4 shows 
further details on the NES prediction analysis. The molecular structure of RhoE was 
visualised as three dimensional individual proteins using PyMOL Molecular Visualisation and 
Figure 39 shows a clear visualisation of NES sequence of RhoE in 3D form.  
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Figure 39: NES predicted in human RhoE (pdb: 1M7B) is visualised at different orientations. 
The high resolution structure of RhoE that appears with the NES was visualised in PyMOL 
Molecular Visualisation and retrieved in PNG file format. The predicted NES 
(TQRIEL73SL75) in RhoE was indicated with labelled of amino acids, and the position in 3D 
is visualised at different directions. (A) NES sequence view at vertical axis (B) NES sequence 
view at diagonal direction (C) NES sequence view at skew position.  
 
 
(A) 
(B) (C) 
180 
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Figure 39 (A), (B) and (C) are the visualisation of NES at different directions. It is 
clear that NES is located at the periphery of RhoE protein folding structure. The existence of 
NES at peripheral position has made RhoE visible and enables the recognition by exportin. In 
addition, the leucine rich region of NES enhances exportin affinity to RhoE and it can 
accelerate the anchoring ability between these proteins complexes. Thus, this interaction is 
likely to be important for subcellular localisation of RhoE to exit the nucleus. The existence 
of NES in RhoE could possibly create a specific docking site for protein-protein interactions 
with the exportin.  
This experiment was conducted to look at the RhoE expression, and to determine 
whether the treatment with NES inhibitor could block this dynamic process. Nuclear and 
cytoplasmic fraction was prepared to confirm the hypothesis. In the beginning, 1.0 million 
units of U87 cells were cultured in 100 mm diameter of tissue culture dishes for a series of 
concentration, starting from 0.0 nM and up to 15.0 nM. U87 cell was grown for 24 h before it 
was treated with the NES inhibitor, Leptomycin B (LepB). The whole cell lysate, nuclear and 
cytoplasmic fraction of U87 cell were prepared for 6 h post LepB treatment (see Section 
2.2.1.2). The samples then underwent SDS-PAGE, transferred to PVDF membrane, and 
subjected for immunoblotting. Figure 40 (A) shows the scanned images of RhoE blots for 
whole cell lysate as well as individual subcellular fractions, nuclei and cytoplasm. Figure 40 
(B) and 40 (C) are loading control for this experiment. 
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(B) SSRPI blots 
 
 
 
 
 
 
 
 
 
 
 
(C) -tubulin blots 
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Figure 40: The RhoE expression in U87 cells is unaffected by the inhibition of NES. After 6 h 
treatment with the increased concentration of Leptomycin B (LepB) (0.0-15.0 nM), U87 cells 
were lysed in a buffer containing Nonidet P-40. Nuclear and cytoplasmic fractions were 
prepared, separated by SDS-PAGE and immunoblotted with an antibody against Rnd3/RhoE. 
The effective isolation of nuclear and cytoplasmic fractions was confirmed using antibodies 
against SSRPI and -tubulin respectively. These blots represent the result of only a single 
experiments (n = 1).  
(A) RhoE blots of the whole cell lysate, nuclear fraction and cytoplasm of U87 cells.  
(B) Nuclear loading marker; SSRPI blot detected at 92 kD is a loading control for nuclei 
representing equal protein loaded for each sample from the nuclear fraction. 
(C) Cytoplasm loading marker; -tubulin detected at 55 kD is a loading control for cytoplasm 
representing equal protein loaded for each sample from the cytoplasmic fraction. A similar 
loading maker was used for the whole cell lysate. 
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As shown in Figure 40 (A), there is relatively more expression of RhoE in the nuclear 
of U87 cells for 2.5 nM, 5.0 nM and 15.0 nM of LepB relatively than the control, 0 nM.  In 
contrast, U87 cells that were treated with 10.0 nM of LepB showed a similar expression with 
U87 cells without LepB treatment, 0 nM. The RhoE expression level fluctuated when 
increasing the dosage of LepB. SSRPI blots in Figure 40 (B) confirmed that each sample 
tested for nuclear fraction has been loaded equally in the Western blot. The whole cell lysate 
and cytoplasmic fractions also have similar findings. -tubulin blots in Figure 40 (C) was 
used as the loading marker for both fractions.   
The result in this experiment was contrary to the earlier speculation that NES is 
essential for the localisation of RhoE to the nucleus of glioblastoma. The expression was not 
affected by LepB as showed in Figure 40 (A) that the RhoE expression was inconsistently 
increased in U87 cells. The technical incompetence was not the reason for fluctuated 
expression of RhoE at 5.0 to 10.0 nM, and it was confirmed by loading markers, SSRPI in 
Figure 40 (B) for nuclei and -tubulin in Figure 40 (C) for the whole cell lysate and 
cytoplasm. The increased of LepB treatment did not affect the retention of this protein in the 
nucleus. The RhoE expression was independent of NES and low affinity to exportin, but it 
was possibly regulated at the gene level.  
In principle, one or two clusters of basic residues of NLS are recognised by the import 
receptor, importin. The RhoE destined for the nucleus possibly contains targeting sequences 
termed nuclear localisation signal (NLS). In principle, NLS is recognised by the adaptor 
molecule which is importin alpha (Imp). Then, this cargo then links to the carrier molecule 
or intermediate that is called importin beta (Imp). The complex of cargo protein            
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(RhoE-Imp-Imp) translocates into the nucleus crossing the nuclear pore within the nuclear 
envelope.  
Basically, the process of DNA delivery is internalised to the nucleus to allow RhoE 
overexpression. To understand the mechanism of nuclear-cytoplasmic machinery, this study 
used a number of FLAG-tagged RhoE cDNA constructs that have been generated by 
Komander et al. (2008). In brief, they constructed a variety of mutants that prevent RhoE 
from interacting with its potential protein binding partners including the importin. 
Manipulating these constructs in this study was beneficial in order to identify novel RhoE 
interacting partners in U87 cells. Identification and characterisation of gene modifications for 
individual mutants were described further in Chapter 5. One of the mutants generated allied 
with disruption of ROCK1: RhoE interface which is RhoE double mutants (RhoET173R/V192R) 
and these constructs were applied to U87 cells to investigate if localisation of RhoE to the 
nucleus was related to the interaction with either Imp or Imp. 
RhoE wild-type (RhoEWT) and RhoE double mutants (RhoET173R/V192R), both with       
FLAG-tagged RhoE epitope were transfected into U87 cells. Overexpression vectors 
containing empty vector (EV) were also applied for the control of the experiment using 
construct plasmid pCMV5 EV FLAG. As recommended by Wallenstein et al. (2010), a serum 
free medium was used at the beginning of the transfection to reduce the interference of growth 
factor by the presence of foetal bovine serum (FBS). Then, the serum free medium was 
replaced with a complete medium, 8 hours post transfection. The nuclear and cytoplasmic 
fractions of U87 cells were prepared for 42 hours post-transfection.  
Nuclear and cytoplasmic fractions were prepared for FLAG-RhoE pulled down assay. 
Co-Immunoprecipitation (Co-IP) technique was used to pull-down RhoE from a combination 
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of nuclear and cytoplasmic fractions of the transfected U87 cells. Three (3) tissue culture 
dishes with 150 mm diameter were pre-coated with animal gelatine 0.1 % (w/v) to allow 
stratified and optimum growth for U87 cells before the transfection process. Each plate was 
assigned for in vitro culture of 2.85 million units of U87 cells overnight until they reached     
60 % to 70 % confluent and ready for transfection. 
Further, these cell fractions were utilised for Co-IP to pull down the RhoE and 
interacting binding partners using FLAG antibody. At the same time, negative control for the 
Co-IP experiment was also conducted using the reagent blank without candidate protein 
sample. Then, yields from Co-IP samples underwent SDS-PAGE, transferred to PVDF 
membrane, and subjected for immunoblotting. Figure 41 shows scanned images of 
immunoblot for the cargo carrier, the Importin-7 (Imp), the FLAG-RhoE and RhoE blots for 
individual constructs. 
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Figure 41: Overexpressed RhoE in U87 cells (RhoEWT) shows high affinity to Imp, 
indicating that the nuclear localisation signal (NLS) existed in RhoE. RhoE wild-type 
(RhoEWT) and RhoE double mutants (RhoET173R/V192R) with FLAG-tagged RhoE epitope were 
transfected into U87 cells. Overexpression vectors containing empty vector (EV) were also 
applied for the control of the experiment using construct plasmid pCMV5 EV FLAG. Co-
Immunoprecipitation (Co-IP) technique was used to pull-down RhoE from a combination of 
nuclear and cytoplasmic fractions of the transfected U87 cells. At the same time, negative 
control for the Co-IP experiment was also conducted using the reagent blank without 
candidate protein sample. Then, yields from Co-IP pulled down assay went through SDS-
PAGE and immunoblotted with antibodies against Imp, Rnd3/RhoE, FLAG-RhoE and -
tubulin. These blots represent the results of a single experiment (n = 1). 
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From left, each lane in Figure 41 respectively represents the empty vector, which are 
RhoE wild-type (RhoEWT), RhoE double mutants (RhoET173R/V192R), and the negative control 
for the Co-IP. The first row shows the immunoblot of Importin-7 (Imp) and more expression 
was found in RhoEWT as compared to the empty vector. Although there was less expression of 
Imp in RhoE T173R/V192R, it was not totally depleted in the double mutants RhoE. The 
negative control for the Co-IP experiment shows a clear lane. 
Regarding transfection efficiency, both constructs performed the same level 
expression of RhoE. However, when looking at the FLAG-RhoE blot, there is a slight 
decrease for the FLAG-RhoE pull down by RhoE double mutants compared to the wild-type. 
-tubulin was used as the loading marker for each sample which shows that total protein was 
equally loaded. However, a cross reaction with IgG hyper-variable chain as indicated by the 
band that appeared at the negative control of Co-IP lane was ambiguous.  
 
4.3 Discussion 
Foster et al. (1996) had initially reported that the localisation of RhoE was to the 
plasma membrane of the post transfected COS7 cell. In agreement, Guasch et al. (1998) has 
supported this finding by demonstrating that RhoE was localised subcellular to the lateral 
membranes of the MDCK cells, and manifested the role of RhoE in cell-cell adhesion.  Later, 
Riento et al. (2003) also investigated the intracellular localisation of RhoE. They extended the 
research by manipulating the interaction of RhoE with ROCK1 and suggested that subcellular 
localisation of RhoE was not limited to the plasma membrane. Instead, they recommended 
that RhoE was also localised to the trans-Golgi network. They used COS7 cell to overexpress 
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RhoE and found that this protein was scattered on intracellular membrane such as in the 
perinuclear region, vesicular structure of Golgi complex and cytoplasm, despite the fact that it 
was primarily localised to the plasma membrane.  
A subsequent study was carried out by a similar working group led by Anne Ridley 
and they demonstrated that ROCK1 binds to and phosphorylates RhoE on seven sites (see 
Section 1.4.3.2). Overexpressed RhoE in COS7 cells showed that the phosphorylated form of 
RhoE was found only in the cytoplasm (Riento et al. 2005a). Further, Riento and the co-
workers found that non-phosphorylated RhoE was associated mostly with membranes in 
Swiss 3T3 fibroblasts, where it sequestered ROCK1 that was associated with myosin (Riento 
et al. 2005b). Moreover, they also studied endogenous RhoE in PDGF starved Swiss 3T3 as 
well as NIH 3T3 cells, induced RhoE phosphorylation at the specific site, Ser11. However, the 
localisation of RhoE in these cells after phosphorylation was unsuccessful due to the low 
expression level of RhoE (Riento et al. 2005b).  
After that, they used HeLa cells and carried out a similar PDGF starved stimulation to 
increase the phosphorylation of RhoE. As a result, they observed that RhoE was localised to a 
perinuclear region at the beginning of the stimulation but diffused to the cytoplasm after the 
phosphorylation (Riento et al. 2005b). A parallel observation was also demonstrated by 
Komander et al. (2008), in which they found that the cellular localisation of RhoE also altered 
as the phosphorylation was affected by ROCK1. Komander et al. (2008) suggested that 
ROCK1 promotes phosphorylation event to stabilise RhoE and prevent stress fibre assembly. 
Most recently Gomez et al. (2014) demonstrated that RhoE was found at the atypical part of 
the cytoplasm, between the nucleus and the ductal lumen of Leydig cells in testicular tissue. 
Nevertheless, neither of these studies mentioned that RhoE was found exactly in the nucleus. 
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Thus, the localisation of RhoE to the nucleus that was demonstrated in Section 4.2.1 and 
Section 4.2.2 is novel, and the finding is expected to bring a huge impact to the development 
of glioblastoma. 
ROCK1 is a well characterised serine/threonine kinase that functions downstream of 
RhoA to regulate the myosin light chain (MLC) by phosphorylating and blocking the activity 
of MLC phosphatase (Chardin 2006). ROCK1 also interacts with and phosphorylates RhoE as 
previously described in Section 1.4.3.2. Results in Section 4.2.3 and 4.2.4 show that ROCK1 
affected the stabilisation of RhoE in glioblastoma. However, the mechanism to stabilise RhoE 
in ROCK1 depleted U87 cells is poorly understood. A slightly similar research was conducted 
by Riento et al. (2005b) to verify whether RhoE protein stability is regulated by ROCK1 
phosphorylation. Riento et al. (2005b) tried to overexpress FLAG-tagged wild-type RhoE 
(RhoEWT) in COS7 cells with or without myc-D1 ROCK1. They consistently observed that 
the expression of ROCK1 could increase the amount of RhoE protein. Therefore, they 
concluded that ROCK1 phosphorylation increases the stability of RhoE. 
U87 cells treated with the ROCK inhibitor, Y27632 suggested that kinase activity of 
ROCK1 was not solely required for RhoE localisation to the nucleus as described in Section 
4.2.5. In principle, RhoE binds to the kinase domain of ROCK1 that is localised at the          
N-terminal region, besides blocking the kinase activity of ROCK1. The region of 76 to 375 in 
ROCK1 was not sufficient for RhoE binding as it also required extended residues, starting 
from 1 to 375 of amino acids within the N-terminal region of ROCK1. Consequently, the Rho 
binding domain (RBD) was hindered from RhoA binding due to the formation of an auto-
inhibition loop. As a result, RhoA was prevented from binding to ROCK1 when RhoE was 
bound to ROCK1. Loirand and co-workers (2006) also disclosed that the phosphorylation 
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state of RhoE did not affect the binding to ROCK1. Considering that U87 cells were treated 
with Y27632 to inhibit ROCK1 for 3h, followed by PMA to activate conventional PKC for 
15 min, these applications enabled translocation of RhoE to exit the nucleus and enter the 
cytoplasm. Thus, the result consistently showed that RhoE can also be phosphorylated by 
other kinases. 
 Results in Section 4.2.5 and literature review clearly show that RhoE is a substrate of 
both kinases, ROCK1 and PKC. However, ROCK1’s effect is antagonistic to PKC in 
terms of translocating RhoE in and out of the nucleus and the cytoplasm of U87 cells. As 
described in Section 1.4.3.4, ROCK1 and PKC are well known to share a common 
phosphorylation recognition sequence in RhoE; particularly at Ser11 and Ser240. The inhibition 
of either one of the kinases, PKC and ROCK1 with Gӧ6976 and Y27632 respectively, 
encouraged the localisation of RhoE to the nucleus. This is consistent with the treatment of 
both inhibitors that prevented RhoE from exiting this region. In contrast, the activation of 
conventional PKC which was not novel triggered the localisation of RhoE to the cytoplasm.  
On the other hand, the shuttling process of RhoE and subcellular localisation of either 
to the cytoplasm or the nucleus persistently occurred depending on the substrates availability 
or diverted to the downstream pathway that requires ROCK1: RhoE complexes. The 
accumulation of RhoE in the nucleus potentially indicates that this protein has NES at the 
particular region of its amino acids sequence. This study used Leptomycin B (LepB) as a 
specific inhibitor of NES and the results are shown in Section 4.2.6. This pharmacological 
inhibitor specifically targets at the chromosome region maintenance which is Crm-1-
dependent nuclear export (Mihlan et al. 2013).  
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Ideally, 24 h prior to the treatment of Leptomycin B, RhoE was synthesised in the 
nucleus, translated in the cytoplasm and transported back to the nucleus after phosphorylated 
by the kinases such as ROCK1. The introduction of LepB for 6 h into U87 cells might have 
inhibited NES and led to the RhoE accumulation within the nuclear region. Surprisingly, the 
increased LepB treatment did not affect the accumulation of this protein in the nucleus. RhoE 
expression was found independent to NES, but possibly regulated at the gene level, and RhoE 
possibly has low affinity to exportin. 
This chapter also revealed the preliminary evidence that transportation machinery with 
NLS is essential in translocating RhoE to the nucleus. After the failure to prove the existence 
NES in RhoE, another prediction analysis on RhoE amino acids sequence was conducted with 
the speculation that NLS exists in this protein. Simultaneously, an established FASTA format 
of RhoE protein sequence was searched and copied from UniProtKB (see Section 1.4.1), then 
BLAST to the cNLS mapper prediction programme: (http://nls-mapper.iab.keio.ac.jp/cgi-
bin/NLS_Mapper_form.cgi). This server predicted nuclear localisation signals (NLS) specific 
to the Imp  and Imp  pathways by calculating the level of NLS activity (NLS score).  
As a result, this prediction revealed a lysine (K) and arginine (R) rich region within 
point 207 to 242. There are thirty-six (36) amino acids in a sequence and the following is the 
prediction: 
R207NK209SQR212ATK215R216ISHMPSR223PELSAVATDLR234K235DK237A238K239SCT  
Appendix 5A has a detailed description on NLS prediction analysis. However, the 
visualisation of the NLS position in 3D form of RhoE using PyMol Molecular Visualisation 
software is unavailable. Although the predicted NLS residues were possibly truncated upon 
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crystallisation, it is important to obtain the verification of the hypothesis that NLS exists in 
RhoE. 
Results in Section 4.2.6 demonstrated that the overexpressed RhoE using wild-type 
construct in U87 cells required more carrier molecule or intermediates (Imp) to translocate 
RhoE when more RhoE was available due to overexpression in the cytoplasm. RhoE would 
be transported to the nucleus through nuclear pore complex (NPC) that immediately bound 
Imp, to the cargo carrier, Imp. In contrast, when interaction of RhoE to ROCK1 is 
disrupted, as indicated by U87 cells transfected with RhoE double mutants, there is less 
requirement for the binding to Imp. 
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CHAPTER 5 
IDENTIFICATION OF NOVEL RHOE INTERACTING PROTEINS 
 
5.1 Introduction  
In the previous chapter, RhoE has been identified to localise in the nucleus of U87 
cells and the translocation is independent ROCK1. In contrast, RhoE is rather dependent on 
either PKC or Imp to translocate between the cytoplasm and the nuclei.  U87 cells 
expressing endogenous RhoE at constant level is contrary to the report by Poch et al. (2007) 
that demonstrated low levels of RhoE expression in U87 cells. Due to this contradiction, the 
expression of RhoE needs to be increased; thus the U87 cells were transfected, starved for 8 
hours and then the cultures were serum stimulated for another 34 hours. In order to analyse 
the protein-protein interaction, the U87 cells were transfected with a number of different 
FLAG-tagged RhoE cDNA expression constructs.  
Apart from the interaction with ROCK1, PKC and Imp, the overexpression RhoE is 
also applied in an attempt to identify any potential novel interactions with nuclear proteins. 
This effort is based on preliminary finding by Ryan (2010) where RhoE interacts with several 
proteins that are involved in the nuclear processes which have been previously described in 
Section 1.5. For instance, she identified MCM3 and MCM5 as a part of hexamers subunit 
from the replicative helicase MCM2-7, which are essential for DNA loading. Moreover, she 
also identified ORC3L as a component of 6-subunit origin-recognition complex (ORC) that 
binds to the origin of replication and it is required in assembling pre-replication complex. 
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These nuclear proteins were essential during DNA replication that occurs at G1-phase as well 
as early S-phase of the cell cycle (Riera et al. 2013).   
The preliminary result on the existence of NLS in RhoE and interaction with Imp  as 
previously described in Section 4.2.6 also requires further explanation. Instead of utilising 
Co-IP, the immunoprecipitation technique was applied to pull down the overexpressed RhoE 
from the transfected U87 cells. Following this, the mass spectrometry analysis was carried out 
on the digested proteins, which have been isolated from RhoE pull-down assay. Liposomes 
reagent was used purposely for delivering the gene of interest to incorporate the genome of 
the host. Wong et al. (2007) mentioned that transfection efficiency is dependent on the 
transport system of gene delivery to the host cells. The mechanism by which cationic 
liposome - DNA forming complexes that are internalised and delivered to the nucleus have to 
be determined prior to transfection (Wong et al. 2007). For example, previous researchers 
found several forms of endocytosis that are involved in DNA uptake such as clathrin-
mediated, caveolae-mediated and macropinocytosis. Thus, endocytosis became the most 
preferred route for cell entry (Rejman et al. 2005).  
In addition, the previous chapter has briefly mentioned about a number of FLAG-
tagged RhoE cDNA constructs that have been generated by Komander et al. (2008). They 
constructed a variety of mutants that prevent RhoE from interacting with its potential protein 
binding partners. Modifications of individual mutants were listed in Table 9. Amongst all, one 
of the mutants generated allied with disruption of ROCK1: RhoE interface which is RhoE double 
mutants (RhoET173R/V192R) and needs further investigation. The most exciting about the double mutant 
is their inabilities to pull down ROCK1. Besides, the construct also sustains a loss of stress 
fibre similar to the wild-type phenotype indicated by cell become round up when expressed. 
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Table 9: Mutagenesis of ROCK1: RhoE Interface (Adapted from Komander et al. 2008) 
Types of 
mutants 
Amino acids 
mutated 
Effect on interaction between RhoE and ROCK1 
 
RhoE WT 
 
Nil 
       
Enable interact with ROCK1 
Loss of stress fibres when highly expressed 
 
 
RhoE V56Y 
 
Valine 56 to 
Tyrosine 
 
Mutation of effector site residues 
Maintain stress fibres (dominant negative RhoE 
mutants) 
No inhibition on binding to ROCK1 
 
 
RhoE 
T173R/V192R 
 
Threonine 173 (6 
strand) and Valine  
192 (5 helix) to 
Arginine 
 
 
Unable to pull down ROCK1 
No difference in actin organisation compared to the 
wild-type 
Induced strong reduction of stress fibres (cell 
become 
round up) 
 
RhoEV57Y 
 
Phenylalanine 57 to 
Tyrosine 
 
 
Mutation of effector site residues 
Maintain stress fibre (dominant negative RhoE 
mutants) 
 
 
RhoEY60A 
 
Tyrosine 60 to 
Alanine 
 
Mutation of effector site residues 
No difference in actin organisation compared to the 
wild-type 
Induced strong reduction of stress fibres (cell 
become   round up)  
 
 
RhoEV192R Valine 192 (5 
helix) to Arginines 
Unable to interact with ROCK1 (normal interaction 
occurred in the absence of additional AMP-PNP) 
No difference in actin organisation compared to the 
wild-type 
Induced strong reduction of stress fibres (cell 
become   round up) 
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5.2 Results 
5.2.1  Overexpressed RhoE in the U87 Cells   
The experiment used overexpression vectors that contain wild-type (wt) mouse RhoE 
(pCMV5 FLAG RhoEWT), empty vector (EV) as a control (pCMV5 EV FLAG) and double 
mutant constructs (pCMV5 FLAG RhoET173R/V192R). The immunofluorescence staining for 
FLAG-tagged RhoE of transfected U87 cells with each construct was conducted in the 
experiment as previously described in Section 2.2.1.13. Figure 42 (A), (B) and (C) shows the 
results of the observation under the epifluorescence microscope for each of RhoE mutant, 
allied with the wild-type and empty vector.  
Figure 42 (A) shows that the U87 cells were transfected with empty vector (plasmid 
pCMV5 EV FLAG) which is the result of the empty fluorescence in FLAG staining. This is 
the control for the experiment to ensure that the results on other mutants are not false positive. 
Thus, it means that the primary and secondary antibody conjugated-fluorophore (goat anti 
mouse conjugated FITC) are bound to be very specific to the FLAG-tagged RhoE fusion 
protein.  
Figure 42 (B) shows that the U87 cells were transfected with wild-type (wt) mouse 
RhoE (pCMV5 FLAG RhoEWT) and demonstrated a bright green fluorescent in FLAG 
staining. Both cell compartments were well stained with FLAG-RhoE in either nuclear region 
and/or cytoplasmic region. Based on the observation on actin staining, it is showed that 
overexpressed RhoE has induced the loss of stress fibres as most of the cells became round 
shaped rather than flattened morphology with tentacle-like projections that scatter in the 
marginal area of cells as it was commonly found in non-transfected U87 cells.  
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Figure 42 (C) shows the observation of U87 cells that are transfected with double 
mutants RhoE which is consistent with the result in Chapter 4 (see Section 4.2.5). 
Accordingly, a strong green fluorescence of FITC mainly appeared in the nucleus. This 
observation shows that the interface disruption between RhoE: ROCK1 has led to RhoE 
localisation to the nucleus. 
As shown in Figure 42, principle method used to recognize successful transfection of 
RhoE wild-type (RhoEWT) and RhoE double mutants constructs (RhoET173R/V192R) into the 
U87 cells are by the appearance of the FLAG-tagged RhoE epitope. The overexpression 
vectors containing empty vector (EV) were also applied as a control of the experiment using 
construct plasmid pCMV5 EV FLAG showing disappearance of FLAG-tagged RhoE. The 
FLAG-RhoE was visualised using FITC at 400 ms exposure whereas The F-Actin was 
visualised using TRITC at 900 ms exposure.  The nuclear visualisation of each coverslip used 
DAPI at 100 ms exposure.  Each of the immunofluorescence stainings of the transfected U87 
cells was observed under an epifluorescence microscope visualised at 40 x magnifications.  
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(A) Empty vector 
 
  
 
 
(B) RhoEWT  
 
  
 
(C) RhoET173R/V192R 
 
   
 
 
 
Figure 42: The overexpressed RhoE in U87 cells shows that RhoE was localised to the 
nucleus and cytoplasm in double mutants RhoE. (A) U87 cells transfected with pCMV Empty 
Vector. (B) U87 cells transfected with pCMV5 FLAG-RhoEWT  (C) U87 cells transfected with 
pCMV5 FLAG-RhoET173R/V192R. 
 DAPI                            F-Actin                          FLAG                           Merged 
DAPI                             F-Actin                          FLAG                         Merged 
DAPI                            F-Actin                        FLAG                           Merged 
20 µm  20 µm 20 µm 20 µm 
20 µm 20 µm 20 µm 20 µm 
 
20 µm 20 µm 20 µm 20 µm 
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Following the immunostaining, western blot analysis was carried out. A similar 
overexpression technique to the immunostaining experiment was applied where the U87 cells 
were transfected, starved for 8 hours and then culture was serum stimulated for another 34 
hours. The transfected U87 cells were lysed in buffer containing Nonidet P-40 at 42 hours 
post-transfection. Nuclear and cytoplasmic fractions were prepared, separated by SDS-PAGE 
and immunoblotted with antibodies against anti-FLAG antibody to detect RhoE (29 kD). 
Figure 43 (A) shows the results of immunoblot on overexpressed RhoE. In accordance with 
RhoE expression, an equivalent amount of total protein loaded to each well is verified via 
immunoblotted with antibodies against SSRPI and -tubulin to identify nuclear and 
cytoplasmic marker respectively at (92 kD) and (55 kD) as shown in Figure 43 (B).  
Figure 43 (A) showed the selected of the RhoE constructs that allied with the wild-
type and were successfully transfected into the U87 cells. This observation described the blot 
of FLAG-tagged RhoE at 29 kD for the whole cell lysate, nuclear fraction and cytoplasms. 
The double mutants RhoE (RhoET173R/V192R) appeared to be strongly expressed in the nucleus 
as shown in the fourth lane of the nuclear fraction blot. In parallel, the localisation of RhoE to 
the nucleus in this experiment is not correlated with disruption of residual site in RhoE 
interfacing ROCK1. On the other hand, the localisation of RhoE to the cytoplasm in previous 
result that showed in Figure 42 (B) by RhoEWT construct indicated that the binding at effector 
region by RhoE to ROCK1 is essential in maintaining the stress fibre formation and this 
process commonly occurs in the cytoplasm.  
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(A) RhoE blots 
 
 
 
 
  
                                     
 
                                     
                 
 
 
 
Figure 43: The immunoblot of FLAG confirmed that the double mutants RhoE 
(RhoET173R/V192R) overexpressed in the U87 cells and localised to the nucleus and cytoplasm.  
(A) The localisation of FLAG-RhoE expressed after transfection with RhoE mutant plasmids 
into the U87 cells in whole cell lysate, nuclear and/or cytoplasmic fractions. RhoE wild-type 
(RhoEWT) and other selected RhoE mutant constructs (RhoEV56Y and RhoET173R/V192R) 
transfected into the U87 cells and recognised by FLAG-tagged RhoE epitope. The 
overexpression vectors containing empty vector (EV) were also applied as a control of the 
experiment using construct plasmid pCMV5 EV FLAG. In addition, lane three indicates 
another RhoE mutant construct pCMV5 RhoEV56Y that is a mutation of effector side residues.  
This mutant successfully maintained stress fibres (result not shown) and known as a dominant 
negative RhoE mutant. U87 cells transfected with pCMV5 RhoEV56Y also allow binding to 
ROCK1 and not essential in this study. 
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(B) Loading marker blots  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 Figure 43: (B) The loading control using SSRPI (81 kD) for nuclear and -tubulin (55 kD) 
for cytoplasmic markers. The U87 cells were transfected, starved for 8 hours, and the culture 
were then serum stimulated for another 34 hours. The transfected U87 cells were lysed in 
buffer containing Nonidet P-40 at 42 hours post transfection. The nuclear and cytoplasmic 
fractions were prepared, separated by SDS-PAGE, and immunoblotted with antibodies against 
SSRPI and -tubulin.  These blots are representative of triplicate experiment (n = 3). 
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 5.2.2  Confocal Analysis Confirmed RhoE Localised to the Nucleus of U87 Cells  
Further observation on the transfected U87 cells was conducted under confocal laser 
scanning microscopy (CLSM) to confirm the localisation of RhoE to the nucleus. The U87 
cell were fixed with PFA 4 % (w/v) and immunostained with a mouse monoclonal antibody, 
which raised against the FLAG-tagged RhoE epitope, followed by the secondary antibody 
antimouse conjugated Alexa Fluor 488 nm to visualise the localisation of FLAG-tagged RhoE 
in an individual transfected cell. Figure 44 shows the results; panel (A) for U87 cells 
transfected with pCMV5 FLAG-RhoEWT and panel (B) for U87 cells transfected with 
pCMV5 FLAG-RhoET173R/V192R.  
The localisation of RhoE is widely scattered within both regions, which are nuclear 
and cytoplasmic regions of U87 cells transfected with RhoE wild-type construct (pCMV5 
FLAG-RhoEWT) is shown in Figure 44 (A). In contrast, Figure 44 (B) of RhoE double 
mutants (pCMV5 FLAG-RhoET173R/V192R) indicates discrepancy by most expression of 
FLAG-RhoE in the nuclei. In addition, the dysfunctional RhoE double mutants by the 
replacement of threonine 173 and valine 192 both with arginine, prevent RhoE to bind 
ROCK1.  
More expression of 29 kD RhoE observed in the nucleus of U87 cells as shown in 
Figure 45 is found consistent with the result of the acceleration of nuclear localisation of 
RhoE in ROCK1 depleted U87 cells by the siROCK1 (Figure 33, Chapter 4). The possible 
reason was due to phosphorylation by other kinases and ROCK1 independent. It is clear 
evidence that ROCK1 does not regulate the nuclear localisation of RhoE. Another observation 
is the Imp required for RhoE localisation to the nucleus which is parallel with the NLS 
prediction. Thus, the role of ROCK1 is inessential for the function of RhoE in the nucleus.  
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(A) Confocal image of RhoE wild-type (RhoEWT) 
     
Bright-Field                              FLAG-RhoE                  Merged 
 
(B) Confocal image of RhoE double mutants (RhoET173R/V192R) 
     
Bright-field                              FLAG-RhoE       Merged 
 
Figure 44: The localisation of RhoE to the nucleus of U87 cells at 42 hours post-transfection. 
The immunostaining of U87 cells was conducted for FLAG to detect RhoE. The primary 
antibody used an anti-FLAG which was raised in a mouse to detect RhoE. On the other hand, 
the secondary antibody used an anti-mouse with conjugated Alexa Fluor 488nm, which was 
raised in a goat that has green fluorescence. Laser acquisition and vertical sectioning were 
applied within multiple layers of U87 cells towards a region of interest (ROI) on the 
coverslips until up to 100 layers via Z-Stack experiment. The thickness of the layers on each 
selected ROI is fixed to create an accurate overlapping between channels (bright field and 488 
nm laser). (A) Confocal image of RhoE wild-type (RhoEWT) and (B) Confocal image of RhoE 
double mutants (RhoET173R/V192R). (1) Arrow indicates nuclei of U87 cells; (2) Arrow 
indicates cytoplasm of U87 cells.  
1 
2 
1 
2 
15 µm 15 µm 15 µm 
15 µm 15 µm 15 µm 
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Original sequence: RhoE (V192) or RhoE (T173/V192)                        
 
     
Mutated sequence of double mutant RhoE (R173/R192) 
Figure 45: The high-resolution structure of RhoE interacts with ROCK1 (pdb: 2V55) -
heterodimer was visualised in PyMOL Molecular Visualisation and retrieved in PNG file 
format. Localisation of single mutant or double mutant RhoE interfacing ROCK1 lead to 
disruption of RhoE: ROCK1 interaction. Each mutated residue is shown in blue stick within 
folding protein structure.  
 
 
Enlarged 
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RhoE 
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5.2.3  Bioinformatics Analysis on RhoE Pull-Down Assay     
5.2.3.1 Immunoprecipitation Followed by Mass-Spectrometry Analysis  
The identification of the genes that encode the regulatory proteins involved in most of 
the nuclear processes in U87 human glioblastoma cells was necessary in this study. The 
nuclear processes include protein biosyntheses such as the transcription and translation of the 
genes, DNA replication, cell cycle, mitosis, and telomere maintenance. Notably, the 
regulatory proteins were speculated to be more likely found in the nuclei. In addition, 
cytosolic protein is also a major interest as it is related to a GTPase activity, active transport, 
metabolic processes, as well as the protein stabilisation for post-translational modification of 
RhoE. Thus, obtaining the list of genes from RhoE pull-down assay is a basic requirement in 
further analysis using bioinformatics applications. 
The source of large gene lists was obtained from the mass spectrometry data of RhoE 
pull-down assay. This assay was prepared via the immunoprecipitation of RhoE wild-type 
(RhoEWT) and RhoE double mutants (RhoET173R/V192R) that were transfected into the U87 cells 
with FLAG-tagged RhoE epitope. Pertaining to this hypothesis, the RhoE was 
immunoprecipitated from a combination of nuclear and cytoplasmic extracts of the transfected 
U87 cells. Next, the immunoprecipitated proteins were separated by SDS PAGE and the 
protein bands were stained with Coomassie blue. Figure 46 shows the result for the 
immunoprecipitation of RhoEWT and RhoE T173R/V192R aligned with the empty vector (EV) as 
the control of the experiment.  
Next, these protein bands were excised from the gel and the proteins were digested 
into the peptides for identification (Newton et al. 2008). Using reverse HPLC coupled to an 
ion trap mass spectrometer, the peptides belonging to the proteins in the immunoprecipitated 
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sample were identified by comparing the recorded peptide fragmentation pattern with the 
database of the peptide sequences (FASTA) (Lodge et al. 2007). 
The novel binding proteins that interacted with RhoE were found by BLAST in the 
sequence of peptides. The description of the RhoE-interacting protein partners were encoded 
by their accession numbers. Then, the individual accession numbers were renamed via Gene 
Cards: the common gene identifiers that provide genomic, proteomic, transcriptomic, genetic, 
and functional information of all known and predicted human genes. In addition, the Gene 
Cards coding system is acknowledged by majority of genes uploader in the bioinformatics 
application system. 
In recent years, the high throughput enrichment tools for analysing the list of genes 
include DAVID (2008), BioVenn (2008), BioProfiling (2011) and STRING (2013). However, 
none of these analysing tools could be considered as a “gold” standard procedure due to their 
own limitations (Huang et al. 2009). Thus, this research decided to exploit DAVID in its first 
attempt of analysing the genes. As a result, there are 195 genes discovered from 
RhoET173R/V192R, which are less than 229 genes found in. Table 10 and Table 11 list the 
specific genes obtained for the experiment. The U87 cells transfected with both constructs; 
RhoEWT and RhoET173R/V192R. 
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Figure 46: The immunoprecipitation of RhoE wild-type (RhoEWT) and RhoE double mutants 
(RhoET173R/V192R) that are compared to the Empty Vector. The individual lane shows 
distribution of monomeric protein after 2-D separation via electrophoresis through SDS-
PAGE followed by staining with Coomassie blue. The fade FLAG-RhoE band was only 
found in RhoEWT and RhoET173R/V192R but none could be found in Empty Vector. 
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5.2.3.2 Manipulating Bioinformatics Tools to Identify Novel RhoE Binding Partners 
The Database for Annotation Visualisation and Integrated Discovery (DAVID) is the 
bioinformatics software that analyses highly complex and massive volume datasets. This 
bioinformatics application modulates the extraction of structural features in the gene list into a 
more understandable biological explanation for the output gene list. DAVID was used to 
identify novel RhoE binding partners. It is essential to analyse of data from a huge list of 
genes in determining a subsequent effort in revealing high-throughput proteomic data. 
Moreover, bioinformatics analysis of the abundance of genomics and proteomics data offers 
precise values for further investigation of diverse biological mechanisms that are linked to 
cancer as well as other diseases (Huang et al. 2008).  
On the other hand, Huang et al. (2008) suggested several characters to demonstrate a 
satisfactory gene list. First, a definitive value from a massive gene list is represented by 
functional genes or essential markers that are correlated to the investigation. For example, 
most of the pulled down genes during RhoE overexpression for this study were involved in 
diverse biological processes as listed in Table (A) and Table (B) (see Appendix 6). Second, an 
appropriate amount of genes appeared moderate, above hundred and below a few thousands. 
For instance, this study discovered 229 genes for RhoEWT and 195 for RhoET173R/V192R. Third, 
the selection of genes typically met the statistical limit. The difference relies on the statistic 
comparison using t-test analysis, for genes expressed in the control of the experiment against 
the subjected cells (p < 0.05). In this study, the comparison was made particularly between 
glioma transfected with empty vector against glioma transfected with either RhoEWT or 
RhoET173R/V192R. 
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In agreement, the additional characters to indicate satisfactory gene list also include the 
trend of overexpression or underexpression of the genes. A particular set of genes is 
frequently up-regulated when it takes part in the specific cellular functions. Otherwise, every 
functional gene should not arbitrarily appear in any available mechanism intracellularly 
(Huang et al. 2008). Moreover, the significant list of genes should maintain advancement and 
offer systematic biological input rather than vague information although the arbitrary gene list 
has similar extent while performing DAVID analysis (Huang et al. 2008).  
A similar working group also emphasised that the lists of genes are much more valuable if 
several replication could be done and it must be repeatable in different batches of the 
experiment. By limiting the variables, an individual set of gene list will be statistically tested 
to create an identical gene list under the similar setting. Finally, the most important character 
of a satisfactory gene list should exhibit a discrete feature of a high-throughput data that can 
be validated. For instance, performing similar bench-work in the laboratory might be able to 
verify the validity of the existing data (Huang et al. 2008).  
Therefore, a functional annotation chart in DAVID was used to provide the enrichment of 
typical gene ontology terms in this study. This tool has enabled the identification of the most 
relevant biological terminology associated with the gene list obtained from mass 
spectrometry. Then, the results of the appropriate gene cluster were functionally classified 
into similar biological processes or molecular functions. Table 10 and Table 11 show the 
satisfactory gene lists for the U87 cells transfected with RhoEWT and RhoET173R/V192R. 
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Table 10: Functional annotation chart showing RhoE (Rnd3) and its binding partners that are 
clustered into molecular function (MF) and biological processes (BP) in the U87 cells 
transfected with pCMV5 FLAG-RhoEWT 
CATEGORY SCORE FUNCTIONAL ANNOTATION 
CHART 
SP_PIR_KEYWORDS 50/229 (21.6%) 
p value 1.8 x10-9 
 
Nucleotide Binding 
(ATP1A1, DX3Y, DDX47, GNAS, GTPBP4, 
NAT10, RND3, RUVBL1, RUVBL2, 
SMARCA5, TXK, XRCC5, XRCC6, 
ACTBL2, ALDH18A1, RARS, ATR, 
CSNK2A2, CCT3, EEF1A1, EIF5B, QARS, 
EPRS, HSP90AA1, HSP90B1, HNRNPU, 
HK1, TUBA1B, LARS, MARS, MCM5, 
MYO1C, NMNAT1, FARSA, PIK3CG, 
PRKCD, SEPT7, SEPT9, SRPR, SRPRB, 
ATAD3B, SNRNP200, RECQL, EIF4A, 
SMC1A, SMC2, SMC4,  TUBB2B, VARS, 
VDAC2) 
 
 
16/229 (6.9%) 
p value 1.8 x10-7 
 
Methylation  
(RND3, EEF1A1, FAM120A, FBL, FMR1, 
GAPDH, HNRNPK, HNRNPU, HIST1H2BC, 
HIST4H4, HIST3H3, TUBA1B, ILF3, 
MYO1C, NCL, SNRPD3) 
 
 
11/229 (4.8%) 
p value 5.6 x10-3 
 
GTP Binding  
(GNAS, GTPBP4, RND3, EEF1A1, EIF5B, 
TUBA1B, SEPT7, SEPT9, SRPR, SRPRB, 
TUBB2B) 
 
UP_SEQ_FEATURE 11/229 (4.8%) 
p value 2.6 x10-3 
 
Nucleotide phosphate-binding region: GTP 
(GNAS, GTPBP4, RND3, EEF1A1, EIF5B, 
TUBA1B, SEPT7, SEPT9, SRPR, SRPRB, 
TUBB2B) 
 
 
4/229 (1.7%)  
p value 2.2 x10-3 
 
Lipid moiety-binding region: S-farnesyl 
cysteine:  
(RND3, LMNA, LMNB, NAP1L1)  
GOTERM_BP_FAT 14/229 (6.1%) 
p value 1.2x10-2 
Cytoskeleton organisation:  
(RND3, CAV1, CFL1, FLNA, FMNL2, 
TUBA1B, EZR, KRT4,  KRT6C, KRT9, 
MACF1, SMC1A, SDCBP, TCHH) 
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CATEGORY SCORE FUNCTIONAL ANNOTATION 
CHART 
GOTERM_MF_FAT 59/229 (25.5%) 
p value 3.9 x 10-6 
Nucleotide binding: 
(ATP1A1, DDX3Y, DDX47, GNAS, 
GTPBP4, NAT10, RND3, ARHGEF5, 
RUVBL1, RUVBL2, SMARCA5, TXK, 
XRCC5, XRCC6, ACTBL2, ALDH18A1, 
RARS, ATR, CSNK2A2, CCT3, EEFF1A1, 
EIF3G, EIF5B, QARS, EPRS, GAPDH, 
HSP90AA1, HSP90B1, HNRNPM, 
HNRNPR, HNRNPU, HK1, HADHA, 
TUBA1B, LARS, MATR3, MARS, MCM5, 
MYO1C, NMNAT1, NCL, FARSA, PIK3CG, 
PRKCD, SEPT7, SEPT9, SRPR, SRPRB, 
ATAD3B, SNRNP200, RECQL, EIF4A1, 
SNRNP70, SMC1A, SMC2, SMC4, 
TUBB2B, VARS, VDAC) 
 
 
 
 
 
 50/229 (21.6%) 
p value 1.2 x 10-5 
Purine ribonucleotide binding: 
(ATP1A1, DDX3Y, DDX47, GNAS, 
GTPBP4, NAT10, RND3, ARHGEF5, 
RUVBL1, RUVBL2, SMARCA5, TXK, 
XRCC5, XRCC6, ACTBL2, ALDH18A1, 
RARS, ATR, CSNK2A2, CCT3, EEF1A1, 
EIF5B, QARS, EPRS, HSP90AA1, HSP90B1, 
HNRNPU, HK1, TUBA1B, LARS, MARS, 
MCM5, MYO1C, NMNAT1, FARSA, 
PIK3CG, PRKCD, SEPT7, SEPT9, SRPR, 
SRPRB, ATAD3B, SNRNP200, SMARCA5, 
EIF4A1, SMC1A, SMC2, SMC4, TUBB2B, 
VARS)  
 
 
 
 
 50/229 (21.6%) 
p value 1.2 x 10-5 
Ribonucleotide binding:  
(ATP1A1, DDX3Y, DDX47, GNAS, 
GTPBP4, NAT10, RND3, ARHGEF5, 
RUVBL1, RUVBL2, SMARCA5, TXK, 
XRCC5, XRCC6, ACTBL2, ALDH18A1, 
RARS, ATR, CSNK2A2, CCT3, EEF1A1, 
EIF5B, QARS, EPRS, HSP90AA1, HSP90B1, 
HNRNPU, HK1, TUBA1B, LARS, MARS, 
MCM5, MYO1C, NMNAT1, FARSA, 
PIK3CG, PRKCD, SEPT7, SEPT9, SRPR, 
SRPRB, ATAD3B, SNRNP200, SMARCA5, 
EIF4A1, SMC1A, SMC2, SMC4, TUBB2B, 
VARS) 
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CATEGORY SCORE FUNCTIONAL ANNOTATION 
CHART 
GOTERM_MF_FAT 9/229 (3.9%) 
p value 1.2 x 10-2 
 
 
 
GTPase activity:  
(GNAS, GTPBP4, RND3, EEF1A1, EIF5B, 
TUBA1B, SEP9, SRPR, TUBB2B) 
 12/229 (5.2%) 
p value 2 x10 -2 
GTP binding: 
(GNAS, GTPBP4, RND3, ARHGEF5, 
EEF1A1, EIF5B, TUBA1A, SEPT7, SEPT9, 
SRPR, SRPRB, TUBB2B) 
 
 
 
 12/229 (5.2%) 
p value 2.4 x10 -2 
 
 
Guanyl ribonucleotide binding: 
(GNAS, GTPBP4, RND3, ARHGEF5, 
EEF1A1, EIF5B, TUBA1B, SEPT7, SEPT9, 
SRPR, SRPRB, TUBB2B) 
 
 
 
 12/229 (5.2%) 
p value 2.4 x10 -2 
 
 
Guanyl nucleotide binding: 
(GNAS, GTPBP4, RND3, ARHGEF5, 
EEF1A1, EIF5B, TUBA1B, SEPT7, SEPT9, 
SRPR, SRPRB, TUBB2B) 
 
 
 
Note:  
Thirteen (13) functional annotation clusters of gene that closely interacted with RhoE by U87 
cells transfected with RhoEWT  
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Table 11: Functional annotation chart showing RhoE (Rnd3) and its binding partners that are 
clustered into molecular function (MF) and biological processes (BP) in U87 cells transfected 
with pCMV5 FLAG-RhoE T173R/V192R 
CATEGORY SCORE FUNCTIONAL ANNOTATION 
CHART 
SP_PIR_KEYWORDS 44/195 (22.6%) 
p value 6.2 x 10-9 
Nucleotide binding 
(SNRNP35, ATAD3A, DDX1, DDX18, DDX27, 
DDX3Y, RECQL, RND3, ACTG2, DARS, 
BAZ1B, CSNK2A2, CLCN3, DCTPP1, QARS, 
EPRS, GBP1, HSPA1A, HSP90AA1, HNRNPU, 
LARS2, KARS, MARS, MTHFD1, MAST2, 
MCM3, MCM5, MLL, PKLR, CCT8, EIF4A1, 
PRKDC, SRP72, SMC1A, SMC2, SMC3, 
SMC4, TTN, TOP2B, TUBA1A, TUBB2C, 
UBE2B, VARS, VDAC2) 
 
 
 
 
8/195 (4.1%) 
p value 1.1 x 10-2 
Methylation 
(RND3, FBL, HNRNPK, HNRNPU, 
HIST1H2BH, HIST1H4C, NCL, PABPC1) 
 
 
 
 
 
GOTERM_BP_FAT 16/195 (8.2%) 
p value 5.1 x 10-4 
Cytoskeleton organisation 
(RND3, CDSN, CAV1, CFL1, FLNA, FMNL2, 
EZR, KRT16, KRT4, KRT9, MAP1B, NOP2, 
SMC1A, SMC3, TTN, UBE2B) 
 
 
 
 
 
7/195 (3.6%)  
p value 7.3 x 10-2 
Actin cytoskeleton organisation 
(RND3, CALD1, CFL1, FLNA, FMNL2, EZR, 
TTN) 
 
 
 
 
 
7/195 (3.6%) 
p value 9.1 x 10-2 
Actin filament-based process 
(RND3, CALD1, CFL1, FLNA, FMNL2, EZR, 
TTN) 
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CATEGORY SCORE FUNCTIONAL ANNOTATION 
CHART 
GOTERM_MF_FAT 55/195 (28.2%) 
p value 1.2 x 10-5 
Nucleotide binding 
(SNRNP35, ATAD3A, DDX1, DDX18, DDX27, 
DDX3Y, RECQL, RND3, STEAP3, ACTG2, 
DARS, BAZ1B, CSNK2A2, CLCN3, DCTPP1, 
EIF3G, QARS, EPRS, GBP1, HSPA1A, 
HSP90AA1, HNRNPM, HNRNPU, HADHA, 
LARS2, KARS, MARS, MTHFD1, MAST2, 
MCM3, MCM5, MLL, NCL, PARP1, PABPC1, 
PKLR, RPS24, CCT8, EIF4A1, PRKDC, SRP54, 
SFRS2B, SART3, SMC1A, SMC2, SMC3, 
SMC4, SYNCRIP, TTN, TOP2B, TUBA1A, 
TUBB2C, UBE2B, VARS, VDAC2) 
 
42/195 (21.5%) 
p value 9.0 x 10-4 
Ribonucleotide binding 
(SNRNP35, ATAD3A, DDX1, DDX18, DDX27, 
DDX3Y, RECQL, RND3, ACTG2, DARS, 
BAZ1B, CSNK2A2, CLCN3, QARS, EPRS, 
GBP1, HSPA1A, HSP90AA1, HNRNPU, LARS, 
KARS, MARS, MTHFD1, MAST2, MCM3, 
MCM5, MLL, PKLR, CCT8, EIF4A1, PRKDC, 
SRP54, SMC1A, SMC2, SMC3, SMC4, TTN, 
TOP2B, TUBA1A, TUBB2C, UBE2B, VARS) 
 
42/195 (21.5%) 
p value 9.0 x 10-4 
Purine ribonucleotide binding 
(SNRNP35, ATAD3A, DDX1, DDX18, DDX27, 
DDX3Y, RECQL, RND3, ACTG2, DARS, 
BAZ1B, CSNK2A2, CLCN3, QARS, EPRS, 
GBP1, HSPA1A, HSP90AA1, HNRNPU, 
LARS2, KARS, MARS, MTHFD1, MAST2, 
MCM3, MCM5, MLL, PKLR, CCT8, EIF4A1, 
PRKDC, SRP54, SMC1A, SMC2, SMC3, 
SMC4, TTN, TOP2B, TUBA1A, TUBB2C, 
UBE2B, VARS) 
 
43/195 (22.1%) 
p value 1.1 x 10-3 
Purine nucleotide binding 
(SNRNP35, ATAD3A, DDX1, DDX18, DDX27, 
DDX3Y, RECQL, RND3, STEAP3, ACTG2, 
DARS, BAZ1B, CSNK2A2, CLCN3, QARS, 
EPRS, GBP1, HSPA1A, HSP90AA1, HNRNPU, 
LARS2, KARS, MARS, MTHFD1, MAST2, 
MCM3, MCM5, MLL, PKLR, CCT8, EIF4A1, 
PRKDC, SRP54, SMC1A, SMC2, SMC3, 
SMC4, TTN, TOP2B, TUBA1A, TUBB2C, 
UBE2B, VARS) 
 
Note: 
Nine (9) functional annotation clusters of gene that interacted with RhoE (Rnd3) by U87 cells 
transfected with RhoE T173R/V192R 
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As shown in DAVID analysis on RhoEWT - Table 10 and RhoET173R/V192R - Table 11 
using a functional annotation chart, it was discovered that RhoE binding partners of both 
constructs are clustered into several similar functions including nucleotide binding, 
methylation and cytoskeleton organisation. Interestingly, the genes that are clustered into 
nucleotide binding such as purine nucleotide or ribonucleotide are statistically enriched         
(p < 0.05). Moreover, the novel interaction of RhoE with mini-chromosomal maintenance 
(MCM) proteins (MCM3 and MCM5) is strong evidence that RhoE is involved in regulating 
the nuclear process of U87 human glioblastoma. MCM proteins are well-known as the 
replicative helicase that is commonly loaded onto the double stranded DNA at the replication 
origins.  
I tried BioVenn to evaluate the overlapping genes expressed in the U87 cells 
transfected with RhoEWT over RhoE T173R/V192R. For this procedure, the large gene lists have to 
be classified into similar molecular functions. Manipulating the BioProfiling.de online 
software helps to cluster of the identical gene ontology terms into individual molecular 
functional profiling with the statistically enrichment scheme.  This tool enables me to narrow 
down the selection of individual genes rather than randomly choosing the gene of interest. 
Figure 47 shows the result for the overlapping genes between the U87 cells transfected with 
RhoEWT over RhoET173R/V192R. There is about 68% similarity for the functional genes in 
RhoET173R/V192R with the function of genes in RhoEWT. 
Finally, DAVID was also used in conjunction with Search Tool for Retrieval of 
Interacting Genes/Proteins (STRING) for this research. STRING is able to demonstrate high 
significant network connectivity between protein rather than setting it in random. 
Nevertheless, according to the data in Table 10 and 11, STRING showed unreliable 
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interaction between RhoE with other potential protein partners observed by DAVID, where 
RhoE has a frequent interaction with ROCK1 as an intermediate whilst expanding the 
network (results not shown). Although ROCK1 is known to have an interaction with RhoE, it 
was not successfully pulled down by immunoprecipitation technique. Thus, more advance 
research on interaction of RhoE with PKC should be done in the future as it consistently 
existed in the mass spectrometry data. 
. 
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Figure 47: Bio-Ven – a web application for the comparison and visualisation of biological list 
using area-proportional Venn diagrams. ID Set X represents a total of 65 GO term list found 
in U87 cells transfected with RhoEWT whereas ID Set Y represents a total of 51 GO term list 
found in U87 cells transfected with RhoET173R/V192R. The total overlapping between ID Set Y 
with ID set X is 44 GO term list. This is equals to 68% similarity shared between RhoE 
double mutants with the wild-type. 
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5.2.4  RhoE Involves in DNA Replication of U87 Glioblastoma Cells   
Section 5.2.4.2 showed that RhoE interacts with nucleotide binding protein, 
particularly in the purine base. This result is consistent between RhoE wild-type and RhoE 
double mutants. Interestingly, minichromosomal maintenance proteins (MCMs) that are 
involved in DNA replication was found to be RhoE interacting binding partner (result was not 
shown). Similarly, MCMs play a critical role in the initiation of DNA synthesis and the 
expressions are correlated with cell proliferation as DNA replication precedes each cell 
division as previously described in Section 5.1.  
Interestingly, MCM3 represents a glioma-associated antigen and therefore becomes a 
potential tumour marker for brain tumour. Sӧling et al. (2005) demonstrated that MCM3 is 
overexpressed in human with brain malignancies but it does not occur in healthy people. They 
have examined the immunoreaction of MCM3 via a serological test using the serum 
specimens from the patients with brain tumour and metastasis and comparing the specimens 
with the control of serum specimen from healthy people (Soling et al. 2005). Therefore, an 
investigation on the interaction between RhoE and MCM3 is relevant to reveal the function of 
RhoE in glioblastoma during DNA replication 
A RhoE knockdown experiment was conducted using RNA interference approach and 
it used RhoE oligo A and RhoE oligo B for 48 hours. This method was previously explained 
in section 2.2.2.1. At the same time, a non-silencing control was used as the control of the 
experiment. The U87 cells were lysed in a buffer containing Nonidet P-40, and nuclear 
cytoplasmic fractions were prepared, separated by SDS-PAGE, and immunoblotted with the 
antibodies against RhoE, MCM3, and -tubulin. Result for this experiment is shown in Figure 
48, which particularly displayed only MCM3 blot. 
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Figure 48: The immunoblots of MCM3 accumulation in U87 cells with and without the 
presence of RhoE. U87 cells were lysed in a buffer containing Nonidet-P 40 and nuclear. 
Cytoplasmic fractions were prepared, separated by SDS-PAGE, and immunoblotted with an 
antibody against MCM3. An effective isolation of nuclear and cytoplasmic fractions was 
confirmed using antibodies against Lamin A/C and a-tubulin, respectively (result not shown). 
These data are representative of three separate experiments (n = 3). 
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Figure 48 shows relatively more MCM3 were accumulated in the nuclear after the 
RhoE knockdown. The amount of MCM3 protein was decreased in cytoplasm and this was 
due to protein accumulation in the nucleus. Following western blot, a densitometry analysis 
was carried out using Image J on the MCM3 blot to evaluate the distribution of this protein 
between nucleus and cytoplasm with and without the presence of RhoE in the U87 cells. 
Figure 49 shows result on densitometry analysis of MCM3.  
The intensity of MCM3 in the nuclear reached about four to six fold than in the 
cytoplasm in the RhoE-depleted U87 cells. The difference of intensity between nuclear and 
cytoplasmic MCM3 in this condition was found statistically significant (p < 0.05) and this is 
true for both oligos (RhoE oligo A and RhoE oligo B). In contrast, the MCM3 intensity 
between nuclear and cytoplasm in control condition (Control oligo) was not significantly 
different and the MCM3 proportion between both fractions (almost equal to 1.0).  
MCM3 localisation was further investigated via immunostaining followed by 
observation under epifluorescence microscope. Figure 49 shows the result. The depletion of 
RhoE promotes localisation of MCM3 to the nucleus indicated by strong green fluorescence 
(image represented in black and white) in the nuclei of U87 cells with siRhoE using both 
oligoes, A and B. This observation was contradicted to the control condition when MCM3 
was evenly distributed between nuclear and cytoplasm. 
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(*) (p <  0.05) (n = 3) 
 
Figure 49: Densitometry analysis using Image J for the semi-quantification of the MCM3 
intensity in U87 cells with and without the presence of RhoE from three separate experiments 
(n = 3). Data were statistically evaluated using Welch Two Sample t-test used for paired 
samples, (*) (p value < 0.05). The error bars show the standard error of the mean (S.E.M) for 
each datasets of three separate experiments (n = 3). 
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Figure 50: MCM3 is a novel interacting partner for RhoE. Depletion of RhoE promotes the 
localisation of MCM3 to the nucleus. (A) MCM3 in control condition; (B) MCM3 in siRhoE 
using RhoE oligo A; (C) MCM3 in siRhoE using oligo B.  Right: Nuclear visualisation using 
DAPI at 300ms exposure, 40 x magnification. Left: Black and white image of MCM3 
showing exact localisation of MCM3 using MCM3 antibody at 900ms exposure, 40 x 
magnification. 
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5.3 Discussion 
RhoE is known to interact with ROCK1 via phosphorylation to increase its stability 
through its binding to the kinase domain (Sebti and Der 2003). Referring to the previous work 
by Komander et al. (2008), they confirmed that a high-resolution structure of RhoE in 
complex with the ROCK1 kinase domain was substantially found as a diverse 
phosphorylation site. A crystal diffraction analysis by the same working group also 
demonstrated that RhoE binds to ROCK1 specifically at the C-lobe of -G helix domains. In 
particular, this area is adjacent to the catalytic site of ROCK1 that is located at N and C 
termini, but at a far distance from RhoE effector region.  
Important aspect in this study was manipulating the interaction RhoE to ROCK1 in 
investigating the localisation of RhoE to the nucleus. Mutations of RhoE construct carried by 
the mammalian expression vector plasmid; pCMV5 contains the substitution of threonine 173 
at 5 strand and valine 192 at 5 helix; both into arginine. Although, this mutant is unable to 
pull down ROCK1, it has maintained its ability to reorganise actin similar to the wild-type. 
This mutant induced substantial reduction of stress fibres thus making the cells to appear with 
round up phenotype. In parallel, results on F-actin staining in U87 cells demonstrated that 
RhoE double mutants (RhoET173R/V192R) are vulnerable to lose stress fibre. This phenotype 
consistently showed that ROCK1: RhoE interaction is crucial in maintaining stress fibre.  
The validation of F-actin staining was made using a mutant construct, RhoEV56Y. This 
RhoE construct has the mutation at effector site residues. There is an impact of having the 
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mutation in the effector region as it would possibly attenuate RhoE-mediated disorganisation 
of the actin cytoskeleton. However, this mutant successfully maintained stress fibres (result 
not shown) and known as dominant negative RhoE mutant. U87 cells transfected with 
pCMV5 RhoEV56Y still allows interaction to ROCK1. Thus, this mutant has proven that 
ROCK1 is functional. ROCK1 dysfunctional by specific RhoE cascade only occur by 
blocking the interaction to its effector region (Komander et al. 2008).  
In this study, Lipofectamine LTX Plus (Invitrogen) was used for optimal transfection 
of U87 cells. The manufacturer provides improved protocols with the liposome. LTX-
transfected DNA enters the cell via clathrin-mediated endocytosis with both pathways 
assembling at the late endosome or lysosome during lipid delivery (Rejman et al. 2005). As a 
result, challenging cell types such as U87 cells that have morphologies quite similar to 
primary neural progenitor cells as well as primary fibroblasts cells have successfully gone 
through plasmid transfection. Moreover, this reagent offers a balance of potency and 
gentleness for the U87 cells, resulting in high transfection efficiencies and viabilities. 
The viable count of U87 cell was determined using disposable cell counter with a tiny 
16 grids that represent cell number times 10 000 per mL of the newly-split U87 cells. 10 µL 
out of 10 mL cell suspension pipetted onto the grid and it was observed under the light 
microscope. It is good to maintain the counted cell number at 300 000 cells at the beginning 
of the experiment. Theoretically, the consistency in applying an equal number of cells 
preserved potency in expressing FLAG-tagged RhoE fusion protein carried by the vector, and 
in this case, plasmid pCMV5 at the same expression level because the cells are sufficient. The 
equivalent number of the U87 cell was most likely to be adequate for the vector to incorporate 
the DNA of interest into the genome of the host during the transfection. 
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DAVID application is used to cluster the abundance of gene into a more comprehensive 
set of functional classification to understand the biological meaning behind the huge gene list. 
For instance, the high-throughput data can be collectively translated into a sophisticated 
biological data which are more precise into a designated gene ontology (GO) term. Then, 
these gene clusters are classified into excessive glossary and terminologies that demonstrate a 
link between “many-genes-to-many-terms” on two-dimensional (2-D) graphical perspective. 
As a result, any gene that is out of the list, but closely linked to the marker genes could also 
be retrieved.  
Moreover, DAVID would make it possible to determine the potential interacting protein 
partners for RhoE (RND3) in regulating multiple nuclear processes in glioblastoma. DAVID 
tools offer analysis of the gene signature and profiling as well as related biomarkers for 
particular diseases. This application is also utilised for intensive search on individual domain 
and motif of the specific protein. Besides that, DAVID is also applied to confirm the 
determination for the functional group of the gene as it serves as a guide for the literature as 
well as adapting into the alternative gene description.  
Although the protein-protein interactions analysis by DAVID was widely discussed in this 
section but bioinformatics analysis was also carried out using other applications such as 
BioProfiling and BioVenn (Antonov 2011;Hulsen et al. 2008) as well as STRING 
(Franceschini et al. 2013) simultaneously. Besides, this study aimed to find the potential 
interacting binding partners of RhoE and determining whether the interaction is either direct 
or indirect using DAVID, which are still uncertain at this stage. The purpose of performing 
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bioinformatics analysis using different application is to confirm that the results demonstrated 
on protein-protein interactions by DAVID is neither artefact nor retrieved by chance. On the 
other hand, the coverage of annotation is extended from the only GOTERM (Gene Ontology) 
to another annotation category including protein-protein interactions, protein functional 
domains, disease associations, bio-pathways, sequence features, homology, gene functional 
summaries and gene expression (Antonov 2011; Franceshini et al. 2013).  
RhoE also involves in DNA replication of U87 cells. In this study, the investigation on the 
participation of MCM3 as part of replicative helicase (MCM2-7 double hexamer) is clear 
evidence that RhoE interaction to this nuclear protein has triggered the localisation of RhoE to 
the nucleus. MCM3 has important role in replication of DNA and interaction of RhoE to this 
protein during nucleotide binding is novel. Thus, this discovery is important because 
overexpression of protein complex in DNA replication can be manipulated to regulate cancer. 
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CHAPTER 6 
CONCLUDING REMARKS AND FUTURE DIRECTIONS 
 
6.1 Conclusion  
The loss of RhoE expression in U87 human glioblastoma has decreased the number of 
cells entering the S-phase. On the other hand, the progression into the S-phase is promoted by 
the presence of RhoE. The siRhoE U87 cells were unable to incorporate BrdU, in the place of 
thymidine in the DNA of cycling cells during the labelling period as the S-phase entry is 
restricted for RhoE depleted U87 cells.  
The effect of RhoE on apoptosis in U87 human glioblastoma cells was the dissociation 
from its cytoskeletal functions. ROCK inhibition using Y27632 could promote cell survival in 
U87 cells after increasing the concentration of cisplatin treatment by the indication that RhoE 
interacts with another protein, such as Rac1and not exclusively ROCK1. The depletion of 
RhoE in U87 cells in increasing apoptosis is confirmed by the formation of cleaved caspase 3 
and condensed nuclei with and without cisplatin treatment. Although Y27632 was introduced 
to inhibit ROCK1, the apoptosis in siRhoE U87 cells still occurred, but the cell death was 
independent ROCK1.  
In summary, the loss of RhoE in glioma did not protect cell from apoptosis. This data 
contradicted the findings by Poch et al. (2007) when they repeatedly observed apoptosis in the 
presence of RhoE. Ryan (2010) found contrary finding when she discovered the presence of 
 194 
 
RhoE in promoting cell death in keratinocytes. Thus, the molecular signature defines the 
resistant phenotype that varies between tumours and glioma responded with cisplatin 
resistance.  
The phosphorylation sites prediction encourages earlier speculation of that higher 
molecular weight RhoE (29kD) in U87 cells is potentially phosphorylated which is shown in 
Section 4.2.1. It was discovered that more expression of RhoE in the nucleus of U87 cells in 
either the inhibition of ROCK1 or PKC. This finding suggested that ROCK1 is not solely 
required in translocating RhoE into the nucleus. The introduction of PMA for a short duration 
(15 min) to the U87 cells has led to the loss of RhoE in the nucleus. The inhibition of ROCK1 
prevents the loss of RhoE from the nucleus. The experiment discovered that the activation of 
novel PKC by PMA has increased the upper band of RhoE (29kD) and it remains more in 
the nucleus compared to the active convensional PKC (Figure 36).  
Although RhoE can intracellularly traverse on its own by passive diffusion due to its 
low molecular weight (27-29 kD), but the complex formation to the kinases might increase 
the size. Higher molecular weight protein is formed when RhoE complexes with the serine 
and threonine kinases, be either ROCK1 with 160 kD or PKC with 80 kD. Therefore, the 
translocation of RhoE between nucleus and cytoplasm has to be facilitated by 
nucleocytoplasmic transport and the available mechanism to date, which is the KPN (importin 
and exportin) (Tran et al. 2014). Ideally, the attempt in using Co-IP should be able to pull 
down the cargo proteins – Imp, RhoE and the cargo carrier, which is Imp. Imp is an 
adaptor molecule whereas RhoE provides NLS. Then, the cargo translocated from cytoplasm 
to the nuclear and is assisted by carrier protein, Imp. 
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Figure 41 shows the preliminary result (see Section 4.2.6) and found that U87 cells 
transfected with RhoEWT show high affinity to Imp. In parallel, the mass spectrometry 
analysis also discovered that RhoE interacts with KPNA2 – the Imp (see Appendix 6 A). 
The protein-protein interaction between RhoE with Imp is presumed to be indirect as Imp 
functions as an adaptor that recognises NLS and this signal potentially exists in RhoE protein. 
In conclusion, KPN influences the mechanisms of nucleocytoplasmic transport of RhoE in 
complex with the kinases of either ROCK1 or PKC in glioblastoma cells, via recognition of 
NLS.  
The MCM protein is also known as the replicative helicase, which is essential during the 
replication of DNA and novel interaction with RhoE during nucleotide binding. This protein 
is believed to bring salt-stabilise complex in DNA (Samson and Bell 2013).  The 
overexpression of protein complex involved in DNA replication origin licensing factors is 
known to regulate cancer (Champeris Tsaniras et al. 2014). For example, the participation of 
MCM proteins have been shown to efficiently deregulate the cell cycle, particularly during 
cancer cells development. In agreement to the statement, Riera et al. (2014) claimed that the 
replicative helicase (MCM2-7 double-hexamer) needs to be activated in the S-phase for the 
active Cdc45-MCM-GINS (CMG) helicase that surrounds the newly formed single-stranded 
DNA. The formation of CMG component is required to unwind the DNA to let the double 
helix DNA, synthesises the new DNA strands that are complementary to the two parental 
strands (Riera and Speck 2014).  
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6.2 Model Postulation on the Role of RhoE in Glioblastoma 
This research aimed to analyse the role of RhoE in the nucleus as well as 
understanding the mechanism on how RhoE translocates into the nucleus. The manipulation 
of glioblastoma as a model of an abnormal living cell system has brought huge advantage as it 
is very difficult to treat glioblastoma (see Section 1.2). It is important to find the molecular 
insight through the study on protein-protein interaction in U87 cells since the preliminary 
experiment found that RhoE is highly expressed in the nucleus of glioma than healthy cells. 
The ability to tackle the abnormality of cell behaviour like glioblastoma could provide a 
magnitude for any deformity that is caused by other cancer cell type. 
The analyses on cell cycle and apoptosis in U87 cells discovered that RhoE is a 
positive regulator and a tumour enhancer. The RNAi technique was used to knockdown RhoE 
and siRhoE has led the decrease in the number of cells entering the S-phase. It is possible to 
fail assembling a proper pre-replication complex as siRhoE could lead to the accumulation of 
MCM3 in the nucleus of U87 cells. As previously mentioned in Section 5.1, the assembly of 
MCM protein is essential during the DNA replication that occurs at the G1-phase as well as at 
the early S-phase of cell cycle. Therefore, the deformity of MCM protein complex formation 
could promote the initiation of DNA replication when inappropriate multiple MCM2-7 
double-hexamers are loaded in the DNA. In agreement, the inhibition of helicase loading is 
inspected by a licensing checkpoint. Thus, the uncontrolled proliferation in U87 human 
glioblastoma by control oligo might occur when lose this checkpoint, making the cell 
vulnerable to helicase loading (Riera et al. 2014).  
In summary, this study has proposed a model of localisation of RhoE to the nucleus 
which is shown in Figure 51. The endogenous RhoE primarily localises to the nucleus of U87 
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cells. The inhibition of ROCK1 causes endogenous RhoE to accumulate in the nucleus 
whereas the inhibition of conventional PKC prevents the translocation of RhoE to exit the 
nucleus. The inhibition of ROCK1 and PKC block endogenous RhoE from exiting the 
nucleus. The activation of conventional PKC promotes RhoE to exit the nucleus and 
translocates into the cytoplasm. Furthermore, the inhibition of ROCK1 followed by the 
activation of conventional PKC could promote RhoE to enter the cytoplasm, allowing the 
interaction with 14-3-3 and sequestering into the plasma membrane.  
The most exciting observation in this experiment was the activation of novel PKC by 
PMA exhibit an increased the upper band of RhoE (29kD) and it remains more in the nucleus 
consistent with the active conventional PKC during ROCK1 inhibition (Figure 36, Chapter 4). 
The presence of NLS in RhoE promotes the recognition by the nucleocytoplasmic transporter 
(Importin, Imp /) and directs RhoE: PKC complex to enter the nucleus. Then, interacts 
with helicase loading and regulates the cell cycle. Figure 51 shows a model proposed for the 
localisation of RhoE to the nucleus. 
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Figure 51:  Model of the localisation of RhoE to the nucleus. The activation of PKC led to 
increasing the upper band of RhoE (29kD) and triggered translocation of RhoE to the nucleus 
even though without the assistance of ROCK1. The presence of nuclear localisation signal 
(NLS) in RhoE promotes the recognition by the nucleocytoplasmic transporter (Importin, Imp 
/) and directs RhoE: PKC complex to enter the nucleus, interacts with helicase loading 
(MCM3 and MCM5 as well as ORC3L), and regulates the cell cycle. 
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6.3 Suggestions for Future Work 
6.3.1 Microarray Analysis of RhoE Function in U87 Human Glioblastoma Cell Line 
A sophisticated genomic tool like “transcriptomic profiling” can be used to understand 
the relevant signalling cascade of regulatory protein at the gene level by linking the cell 
differentiation in the development of tissue. Besides that, Soulet et al. (2010) discovered the 
related molecular processes using the chicken chorioallantoic membrane (CAM) model. They 
implanted the tumour tissue in the CAM and successfully revealed a significant number of 
advanced biomarkers that were up-regulated at different time intervals as compared to the 
control of the experiment. Furthermore, the signalling cascades of the particular regulatory 
protein are also consistent with several biomarkers that were accelerated in the chick embryo 
model. Then, they extended the transcriptome analysis in the “wound model” using CAM, 
which is an alternative model for cell differentiation during tissue development.  
In collaboration with Professor Falciani and S. Durant, an investigation was done on 
the U87 human glioblastoma cell line, which was implanted into the Chick Chorioallantoic 
Membrane, (CAM) to investigate tumour cell progression. The implantation of the tumour 
cells was done by either in control condition or after RhoE knock down that has a high 
potential in revealing the progression of tumour phenotypic expression in vivo by 
distinguishing the difference with or without the presence of RhoE. This study has prepared 
the mRNA samples from the implanted tumour and checked the samples over the period of 
time after the implantation to discover any possible signalling protein that directly or 
indirectly interacted with RhoE when RhoE expression is either upregulated or 
downregulated.  
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In addition, the identification of RhoE protein partners and the pathways that are 
involved in tissue granulation and neoangiogenesis ensured that the simulation of study for    
in vitro is consistent with the study for in vivo. The microarray analysis of the genes is        
up-regulated and down-regulated in U87 cells lines after the knock down of RhoE. The chick 
chorioallantoic wound model might be able to produce evidence if RhoE is one of the gene 
signatures for tumour markers. 
  
6.3.2 Phosphorylation Status of RhoE  
RhoE has a number of serine phosphorylation sites. The preliminary data indicate the 
differences in the phosphorylation status of nuclear RhoE when compared to cytosplasmic 
RhoE. The upper band RhoE in U87 glioblasoma cell is possibly phosphorylated and the 
validation was made using phosphatase enzyme to remove phosphate from 29kD RhoE. The 
U87 cell lysate underwent dephosphorylation by removing the phosphate groups from an 
organic compound via hydrolysis. Phosphatase enables the hydrolysis of phosphoric acid 
monoesters into a phosphate ion and a molecule with a free hydroxyl group. As a result, the 
hydrolysis of ATP to ADP and inorganic phosphate will release the protein to unbind with 
phosphate. However, the treatment of U87 cell ysate with calf intestinal phosphatase (CIP) as 
the main source of alkaline phosphatase (ALP) was unsuccessful. The attempt to remove 
upper band RhoE ended with the degradation of other proteins in U87 cell lysate. It was 
previously mentioned that RhoE appeared as double bands, 29 kD and 27 kD, in which 29kD 
is the phosphorylated form of RhoE; whereas 27kD is the non-phosphorylated form. The 
other application of polyacrylamide-bound Mn2+ -Phos-tag to SDS-PAGE was used to 
separate the phosphorylated proteins in the gel to make room for improvement          
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(Kinoshita et al. 2006). As an alternative, the analysis by mass spectrometry would be 
applicable to analyse the phosphorylation status of RhoE (McLachlin and Chait 2001). 
 
6.2.4 Chromatin Immunoprecipitation (ChIP) of RhoE with DNA Helicase Protein 
The accumulation of MCM3 in the nucleus during depletion of RhoE                       
(see Section 5.2.5) has generated a fundamental knowledge on how RhoE regulates 
glioblastoma cells. The study on protein-DNA interaction using ChIP method for before and 
after the treatment with helicase loading inhibitor might offer better explanation on how RhoE 
could indirectly regulate DNA replication, which is consistent with the deregulation of cell 
cycle.  
Besides that, the overexpression of MCM3 in U87 cell might also be beneficial to the 
study if the interaction with RhoE is direct. Instead of using pharmacological compound to 
inhibit DNA helicase loading, the site directed mutagenesis might be applicable to the gene 
encoded MCM3. It is important to consider whether to investigate either inhibition or 
mutation helicase loading followed by pull down MCM3 before determining the effect on 
RhoE interaction. It will be beneficial for future studies to investigate of ChIP as it might be 
able to completely remove RhoE from glioblatoma cells that bound to the chromatin. 
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APPENDIX 1 
SEQUENCE AND ALIGNMENT OF PLASMID RhoEWT                                  
(TRANSFECTED INTO 293T/U87 CELLS) 
 
 
PLASMID pCMV5 RhoE Flag Vector (AmpR)  
CCS   CSA WTK KGG GRG TYA WAT AGC AGA GCT CGT TTA  
GTG AAC CGT CAG AAT TGC CAC CAT GGA CTA CAA GGA 
CGA CGA TGA CAA GAA TTC GAA GGA GAG AAG AGC CAG 
CCA GAA ATT  ATC CAG TAA ATC TAT CAT GGA TCC TAA 
TCA GAA CGT       GAA ATG CAA GAT AGT AGT AGT GGG CGA 
CAG CCA GTG TGG      GAA  AAC CGC GCT GCT CCA CGT CTT 
CGC CAA GGA CTG CTT CCC AGA AAA TTA  CGT CCC TAC 
GGT GTT TGA GAA TTA CAC TGC  CAG TTT TGA AAT CGA 
CAC ACA AAG AAT AGA GTT GAG CCT  GTG GGA CAC TTC 
AGG TTC TCC TTA CTA TGA CAA CGT CCG  TCC ACT CTC 
TTA CCC AGA TTC TGA TGC AGT GCT CAT TTG  CTT TGA 
CAT CAG TAG ACC AGA GAC TCT GGA CAG TGT CTT  AAA 
AAA GTG GAA AGG TGA GAT CCA GGA GTT TTG TCC CAA 
 TAC CAA GAT GCT GTT GGT GGG CTG CAA GTC TGA TCT       
 GCG  GAC AGA TGT CAG CAC ATT AGT GGA ACT CTC AAA 
TCA CAG GCA GAC TCC TGT GTC ATA TGA CCA GGG GGC 
AAA TAT   GGC  CAA GCA GAT CGG AGC  AGC CAC TTA CAT 
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AGA ATG CTC AGC  TTT ACA GTC AGA AAA CAG CGT CAG 
AGA CAT TTT TCA     CGT  CGC CAC CTT GGC GTG TGT AAA 
TAA GAC AAA TAA AAA CGT  TAA GCG GAA CAA ATC GCA 
GAG GGC CAC AAA GCG GAT TTC GCA CAT GCC TAG CAG 
ACC AGA ACT CTC AGC AGT TGC TAC GGA CTT ACG AAA 
GGA CAA AGC GAA GAG CTG TAC TGT GAT  GTG AAA GCT 
TGG GTG GCA TCC CTG TGA CCC CTC CCC AGT  GCC TCT 
CCT GGC CCT GGA AGT TGC CAC TCC AGT GCC CAC CAG 
CCT TGT CCT AAT AAA ATT AAG TTG CAT CAT TTT GTC 
 TGA CTA GGT GTC CTT CTA TAA TAT TAT GGG GTG GAR       
GGG  GGG TGG TAT GGA GCA AGG GCA AGT TGG GAA GAC 
AAC CTG  TAG GGC CTG CGG GGT CTA TGG AAC AAG CTG 
GAG TGC AGT  GGC ACA ATC TTG GCT CAC TGC ATC TCG 
CCT CTG GGT TCA  AGC GAT CTC TGC TCA GCC TCC CGA 
GTT GTG GGA TTC CAG  GCA TGC ATG ACA GCT CAG CTA 
ATT TTT GTT TTT GTA ARA  CGG TTC ACG WAT TGG CAG 
CTG TCT CAT CCT ATY CAG TGA TCT ACC ACT GGC TCG 
ATG CTG ATW MGC KAA ACC AKG CTC  CGT CCG TCT TCT 
GGA ATT AAG WAA YTW ATC ACC AGG A 
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> ref|NM_005168.3| Homo sapiens Rho family GTPase 3 (RND3), mRNA 
Length=2683 
 
 
 Score = 1068 bits (578),  Expect = 0.0 
 Identities = 682/734 (93%), Gaps = 0/734 (0%) 
 Strand=Plus/Plus 
 
Query  91   GAAGGAGAGAAGAGCCAGCCAGAAATTATCCAGTAAATCTATCATGGATCCTAATCAGAA  150 
            ||||||||||||||||||||||||||||||||| |||||||||||||||||||||||||| 
Sbjct  159  GAAGGAGAGAAGAGCCAGCCAGAAATTATCCAGCAAATCTATCATGGATCCTAATCAGAA  218 
 
Query  151  CGTGAAATGCAAGATAGTAGTAGTGGGCGACAGCCAGTGTGGGAAAACCGCGCTGCTCCA  210 
            |||||||||||||||||| || ||||| ||||| |||||||| ||||| ||||||||||| 
Sbjct  219  CGTGAAATGCAAGATAGTTGTGGTGGGAGACAGTCAGTGTGGAAAAACTGCGCTGCTCCA  278 
 
Query  211  CGTCTTCGCCAAGGACTGCTTCCCAGAAAATTACGTCCCTACGGTGTTTGAGAATTACAC  270 
             ||||||||||||||||||||||| || |||||||| ||||| ||||||||||||||||| 
Sbjct  279  TGTCTTCGCCAAGGACTGCTTCCCCGAGAATTACGTTCCTACAGTGTTTGAGAATTACAC  338 
 
Query  271  TGCCAGTTTTGAAATCGACACACAAAGAATAGAGTTGAGCCTGTGGGACACTTCAGGTTC  330 
             ||||||||||||||||||||||||||||||||||||||||||||||||||||| ||||| 
Sbjct  339  GGCCAGTTTTGAAATCGACACACAAAGAATAGAGTTGAGCCTGTGGGACACTTCGGGTTC  398 
 
Query  331  TCCTTACTATGACAACGTCCGTCCACTCTCTTACCCAGATTCTGATGCAGTGCTCATTTG  390 
            ||||||||||||||| ||||| || ||||||||||| ||||| ||||| ||||| ||||| 
Sbjct  399  TCCTTACTATGACAATGTCCGCCCCCTCTCTTACCCTGATTCGGATGCTGTGCTGATTTG  458 
 
Query  391  CTTTGACATCAGTAGACCAGAGACTCTGGACAGTGTCTTAAAAAAGTGGAAAGGTGAGAT  450 
            |||||||||||||||||||||||| |||||||||||| | ||||||||||||||||| || 
Sbjct  459  CTTTGACATCAGTAGACCAGAGACCCTGGACAGTGTCCTCAAAAAGTGGAAAGGTGAAAT  518 
 
Query  451  CCAGGAGTTTTGTCCCAATACCAAGATGCTGTTGGTGGGCTGCAAGTCTGATCTGCGGAC  510 
            |||||| |||||||| |||||||| ||||| ||||| ||||||||||||||||||||||| 
Sbjct  519  CCAGGAATTTTGTCCAAATACCAAAATGCTCTTGGTCGGCTGCAAGTCTGATCTGCGGAC  578 
 
Query  511  AGATGTCAGCACATTAGTGGAACTCTCAAATCACAGGCAGACTCCTGTGTCATATGACCA  570 
            |||||| || |||||||| || ||||| |||||||||||||| || ||||| |||||||| 
Sbjct  579  AGATGTTAGTACATTAGTAGAGCTCTCCAATCACAGGCAGACGCCAGTGTCCTATGACCA  638 
 
Query  571  GGGGGCAAATATGGCCAAGCAGATCGGAGCAGCCACTTACATAGAATGCTCAGCTTTACA  630 
            |||||||||||||||||| ||||| |||||||| ||||| || ||||||||||||||||| 
Sbjct  639  GGGGGCAAATATGGCCAAACAGATTGGAGCAGCTACTTATATCGAATGCTCAGCTTTACA  698 
 
Query  631  GTCAGAAAACAGCGTCAGAGACATTTTTCACGTCGCCACCTTGGCGTGTGTAAATAAGAC  690 
            ||| ||||| ||||||||||||||||||||||| ||||||||||| |||||||||||||| 
Sbjct  699  GTCGGAAAATAGCGTCAGAGACATTTTTCACGTTGCCACCTTGGCATGTGTAAATAAGAC  758 
 
Query  691  AAATAAAAACGTTAAGCGGAACAAATCGCAGAGGGCCACAAAGCGGATTTCGCACATGCC  750 
            ||||||||||||||||||||||||||| ||||| ||||||||||||||||| |||||||| 
Sbjct  759  AAATAAAAACGTTAAGCGGAACAAATCACAGAGAGCCACAAAGCGGATTTCACACATGCC  818 
 
Query  751  TAGCAGACCAGAACTCTCAGCAGTTGCTACGGACTTACGAAAGGACAAAGCGAAGAGCTG  810 
            |||||||||||||||||| ||||||||||||||||||||||||||||||||||||||||| 
Sbjct  819  TAGCAGACCAGAACTCTCGGCAGTTGCTACGGACTTACGAAAGGACAAAGCGAAGAGCTG  878 
 
Query  811  TACTGTGATGTGAA  824 
             ||||||||||||| 
Sbjct  879  CACTGTGATGTGAA  892 
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ORIGIN       
   1 cagtcggctc ggaattggac ttgggaggcg cggtgaggag tcaggcttaa aacttgttgg 
  61 aggggagtaa ccagcctgct cctctcgctc tcctcctcgt ctgcgccgcg tttcagagag 
 121 aaaattcctg ttccaagaga aaataaggca acatcaatga aggagagaag agccagccag 
 181 aaattatcca gcaaatctat catggatcct aatcagaacg tgaaatgcaa gatagttgtg 
 241 gtgggagaca gtcagtgtgg aaaaactgcg ctgctccatg tcttcgccaa ggactgcttc 
 301 cccgagaatt acgttcctac agtgtttgag aattacacgg ccagttttga aatcgacaca 
 361 caaagaatag agttgagcct gtgggacact tcgggttctc cttactatga caatgtccgc 
 421 cccctctctt accctgattc ggatgctgtg ctgatttgct ttgacatcag tagaccagag 
 481 accctggaca gtgtcctcaa aaagtggaaa ggtgaaatcc aggaattttg tccaaatacc 
 541 aaaatgctct tggtcggctg caagtctgat ctgcggacag atgttagtac attagtagag 
 601 ctctccaatc acaggcagac gccagtgtcc tatgaccagg gggcaaatat ggccaaacag 
 661 attggagcag ctacttatat cgaatgctca gctttacagt cggaaaatag cgtcagagac 
 721 atttttcacg ttgccacctt ggcatgtgta aataagacaa ataaaaacgt taagcggaac 
 781 aaatcacaga gagccacaaa gcggatttca cacatgccta gcagaccaga actctcggca 
 841 gttgctacgg acttacgaaa ggacaaagcg aagagctgca ctgtgatgtg aatctttcat 
 901 tatctttaat gaagacaaag gaatctagtg taaaaaacaa cagcaaacaa aaaggtgaag 
 961 tctaaatgaa gtgcacagcc aaagtcatgt ataccagagg cttaggaggc gtttgagagg 
1021 atactcatct ttttggaatc ctgaccttag gttcggcatg tagaccaagt gatgagaagt 
1081 gaatacatgg aagagttttt aagtgtgact tgaaaaatat gccaaaaaat gagagataca 
1141 aatgagctag aggaagatga ggggggatgc gagtacctcc aagaagaaaa atcacactct 
1201 gaatggtgct tgcatttttg ggtttttttt ttttgttata atctattcat ggatctccac 
1261 tttgatttaa tttttaaatg ttttaatctc ctttacaaaa agtatacgtt aatataccgt 
1321 cctcaagggg gaactggcac tgtgacctta gcatttagtt ttctagagga tgtgatctaa 
1381 tttctttcta gctcatcatt aaaaaggaaa ttgtatcagg acccatggga tatatccaga 
1441 ggcaaacttt atgaggcttt gaaatcttgc cttcctgaag atagctgagt aggatggttc 
1501 taaggaaagc ctttgcaatc ttgcaagatt tgtagaccag cactacaaag atcgcataga 
1561 tcaaatagga aaaaaaatgt cgatttttat tcagtctgat ggttctgttc ttcattgtga  
1621 ttgtcattaa aaagtggtaa attgctcaat gtaatatttt tgtgcgctgt ttagaagttg 
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1681 tgtgattttt tgccatcgtt gataaaaatg caaagtcaaa taaaaggtgt cttggtttga 
1741 tgtcatagaa tgatccaagg agagaaaaaa ggtagttact gttttcacca gaaaaggtaa 
1801 tgagtgaagg aaagaatagt agcagaaagc acagtttgtg agtaaagctg tctggaatta 
1861 agttaccaaa aatacaaagc aaaaggacta ttattttggg ttgaagctcc aaaactgaca  
1921 gcatctgata atctgttggt ttatttcact tttcattaaa tgaacattga tgagagaaga 
1981 tgccacttac ccaagcttta gagaatccct agtggaagat tatatgataa actttcagtc 
2041 ctgacataac actagggcat ttctagagtg tcattgctaa aacctcactg aacagatgca 
2101 gccaaggtct gtgttcagca cttggtctct gttgttacgt aaaataataa gcatttaaaa 
2161 tagtttacag atatttttga ccagttcctt ttagagattc tttcagagaa gaaaccagat 
2221 ctgacctgtt tattgttggc gcttgttgaa aacgagcttt ctttcccatg atagtgcttc 
2281 gtttttgaag tgttgaagct gtgctcccct taaatcgtgg caggagagat taaggtaatt 
2341 acaacactca gttctatgtc ttacaagcac tttgtcttgt ctctgcaaga aaattcgatt 
2401 ccagtcattt cccataaaat acagacattt taccaacata atatgctttg attgatgcag 
2461 cattatgctt tgggcagtat tacaaaatag ctggcgagtg ctttctgtat ttaaatattg  
2521 taaaaagaaa ataagttata actgttataa agcagaactt ttgttgcatt ttttaaactg 
2581 ttgaagtcac tgtgtatgtt tgtttggtca atgtttccgc agtatttatt aaaacatact 
2641 ttttttttct tcaaataaaa aagtaaccat gtctttgtct aaa 
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APPENDIX 2 
SEQUENCE AND ALIGNMENT OF EMPTY VECTOR PLASMID    
(TRANSFECTED INTO 293T/U87 CELLS) 
 
 
Plasmid pCMV EV Flag (KanR) 
CSS CRA TKK GGG GYA TAT AGC AGA GCT GGT TTA GTG 
AAC CGT CAG ATC CGC TAG CCG GAC TCA GAT CTC GAG 
CTC    AAG  CTT GSC GCC ACC ATG GAC TAC AAG GAC GAC 
GAT GAC   AAG  GGA TCC GGT ACC TCT AGA ATT CTG CAG 
TCG ACG GTA CCG  CGG GCC CGG GAT CGA TCC ACC GGA 
TCT AGA TAA CTG ATC  ATA ATC AGC CAT ACC ACA TTT 
GTA GAG GTT TTA CTT GCT  TTA AAA AAC CTC CCA CAC 
CTC CCC CTG AAC CTG AAA CAT AAA ATG AAT GCA ATT 
GTT GTT GTT AAC TTG TTT ATT GCA  GCT TAT AAT GGT  
TAC AAA TAA AGC AAT AGC ATC ACA AAT  TTC ACA AAT  
AAA GCA TTT TTT TCA CTG CAT TCT AGT TGT  GGT TTG 
TCC AAA CTC ATC AAT GTA TCT TAA CGC GTA AAT  TGT 
AAG CGT TAA TAT TTT GTT AAA ATT CGC GTT AAA TTT  
TTG TTA AAT CAG CTC ATT TTT TAA CCA ATA GGC CGA 
AAT  CGG CAA AAT CCC TTA TAA ATC AAA AGA ATA GAC 
CGA GAT  AGG GTT GAG TGT TGT TCC AGT TTG GAA CAA 
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GAG TCC ACT  ATT AAA GAA CGT GGA CTC CAA CGT CAA 
AGG GCG AAA AAC  CGT CTA TCA GGG CGA TGG CCC ACT 
ACG TGA ACC ATC ACC  CTA ATC AAG TTT TTT GGG GTC  
GAG GTG CCG TAA AGC ACT  AAA TCG GAA CCC TAA AGG 
GAG CCC CCG ATT TAG AGC TTG  ACG GGG AAA GCC GGC 
GAA CGT GGC GAG AAA GGA AGG   GAA GAA GCG AAA GGA 
GCG GGC GCT AGG GCG CTG GCA AGT GTA  GCG GTC ACG 
CTG CGC GTA ACC ACC ACA CCC GCC GCG CTT  AAT GCG 
CCG CTA CAG GGC GCG TCA GTG GCA CTT TTC   GGG  GAA 
ATG TGC GCG GAA CCC CTA TTT GTT ATT TTT CTA ATA 
CAT TCA ATA TGT ATC CGC TCA TGA GAC ATA ACC CTG 
ATA  ATG CTT CAT ATA TTG AAA AGG AGA GTC CTG AGC 
GGA      AGA CCA GCT GTG ATG TGT GTC AGT AGG TGT  GAA 
AGT CCC AGC  TCC CAG CAG CAG AGT ATG CAA GCA TGC 
ATC TCA TAG TCA  GCA CAG KGK GAA GTC CCA GCT CCC 
AGC AGS MRA GTA TGC  AAG CAT GCA TCT CAT TAG TMR 
CAA CAW AGT CCG CCC TA 
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> gb|AF028239.1|AF028239  Mammalian expression vector pCMV-Script, complete sequence 
Length=4278 
                                                    
 Score = 1444 bits (744),  Expect = 0.0 
 Identities = 786/792 (99%), Gaps = 6/792 (1%) 
 Strand=Plus/Plus 
 
Query  191   TGATCATAATCAGCCATACCACATTTGTAGAGGTTTTACTTGCTTTAAAAAACCTCCCAC  250 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  965   TGATCATAATCAGCCATACCACATTTGTAGAGGTTTTACTTGCTTTAAAAAACCTCCCAC  1024 
 
Query  251   ACCTCCCCCTGAACCTGAAACATAAAATGAATGCAATTGTTGTTGTTAACTTGTTTATTG  310 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1025  ACCTCCCCCTGAACCTGAAACATAAAATGAATGCAATTGTTGTTGTTAACTTGTTTATTG  1084 
 
Query  311   CAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCAtttt  370 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1085  CAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTT  1144 
 
Query  371   tttCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTAACGCGTAAATT  430 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1145  TTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTAACGCGTAAATT  1204 
 
Query  431   GTAAGCGTTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTTT  490 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1205  GTAAGCGTTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTTT  1264 
 
Query  491   AACCAATAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAAGAATAGACCGAGATAGGG  550 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1265  AACCAATAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAAGAATAGACCGAGATAGGG  1324 
 
Query  551   TTGAGTGTTGTTCCAGTTTGGAACAAGAGTCCACTATTAAAGAACGTGGACTCCAACGTC  610 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1325  TTGAGTGTTGTTCCAGTTTGGAACAAGAGTCCACTATTAAAGAACGTGGACTCCAACGTC  1384 
 
Query  611   AAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCACCCTAATCA  670 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1385  AAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCACCCTAATCA  1444 
 
Query  671   AGTTTTTTGGGGTCGAGGTGCCGTAAAGCACTAAATCGGAACCCTAAAGGGAGCCCCCGA  730 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1445  AGTTTTTTGGGGTCGAGGTGCCGTAAAGCACTAAATCGGAACCCTAAAGGGAGCCCCCGA  1504 
 
Query  731   TTTAGAGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGAAG-AAGCGAAA  789 
             ||||||||||||||||||||||||||||||||||||||||||||||||||| |||||||| 
Sbjct  1505  TTTAGAGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGAAGAAAGCGAAA  1564 
 
Query  790   GGAGCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACGCTGCGCGTAACCACCACACCC  849 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1565  GGAGCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACGCTGCGCGTAACCACCACACCC  1624 
 
Query  850   GCCGCGCTTAATGCGCCGCTACAGGGCGCGTCA-GTGGCACTTTTCGGGGAAATGTGCGC  908 
             ||||||||||||||||||||||||||||||||| |||||||||||||||||||||||||| 
Sbjct  1625  GCCGCGCTTAATGCGCCGCTACAGGGCGCGTCAGGTGGCACTTTTCGGGGAAATGTGCGC  1684 
 
Query  909   GGAACCCCTATTTG-TTATTTTTCT-AATACATTC-AATATGTATCCGCTCATGAGAC-A  964 
             |||||||||||||| |||||||||| ||||||||| |||||||||||||||||||||| | 
Sbjct  1685  GGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAA  1744 
 
Query  965   TAACCCTGATAA  976 
             |||||||||||| 
Sbjct  1745  TAACCCTGATAA  1756 
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ORIGIN       
       1 atgcattagt tattaatagt aatcaattac ggggtcatta gttcatagcc catatatgga 
       61 gttccgcgtt acataactta cggtaaatgg cccgcctggc tgaccgccca acgacccccg 
      121 cccattgacg tcaataatga cgtatgttcc catagtaacg ccaataggga ctttccattg 
      181 acgtcaatgg gtggagtatt tacggtaaac tgcccacttg gcagtacatc aagtgtatca 
      241 tatgccaagt acgcccccta ttgacgtcaa tgacggtaaa tggcccgcct ggcattatgc 
      301 ccagtacatg accttatggg actttcctac ttggcagtac atctacgtat tagtcatcgc 
      361 tattaccatg gtgatgcggt tttggcagta catcaatggg cgtggatagc ggtttgactc 
      421 acggggattt ccaagtctcc accccattga cgtcaatggg agtttgtttt ggcaccaaaa 
      481 tcaacgggac tttccaaaat gtcgtaacaa ctccgcccca ttgacgcaaa tgggcggtag 
      541 gcgtgtacgg tgggaggtct atataagcag agctggttta gtgaaccgtc agatccgcta 
      601 gcgattacgc caagctcgaa attaaccctc actaaaggga acaaaagctg gagctccacc 
      661 gcggtggcgg ccgctctagc ccgggcggat cccccgggct gcaggaattc gatatcaagc 
      721 ttatcgatac cgtcgacctc gagggggggc ccggtaccag gtaagtgtac ccaattcgcc 
      781 ctatagtgag tcgtattaca attcactcga tcgcccttcc caacagttgc gcagcctgaa 
      841 tggcgaatgg agatccaatt tttaagtgta taatgtgtta aactactgat tctaattgtt 
      901 tgtgtatttt agattcacag tcccaaggct catttcaggc ccctcagtcc tcacagtctg 
      961 ttcatgatca taatcagcca taccacattt gtagaggttt tacttgcttt aaaaaacctc 
     1021 ccacacctcc ccctgaacct gaaacataaa atgaatgcaa ttgttgttgt taacttgttt 
     1081 attgcagctt ataatggtta caaataaagc aatagcatca caaatttcac aaataaagca 
     1141 tttttttcac tgcattctag ttgtggtttg tccaaactca tcaatgtatc ttaacgcgta 
     1201 aattgtaagc gttaatattt tgttaaaatt cgcgttaaat ttttgttaaa tcagctcatt 
     1261 ttttaaccaa taggccgaaa tcggcaaaat cccttataaa tcaaaagaat agaccgagat 
     1321 agggttgagt gttgttccag tttggaacaa gagtccacta ttaaagaacg tggactccaa 
     1381 cgtcaaaggg cgaaaaaccg tctatcaggg cgatggccca ctacgtgaac catcacccta 
     1441 atcaagtttt ttggggtcga ggtgccgtaa agcactaaat cggaacccta aagggagccc 
     1501 ccgatttaga gcttgacggg gaaagccggc gaacgtggcg agaaaggaag ggaagaaagc 
     1561 gaaaggagcg ggcgctaggg cgctggcaag tgtagcggtc acgctgcgcg taaccaccac 
     1621 acccgccgcg cttaatgcgc cgctacaggg cgcgtcaggt ggcacttttc ggggaaatgt 
     1681 gcgcggaacc cctatttgtt tatttttcta aatacattca aatatgtatc cgctcatgag 
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     1741 acaataaccc tgataaatgc ttcaataata ttgaaaaagg aagaatcctg aggcggaaag 
     1801 aaccagctgt ggaatgtgtg tcagttaggg tgtggaaagt ccccaggctc cccagcaggc 
     1861 agaagtatgc aaagcatgca tctcaattag tcagcaacca ggtgtggaaa gtccccaggc 
     1921 tccccagcag gcagaagtat gcaaagcatg catctcaatt agtcagcaac catagtcccg 
     1981 cccctaactc cgcccatccc gcccctaact ccgcccagtt ccgcccattc tccgccccat 
     2041 ggctgactaa ttttttttat ttatgcagag gccgaggccg cctcggcctc tgagctattc 
     2101 cagaagtagt gaggaggctt ttttggaggc ctaggctttt gcaaagatcg atcaagagac 
     2161 aggatgagga tcgtttcgca tgattgaaca agatggattg cacgcaggtt ctccggccgc 
     2221 ttgggtggag aggctattcg gctatgactg ggcacaacag acaatcggct gctctgatgc 
     2281 cgccgtgttc cggctgtcag cgcaggggcg cccggttctt tttgtcaaga ccgacctgtc 
     2341 cggtgccctg aatgaactgc aagacgaggc agcgcggcta tcgtggctgg ccacgacggg 
     2401 cgttccttgc gcagctgtgc tcgacgttgt cactgaagcg ggaagggact ggctgctatt 
     2461 gggcgaagtg ccggggcagg atctcctgtc atctcacctt gctcctgccg agaaagtatc 
     2521 catcatggct gatgcaatgc ggcggctgca tacgcttgat ccggctacct gcccattcga 
     2581 ccaccaagcg aaacatcgca tcgagcgagc acgtactcgg atggaagccg gtcttgtcga 
     2641 tcaggatgat ctggacgaag aacatcaggg gctcgcgcca gccgaactgt tcgccaggct 
     2701 caaggcgagc atgcccgacg gcgaggatct cgtcgtgacc catggcgatg cctgcttgcc 
     2761 gaatatcatg gtggaaaatg gccgcttttc tggattcatc gactgtggcc ggctgggtgt 
     2821 ggcggaccgc tatcaggaca tagcgttggc tacccgtgat attgctgaag aacttggcgg 
     2881 cgaatgggct gaccgcttcc tcgtgcttta cggtatcgcc gctcccgatt cgcagcgcat 
     2941 cgccttctat cgccttcttg acgagttctt ctgagcggga ctctggggtt cgaaatgacc 
     3001 gaccaagcga cgcccaacct gccatcacga gatttcgatt ccaccgccgc cttctatgaa 
     3061 aggttgggct tcggaatcgt tttccgggac gccggctgga tgatcctcca gcgcggggat 
     3121 ctcatgctgg agttcttcgc ccaccctagg gggaggctaa ctgaaacacg gaaggagaca 
     3181 ataccggaag gaacccgcgc tatgacggca ataaaaagac agaataaaac gcacggtgtt 
     3241 gggtcgtttg ttcataaacg cggggttcgg tcccagggct ggcactctgt cgatacccca 
     3301 ccgagacccc attggggcca atacgcccgc gtttcttcct tttccccacc ccacccccca 
     3361 agttcgggtg aaggcccagg gctcgcagcc aacgtcgggg cggcaggccc tgccatagcc 
     3421 tcaggttact catatatact ttagattgat ttaaaacttc atttttaatt taaaaggatc 
     3481 taggtgaaga tcctttttga taatctcatg accaaaatcc cttaacgtga gttttcgttc 
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     3541 cactgagcgt cagaccccgt agaaaagatc aaaggatctt cttgagatcc tttttttctg 
     3601 cgcgtaatct gctgcttgca aacaaaaaaa ccaccgctac cagcggtggt ttgtttgccg 
     3661 gatcaagagc taccaactct ttttccgaag gtaactggct tcagcagagc gcagatacca 
     3721 aatactgtcc ttctagtgta gccgtagtta ggccaccact tcaagaactc tgtagcaccg 
     3781 cctacatacc tcgctctgct aatcctgtta ccagtggctg ctgccagtgg cgataagtcg 
     3841 tgtcttaccg ggttggactc aagacgatag ttaccggata aggcgcagcg gtcgggctga 
     3901 acggggggtt cgtgcacaca gcccagcttg gagcgaacga cctacaccga actgagatac 
     3961 ctacagcgtg agctatgaga aagcgccacg cttcccgaag ggagaaaggc ggacaggtat 
     4021 ccggtaagcg gcagggtcgg aacaggagag cgcacgaggg agcttccagg gggaaacgcc 
     4081 tggtatcttt atagtcctgt cgggtttcgc cacctctgac ttgagcgtcg atttttgtga 
     4141 tgctcgtcag gggggcggag cctatggaaa aacgccagca acgcggcctt tttacggttc 
     4201 ctggcctttt gctggccttt tgctcacatg ttctttcctg cgttatcccc tgattctgtg 
     4261 gataaccgta ttaccgcc 
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APPENDIX 3 
PHOSPHORYLATION SITES PREDICTED IN RHOE 
 
 
 
(A) Phosphorylation sites predicted in RhoE 
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(B) Phosphorylated peptide sequences in three (3) amino acids predicted in RhoE 
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APPENDIX 4 
NUCLEAR EXPORT SIGNAL (NES) PREDICTED IN RHOE 
 
 
 
sp_P61587_RND3_-68-T      0.096   0.886   0.588       
sp_P61587_RND3_-69-Q      0.110   0.886   0.595       
sp_P61587_RND3_-70-R      0.088   0.886   0.598       
sp_P61587_RND3_-71-I      0.101   0.886   0.602        
sp_P61587_RND3_-72-E      0.084   0.885   0.596       
sp_P61587_RND3_-73-L      0.319   0.885   0.645       
sp_P61587_RND3_-74-S      0.079   0.873   0.629       
sp_P61587_RND3_-75-L      0.538   0.873   1.125       
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APPENDIX 5 
NUCLEAR LOCALISATION SIGNAL (NLS) PREDICTED IN RHOE 
 
 
 
207- RNKSQRATKRISHMPSRPELSAVATDLRKDKAKSCT -242 
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APPENDIX 6 
LIST OF GENES FROM RHOE PULL DOWN ASSAY 
 
 
 
(A) List of genes obtained from U87 cells transfected with pCMV FLAG-RhoEWT 
(B) List of genes obtained from U87 cells transfected with RhoE double mutants, pCMV 
FLAG-RhoET173R/V192R 
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(A) 
GENE CARDS DAVID ID GENE / PROTEIN DESCRIPTION 
ACTBL2 797358 actin, beta-like 2      Homo sapiens 
ALB 803627 albumin Homo sapiens 
ALDH18A1 793882 aldehyde dehydrogenase 18 family, member A1     Homo sapiens 
AP2M1 789199 adaptor-related protein complex 2, mu 1 subunit Homo sapiens 
ARHGEF5 817871 Rho guanine nucleotide exchange factor (GEF) 5  Homo sapiens 
ATAD3B 796501 similar to AAA-ATPase  TOB3; ATPase family, AAA domain 
containing 3B    Homo sapiens 
ATPA1A 783032 ATPase, Na+/K+ transporting, alpha 1 polypeptide        Homo sapiens 
ATR 806289 ataxia telangiectasia and Rad3 related; similar to ataxia telangiectasia 
and Rad3 related protein       Homo sapiens 
BAG1 798664 BCL2-associated athanogene      Homo sapiens 
C11ORF48 807064 chromosome 11 open reading frame 48     Homo sapiens 
CAPRIN1 820118 cell cycle associated protein 1 Homo sapiens 
CAV1 798707 caveolin 1, caveolae protein, 22kDa     Homo sapiens 
CCDC47 779089 coiled-coil domain containing 47        Homo sapiens 
CCT3 796391 chaperonin containing TCP1, subunit 3 (gamma)   Homo sapiens 
CDHR2 795714 protocadherin 24        Homo sapiens 
CFL1 794115 cofilin 1 (non-muscle)  Homo sapiens 
CIRH1A 792420 cirrhosis, autosomal recessive 1A (cirhin)      Homo sapiens 
COL6A3 797879 collagen, type VI, alpha 3      Homo sapiens 
COPA 787361 coatomer protein complex, subunit alpha Homo sapiens 
COPB2 786977 coatomer protein complex, subunit beta 2 (beta prime)   Homo sapiens 
COX4NB 811425 COX4 neighbour   Homo sapiens 
CPNE5 777897 copine V        Homo sapiens 
CPT1A 783247 carnitine palmitoyltransferase 1A (liver)       Homo sapiens 
CSNK2A2 784435 casein kinase 2, alpha prime polypeptide        Homo sapiens 
CYFIP2 792857 cytoplasmic FMR1 interacting protein 2  Homo sapiens 
DDX3Y 826174 DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-linked      Homo 
sapiens 
DDX47 808234 DEAD (Asp-Glu-Ala-Asp) box polypeptide 47       Homo sapiens 
DNAJB11 793612 DnaJ (Hsp40) homolog, subfamily B, member 11    Homo sapiens 
DSC1 825815 desmocollin 1   Homo sapiens 
DSG1 802187 desmoglein 1    Homo sapiens 
DSP 798372 desmoplakin     Homo sapiens 
EEF1A1 821677 eukaryotic translation elongation factor 1 alpha-like 7; eukaryotic 
translation elongation factor 1 alpha-like 3; similar to eukaryotic 
translation elongation factor 1 alpha 1; eukaryotic translation elongation 
factor 1 alpha 1     Homo sapiens 
EEF1D 813345 eukaryotic translation elongation factor 1 delta (guanine nucleotide 
exchange protein)  Homo sapiens 
EEF1G 781923 eukaryotic translation elongation factor 1 gamma        Homo sapiens 
EIF2S1 815878 eukaryotic translation initiation factor 2, subunit 1 alpha, 35kDa      
Homo sapiens 
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GENE CARDS DAVID ID GENE / PROTEIN DESCRIPTION 
EIF3A 795324 eukaryotic translation initiation factor 3, subunit A   Homo sapiens 
EIF3C 795748 eukaryotic translation initiation factor 3, subunit C   Homo sapiens 
EIF3E 818572 eukaryotic translation initiation factor 3, subunit E   Homo sapiens 
EIF3G 792561 eukaryotic translation initiation factor 3, subunit G   Homo sapiens 
EIF3H 788335 eukaryotic translation initiation factor 3, subunit H   Homo sapiens 
EIF3I 800360 eukaryotic translation initiation factor 3, subunit I   Homo sapiens 
EIF3J 812748 eukaryotic translation initiation factor 3, subunit J   Homo sapiens 
EIF4A1 778310 similar to eukaryotic translation initiation factor 4A; small nucleolar 
RNA, H/ACA box 67; eukaryotic translation initiation factor 4A, 
isoform 1       Homo sapiens 
EIF5B 783097 eukaryotic translation initiation factor 5B     Homo sapiens 
EMG1 782397 EMG1 nucleolar protein homolog (S. cerevisiae)  Homo sapiens 
EPRS 788040 glutamyl-prolyl-tRNA synthetase Homo sapiens 
ERLIN2 810009 ER lipid raft associated 2      Homo sapiens 
EZR 816077 hypothetical protein LOC100129652; ezrin        Homo sapiens 
FAM120A 786904 family with sequence similarity 120A    Homo sapiens 
FAM98A 817972 family with sequence similarity 98, member A    Homo sapiens 
FARSA 785154 phenylalanyl-tRNA synthetase, alpha subunit     Homo sapiens 
FBL 785244 fibrillarin     Homo sapiens 
FCGRT 821143 Fc fragment of IgG, receptor, transporter, alpha        Homo sapiens 
FLNA 786593 filamin A, alpha (actin binding protein 280)    Homo sapiens 
FMNL2 783204 formin-like 2   Homo sapiens 
FMR1 787787 fragile X mental retardation 1  Homo sapiens 
FNDC3B 802811 fibronectin type III domain containing 3B       Homo sapiens 
GANAB 806455 glucosidase, alpha; neutral AB  Homo sapiens 
GAPDH 801768 glyceraldehyde-3-phosphate dehydrogenase-like 6; hypothetical protein 
LOC100133042; glyceraldehyde-3-phosphate dehydrogenase    Homo 
sapiens 
GCN1L1 817738 GCN1 general control of amino-acid synthesis 1-like 1 (yeast)   Homo 
sapiens 
GNAS 809539 GNAS complex locus      Homo sapiens 
GTPBP4 810125 GTP binding protein 4   Homo sapiens 
H2AFX 794356 H2A histone family, member X    Homo sapiens 
HADHA 789097 hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme A 
thiolase/enoyl-Coenzyme A hydratase (trifunctional protein), alpha 
subunit   Homo sapiens 
HIST1H2BC 820197 histone cluster 1, H2bi; histone cluster 1, H2bg; histone cluster 1, H2be; 
histone cluster 1, H2bf; histone cluster 1, H2bc     Homo sapiens 
HIST3H3 816461 histone cluster 3, H3   Homo sapiens 
HIST4H4 784692 784692  histone cluster 1, H4l; histone cluster 1, H4k; histone cluster 4, 
H4; histone cluster 1, H4h; histone cluster 1, H4j; histone cluster 1, H4i; 
histone cluster 1, H4d; histone cluster 1, H4c; histone cluster 1, H4f; 
histone cluster 1, H4e; histone cluster 1, H4b; histone cluster 1, H4a; 
histone cluster 2, H4a; histone cluster 2, H4b   Homo sapiens 
HK1 777438 777438  hexokinase 1    Homo sapiens 
HNRNPK 803294 803294  heterogeneous nuclear ribonucleoprotein K; similar to 
heterogeneous nuclear ribonucleoprotein K Homo sapiens 
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GENE CARDS  DAVID ID GENE / PROTEIN DESCRIPTION 
HNRNPM 791398 heterogeneous nuclear ribonucleoprotein M       Homo sapiens 
HNRNPR 822132 heterogeneous nuclear ribonucleoprotein R       Homo sapiens 
HNRNPU 817941 heterogeneous nuclear ribonucleoprotein U (scaffold attachment factor 
A)        Homo sapiens 
HRNR 779317 hornerin        Homo sapiens 
HSD17B4 785861 hydroxysteroid (17-beta) dehydrogenase 4        Homo sapiens 
HSP90AA1 785761 heat shock protein 90kDa alpha (cytosolic), class A member 2; heat 
shock protein 90kDa alpha (cytosolic), class A member 1      Homo 
sapiens 
HSP90B1 804644 heat shock protein 90kDa beta (Grp94), member 1 Homo sapiens 
IGKV@ 802175 immunoglobulin kappa variable group     Homo sapiens 
ILF3 810501 interleukin enhancer binding factor 3, 90kDa    Homo sapiens 
INTS7 809105 integrator complex subunit 7    Homo sapiens 
IPO13 808279 importin 13     Homo sapiens 
JUP 822268 junction plakoglobin    Homo sapiens 
KCTD10 790367 potassium channel tetramerisation domain containing 10  Homo sapiens 
KIAA0776 810127 KIAA0776        Homo sapiens 
KPNA2 813154 karyopherin alpha 2 (RAG cohort 1, importin alpha 1); karyopherin 
alpha-2 subunit like  Homo sapiens 
KPRP 773413 keratinocyte proline-rich protein       Homo sapiens 
KRT13 772288 keratin 13      Homo sapiens 
KRT4 783234 keratin 4       Homo sapiens 
KRT5 808801 keratin 5       Homo sapiens 
KRT6C 815379 keratin 6C      Homo sapiens 
KRT78 784148 keratin 78      Homo sapiens 
KRT80 814522 keratin 80      Homo sapiens 
KRT9 811716 keratin 9       Homo sapiens 
LARP1 813968 La ribonucleoprotein domain family, member 1    Homo sapiens 
LARS 793517 leucyl-tRNA synthetase  Homo sapiens 
LCN1 810811 lipocalin 1-like 1; lipocalin 1 (tear prealbumin)       Homo sapiens 
LMNA 783908 lamin A/C       Homo sapiens 
LMNB2 779436 lamin B2        Homo sapiens 
LOC100128226 782902 hypothetic protein      Homo sapiens 
LYZ 799441 lysozyme (renal amyloidosis)    Homo sapiens 
MACF1 788987 microtubule-actin crosslinking factor 1 Homo sapiens 
MARS 818141 methionyl-tRNA synthetase       Homo sapiens 
MATR3 786723 matrin 3        Homo sapiens 
MCM5 807548 minichromosome maintenance complex component 5  Homo sapiens 
MRPS22 817976 mitochondrial ribosomal protein S22     Homo sapiens 
MRPS7 804122 mitochondrial ribosomal protein S7      Homo sapiens 
MTA1 800748 metastasis associated 1 Homo sapiens 
MVP 801651 major vault protein     Homo sapiens 
MYO1C 795356 myosin IC       Homo sapiens 
MYOF 783835 myoferlin       Homo sapiens 
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GENE CARDS DAVID ID GENE / PROTEIN DESCRIPTION 
NACA2 820622 nascent polypeptide-associated complex alpha subunit 2  Homo sapiens 
NAP1L1 821882 nucleosome assembly protein 1-like 1    Homo sapiens 
NAT10 822057 N-acetyltransferase 10 (GCN5-related)   Homo sapiens 
NCAM2 795608 neural cell adhesion molecule 2 Homo sapiens 
NCBP1 792438 nuclear cap binding protein subunit 1, 80kDa    Homo sapiens 
NCKAP1 804150 NCK-associated protein 1        Homo sapiens 
NCL 792174 nucleolin       Homo sapiens 
NMNAT1 772256 nicotinamide nucleotide adenylyltransferase 1   Homo sapiens 
NOL6 779120 nucleolar protein family 6 (RNA-associated)     Homo sapiens 
NOP2 821241 NOP2 nucleolar protein homolog (yeast)  Homo sapiens 
NPM3 793886 nucleophosmin/nucleoplasmin, 3  Homo sapiens 
PAIP1 783127 poly(A) binding protein interacting protein 1; similar to poly(A) binding 
protein interacting protein 1 Homo sapiens 
PARVB 825287 parvin, beta    Homo sapiens 
PCBP2 782567 poly(rC) binding protein 2      Homo sapiens 
PGAM5 804781 phosphoglycerate mutase family member 5 Homo sapiens 
PHB2 775357 prohibitin 2    Homo sapiens 
PIK3CG 785330 phosphoinositide-3-kinase, catalytic, gamma polypeptide Homo sapiens 
PML 807701 promyelocytic leukemia; similar to promyelocytic leukemia protein 
isoform 1     Homo sapiens 
PRCKD 797767 protein kinase C, delta Homo sapiens 
PRIM1 783798 primase, DNA, polypeptide 1 (49kDa)     Homo sapiens 
PRPF6 777887 similar to U5 snRNP-associated 102 kDa protein (U5-102 kDa protein); 
PRP6 pre-mRNA processing factor 6 homolog (S. cerevisiae)  Homo 
sapiens 
PRSS1 773661 protease, serine, 1 (trypsin 1); trypsinogen C  Homo sapiens 
PSMD2 793113 proteasome (prosome, macropain) 26S subunit, non-ATPase, 2      Homo 
sapiens 
PSMD3 791833 proteasome (prosome, macropain) 26S subunit, non-ATPase, 3      Homo 
sapiens 
PTPLAD1 784441 protein tyrosine phosphatase-like A domain containing 1 Homo sapiens 
PWP2 782420 WP2 periodic tryptophan protein homolog (yeast)        Homo sapiens 
QARS 795667 glutaminyl-tRNA synthetase      Homo sapiens 
RARS 819048 arginyl-tRNA synthetase Homo sapiens 
RECQL 819070 similar to Werner syndrome protein; Werner syndrome, RecQ helicase-
like Homo sapiens 
RER1 783412 RER1 retention in endoplasmic reticulum 1 homolog (S. cerevisiae)       
Homo sapiens 
RND3 789205 Rho family GTPase 3     Homo sapiens 
RPL11 810885 ribosomal protein L11   Homo sapiens 
RPL13 822027 ribosomal protein L13 pseudogene 12; ribosomal protein L13      Homo 
sapiens 
RPL13A 791016 ribosomal protein L13a pseudogene 7; ribosomal protein L13a 
pseudogene 5; ribosomal protein L13a pseudogene 16; ribosomal protein 
L13a; ribosomal protein L13a pseudogene 18    Homo sapiens 
RPL13AP25 792582 ribosomal protein L13a pseudogene 20; ribosomal protein L13a 
pseudogene 22; ribosomal protein L13a pseudogene 25        Homo 
sapiens 
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RPL15 779090 ribosomal protein L15 pseudogene 22; ribosomal protein L15 
pseudogene 18; ribosomal protein L15 pseudogene 17; ribosomal 
protein L15 pseudogene 3; ribosomal protein L15 pseudogene 7; 
ribosomal protein L15    Homo sapiens 
RPL18 776035 ribosomal protein L18   Homo sapiens 
RPL18A 778688 ribosomal protein L18a pseudogene 6; ribosomal protein L18a     Homo 
sapiens 
RPL21 793235 ribosomal protein L21 pseudogene 134; ribosomal protein L21 
pseudogene 80; ribosomal protein L21 pseudogene 20; ribosomal 
protein L21 pseudogene 46; ribosomal protein L21 pseudogene 45; 
ribosomal protein L21 pseudogene 131; ribosomal protein L21 
pseudogene 16; ribosomal protein L21 pseudogene 53; ribosomal 
protein L21 pseudogene 120; ribosomal protein L21 pseudogene 37; 
ribosomal protein L21 pseudogene 93; ribosomal protein L21 
pseudogene 39; ribosomal protein L21 pseudogene 29; ribosomal 
protein L21 pseudogene 28; ribosomal protein L21 pseudogene 14; 
ribosomal protein L21 pseudogene 98; ribosomal protein L21 
pseudogene 105; ribosomal protein L21 pseudogene 87; ribosomal 
protein L21 pseudogene 128; ribosomal protein L21 pseudogene 69; 
ribosomal protein L21 pseudogene 97; ribosomal protein L21; ribosomal 
protein L21 pseudogene 119; ribosomal protein L21 pseudogene 125 
Homo sapiens 
RPL24 800698 ribosomal protein L24; ribosomal protein L24 pseudogene 6       Homo 
sapiens 
RPL27 784332 ribosomal protein L27   Homo sapiens 
RPL28 820040 ribosomal protein L28   Homo sapiens 
RPL3 802424 ribosomal protein L3; similar to 60S ribosomal protein L3 (L4)  Homo 
sapiens 
RPL30 798725 ribosomal protein L30   Homo sapiens 
RPL4 786754 ribosomal protein L4; ribosomal protein L4 pseudogene 5; ribosomal 
protein L4 pseudogene 4      Homo sapiens 
 
RPL5 804383 ribosomal protein L5 pseudogene 34; ribosomal protein L5 pseudogene 
1; ribosomal protein L5     Homo sapiens 
 
RPL6 795791 ribosomal protein L6 pseudogene 27; ribosomal protein L6 pseudogene 
19; ribosomal protein L6; ribosomal protein L6 pseudogene 10        
Homo sapiens 
RPL7 825605 ribosomal protein L7 pseudogene 26; ribosomal protein L7 pseudogene 
16; ribosomal protein L7; ribosomal protein L7 pseudogene 32; 
ribosomal protein L7 pseudogene 23; ribosomal protein L7 pseudogene 
24; ribosomal protein L7 pseudogene 20    Homo sapiens 
RPL7L1 799659 ribosomal protein L7-like 1; ribosomal protein L7 pseudogene 14; 
ribosomal protein L7 pseudogene 21; ribosomal protein L7 pseudogene 
22; ribosomal protein L7 pseudogene 46     Homo sapiens 
RPL8 801125 ribosomal protein L8; ribosomal protein L8 pseudogene 2 Homo sapiens 
RPLP0 796227 ribosomal protein, large, P0 pseudogene 2; ribosomal protein, large, P0 
pseudogene 3; ribosomal protein, large, P0 pseudogene 6; ribosomal 
protein, large, P0   Homo sapiens 
RPN2 791634 ribophorin II   Homo sapiens 
RPS12 800729 ribosomal protein S12; ribosomal protein S12 pseudogene 4; ribosomal 
protein S12 pseudogene 11; ribosomal protein S12 pseudogene 9      
Homo sapiens 
RPS14 817032 ribosomal protein S14   Homo sapiens 
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RPS15A 788428 ribosomal protein S15a pseudogene 17; ribosomal protein S15a 
pseudogene 19; ribosomal protein S15a pseudogene 12; ribosomal 
protein S15a pseudogene 24; ribosomal protein S15a pseudogene 11; 
ribosomal protein S15a    Homo sapiens 
RPS16 790706 ribosomal protein S16 pseudogene 1; ribosomal protein S16 pseudogene 
10; ribosomal protein S16  Homo sapiens 
RPS17 805465 ribosomal protein S17   Homo sapiens 
RPS2 776216 ribosomal protein S2 pseudogene 8; ribosomal protein S2 pseudogene 
11; ribosomal protein S2 pseudogene 5; ribosomal protein S2 
pseudogene 12; ribosomal protein S2 pseudogene 51; ribosomal protein 
S2 pseudogene 17; ribosomal protein S2 pseudogene 55; ribosomal 
protein S2 pseudogene 20; ribosomal protein S2      Homo sapiens 
RPS20 781689 ribosomal protein S20   Homo sapiens 
RPS23 801872 ribosomal protein S23   Homo sapiens 
RPS26 772335 ribosomal protein S26 pseudogene 38; ribosomal protein S26 
pseudogene 39; ribosomal protein S26 pseudogene 35; ribosomal protein 
S26 pseudogene 31; ribosomal protein S26 pseudogene 20; ribosomal 
protein S26 pseudogene 54; ribosomal protein S26 pseudogene 2; 
ribosomal protein S26 pseudogene 53; ribosomal protein S26 
pseudogene 25; ribosomal protein S26 pseudogene 50; ribosomal protein 
S26 pseudogene 6; ribosomal protein S26 pseudogene 8; ribosomal 
protein S26  Homo sapiens 
RPS27 789083 ribosomal protein S27 pseudogene 29; ribosomal protein S27 
pseudogene 9; ribosomal protein S27 pseudogene 23; ribosomal protein 
S27 pseudogene 13; ribosomal protein S27; ribosomal protein S27 
pseudogene 21; ribosomal protein S27 pseudogene 7; ribosomal protein 
S27 pseudogene 6; ribosomal protein S27 pseudogene 19      Homo 
sapiens 
RPS27L 783803 ribosomal protein S27-like      Homo sapiens 
RPS3 816191 ribosomal protein S3 pseudogene 3; ribosomal protein S3 Homo sapiens 
RPS3A 789968 ribosomal protein S3A pseudogene 5; ribosomal protein S3a pseudogene 
47; ribosomal protein S3a pseudogene 49; ribosomal protein S3A; 
hypothetical LOC100131699; hypothetical LOC100130107       Homo 
sapiens 
RPS4X 791681 ribosomal protein S4X pseudogene 6; ribosomal protein S4X 
pseudogene 13; ribosomal protein S4, X-linked Homo sapiens 
RPS6 808508 ribosomal protein S6 pseudogene 25; ribosomal protein S6; ribosomal 
protein S6 pseudogene 1     Homo sapiens 
RPS7 773042 ribosomal protein S7; ribosomal protein S7 pseudogene 11; ribosomal 
protein S7 pseudogene 4; ribosomal protein S7 pseudogene 10 Homo 
sapiens 
RPS9 798227 ribosomal protein S9; ribosomal protein S9 pseudogene 4 Homo sapiens 
RRBP1 822623 ribosome binding protein 1 homolog 180kDa (dog) Homo sapiens 
RSL1D1 781114 ribosomal L1 domain containing 1        Homo sapiens 
RUVBL1 784165 RuvB-like 1 (E. coli)   Homo sapiens 
RUVBL2 813593 RuvB-like 2 (E. coli)   Homo sapiens 
SDCBP 799644 syndecan binding protein (syntenin)     Homo sapiens 
SEPT7 807411 septin 7        Homo sapiens 
SEPT9 797163 septin 9        Homo sapiens 
SF3B1 819770 splicing factor 3b, subunit 1, 155kDa   Homo sapiens 
SLC25A1 797071 solute carrier family 25 (mitochondrial carrier; citrate transporter), 
member 1 Homo sapiens 
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SLC25A11 802706 solute carrier family 25 (mitochondrial carrier; oxoglutarate carrier), 
member 11       Homo sapiens 
SLC25A13 810512 solute carrier family 25, member 13 (citrin)    Homo sapiens 
SLC25A3 791524 solute carrier family 25 (mitochondrial carrier; phosphate carrier), 
member 3   Homo sapiens 
SLC25A6 823629 solute carrier family 25 (mitochondrial carrier; adenine nucleotide 
translocator), member 6     Homo sapiens 
SMARCA5 789548 SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 5       Homo sapiens 
SMC1A 794773 structural maintenance of chromosomes 1A        Homo sapiens 
SMC2 798960 structural maintenance of chromosomes 2 Homo sapiens 
SMC4 781161 structural maintenance of chromosomes 4 Homo sapiens 
SMN1 773640 survival of motor neuron 1, telomeric; survival of motor neuron 2, 
centromeric  Homo sapiens 
SNRNP200 778808 similar to U5 snRNP-specific protein, 200 kDa; small nuclear 
ribonucleoprotein 200kDa (U5)      Homo sapiens 
SNRNP40 778964 small nuclear ribonucleoprotein 40kDa (U5)      Homo sapiens 
SNRNP70 777820 small nuclear ribonucleoprotein 70kDa (U1)      Homo sapiens 
SNRPD3 822931 small nuclear ribonucleoprotein D3 polypeptide 18kDa    Homo sapiens 
SPTBN1 802976 spectrin, beta, non-erythrocytic 1      Homo sapiens 
SRPR 804747 signal recognition particle receptor (docking protein)  Homo sapiens 
SRPRB 826428 signal recognition particle receptor, B subunit Homo sapiens 
SV2A 820568 synaptic vesicle glycoprotein 2A        Homo sapiens 
TBL2 798215 transducin (beta)-like 2        Homo sapiens 
TCHH 793911 trichohyalin    Homo sapiens 
TECR 800114 glycoprotein, synaptic 2        Homo sapiens 
TMEM109 822806 transmembrane protein 109       Homo sapiens 
TMEM111 775532 transmembrane protein 111       Homo sapiens 
TMEM214 775800 transmembrane protein 214       Homo sapiens 
TSR1 801920 TSR1, 20S rRNA accumulation, homolog (S. cerevisiae)    Homo 
sapiens 
TUBA1B 802675 hypothetical gene supported by AF081484; NM_006082; tubulin, alpha 
1b   Homo sapiens 
 
TUBB2B 799226 tubulin, beta 2B        Homo sapiens 
TXK 810008 TXK tyrosine kinase     Homo sapiens 
TXN 799188 thioredoxin     Homo sapiens 
UTP15 791589 UTP15, U3 small nucleolar ribonucleoprotein, homolog (S. cerevisiae)    
Homo sapiens 
VARS 785609 valyl-tRNA synthetase   Homo sapiens 
VDAC1 798048 voltage-dependent anion channel 1; similar to voltage-dependent anion 
channel 1 Homo sapiens 
VDAC2 785721 voltage-dependent anion channel 2       Homo sapiens 
VIM 814359 vimentin        Homo sapiens 
WDR3 811278 WD repeat domain 3      Homo sapiens 
XRCC5 809635 X-ray repair complementing defective repair in Chinese hamster cells 5 
(double-strand-break rejoining)  Homo sapiens 
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XRCC6 781592 X-ray repair complementing defective repair in Chinese hamster cells 6; 
similar to ATP-dependent DNA helicase II, 70 kDa subunit        Homo 
sapiens 
YWHAB 797325 tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation 
protein, beta polypeptide        Homo sapiens 
YWHAD 795546 tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation 
protein, delta polypeptide       Homo sapiens 
YWHAG 815903 tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation 
protein, gamma polypeptide       Homo sapiens 
YWHAQ 820893 tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation 
protein, theta polypeptide       Homo sapiens 
ZNF234 786428 zinc finger protein 234 Homo sapiens 
ZNF622 787986 zinc finger protein 622 Homo sapiens 
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ABRA 811529 actin-binding Rho activating protein    Homo sapiens 
ACTG2 777533 actin, gamma 2, smooth muscle, enteric  Homo sapiens 
ALB 803627 albumin Homo sapiens 
ANXA2 787053 annexin A2 pseudogene 3; annexin A2; annexin A2 pseudogene 1    
Homo sapiens 
AP2A1 797086 adaptor-related protein complex 2, alpha 1 subunit      Homo sapiens 
AP2M1 789199 adaptor-related protein complex 2, mu 1 subunit Homo sapiens 
ATAD3A 799038 ATPase family, AAA domain containing 3A Homo sapiens 
AZGP1 783250 alpha-2-glycoprotein 1, zinc-binding pseudogene 1; alpha-2-
glycoprotein 1, zinc-binding Homo sapiens 
BAZ1B 803680 bromodomain adjacent to zinc finger domain, 1B  Homo sapiens 
CALD1 799368 caldesmon 1     Homo sapiens 
CAV1 798707 caveolin 1, caveolae protein, 22kDa     Homo sapiens 
CCDC47 779089 coiled-coil domain containing 47        Homo sapiens 
CCT8 821074 similar to chaperonin containing TCP1, subunit 8 (theta); chaperonin 
containing TCP1, subunit 8 (theta) Homo sapiens 
CDSN 795934 corneodesmosin  Homo sapiens 
CFL1 794115 cofilin 1 (non-muscle)  Homo sapiens 
CLCN3 784073 chloride channel 3      Homo sapiens 
COL6A3 797879 collagen, type VI, alpha 3      Homo sapiens 
COPA 787361 coatomer protein complex, subunit alpha Homo sapiens 
CPNE5 777897 copine V        Homo sapiens 
CPT1A 783247 carnitine palmitoyltransferase 1A (liver)       Homo sapiens 
CSNK2A2 784435 casein kinase 2, alpha prime polypeptide        Homo sapiens 
DARS 778056 aspartyl-tRNA synthetase        Homo sapiens 
DCTPP1 776934 dCTP pyrophosphatase 1  Homo sapiens 
DDX1 787752 DEAD (Asp-Glu-Ala-Asp) box polypeptide 1        Homo sapiens 
DDX18 775239 DEAD (Asp-Glu-Ala-Asp) box polypeptide 18       Homo sapiens 
DDX27 806668 DEAD (Asp-Glu-Ala-Asp) box polypeptide 27       Homo sapiens 
DDX3Y 826174 DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-linked      Homo 
sapiens 
DFFA 815701 DNA fragmentation factor, 45kDa, alpha polypeptide      Homo sapiens 
DFFB 822769 DNA fragmentation factor, 40kDa, beta polypeptide (caspase-activated 
DNase)     Homo sapiens 
DMBT1 803041 deleted in malignant brain tumors 1     Homo sapiens 
DNAJB11 793612 DnaJ (Hsp40) homolog, subfamily B, member 11    Homo sapiens 
DSC1 825815 desmocollin 1   Homo sapiens 
DSG1 802187 desmoglein 1    Homo sapiens 
DSP 798372 desmoplakin     Homo sapiens 
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EEF1D 813345 eukaryotic translation elongation factor 1 delta (guanine nucleotide 
exchange protein)  Homo sapiens 
EEF1G 781923 eukaryotic translation elongation factor 1 gamma        Homo sapiens 
EIF2S1 815878 eukaryotic translation initiation factor 2, subunit 1 alpha, 35kDa      
Homo sapiens 
EIF3CL 787931 eukaryotic translation initiation factor 3, subunit C-like      Homo sapiens 
EIF3E 818572 eukaryotic translation initiation factor 3, subunit E   Homo sapiens 
EIF3F 803358 eukaryotic translation initiation factor 3, subunit F; similar to 
hCG2040283    Homo sapiens 
EIF3G 792561 eukaryotic translation initiation factor 3, subunit G   Homo sapiens 
EIF3H 788335 eukaryotic translation initiation factor 3, subunit H   Homo sapiens 
EIF3M 798064 eukaryotic translation initiation factor 3, subunit M   Homo sapiens 
EIF4A1 778310 similar to eukaryotic translation initiation factor 4A; small nucleolar 
RNA, H/ACA box 67; eukaryotic translation initiation factor 4A, 
isoform 1       Homo sapiens 
EPRS 788040 glutamyl-prolyl-tRNA synthetase Homo sapiens 
ERLIN2 810009 ER lipid raft associated 2      Homo sapiens 
EZR 816077 hypothetical protein LOC100129652; ezrin        Homo sapiens 
FBL 785244 fibrillarin     Homo sapiens 
FHAD1 774513 forkhead-associated (FHA) phosphopeptide binding domain 1       Homo 
sapiens 
FLNA 786593 filamin A, alpha (actin binding protein 280)    Homo sapiens 
FMNL2 783204 formin-like 2   Homo sapiens 
FTL 793494 similar to ferritin, light polypeptide; ferritin, light polypeptide     Homo 
sapiens 
GBP1 783739 guanylate binding protein 1, interferon-inducible, 67kDa        Homo 
sapiens 
GCN1L1 817738 GCN1 general control of amino-acid synthesis 1-like 1 (yeast)   Homo 
sapiens 
GFPT2 810770 glutamine-fructose-6-phosphate transaminase 2   Homo sapiens 
GNB2L1 793354 guanine nucleotide binding protein (G protein), beta polypeptide 2-like 1       
Homo sapiens 
GOLGA2 774455 golgi autoantigen, golgin subfamily a, 2        Homo sapiens 
GRP 782874 gastrin-releasing peptide       Homo sapiens 
HADHA 789097 hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme A 
thiolase/enoyl-Coenzyme A hydratase (trifunctional protein), alpha 
subunit   Homo sapiens 
HDLBP 810749 high density lipoprotein binding protein        Homo sapiens 
HIST1H2BH 821062 histone cluster 1, H2bh Homo sapiens 
HIST1H4C 784692 histone cluster 1, H4l; histone cluster 1, H4k; histone cluster 4, H4; 
histone cluster 1, H4h; histone cluster 1, H4j; histone cluster 1, H4i; 
histone cluster 1, H4d; histone cluster 1, H4c; histone cluster 1, H4f; 
histone cluster 1, H4e; histone cluster 1, H4b; histone cluster 1, H4a; 
histone cluster 2, H4a; histone cluster 2, H4b   Homo sapiens 
HNP1 787589 Hypertensive nephropathy        Homo sapiens 
HNRNPK 803294 heterogeneous nuclear ribonucleoprotein K; similar to heterogeneous 
nuclear ribonucleoprotein K Homo sapiens 
 228 
 
GENE CARDS  DAVID ID GENE / PROTEIN DESCRIPTION 
HNRNPM 791398 heterogeneous nuclear ribonucleoprotein M       Homo sapiens 
HNRNPU 817941 heterogeneous nuclear ribonucleoprotein U (scaffold attachment factor 
A)        Homo sapiens 
HRNR 779317 hornerin        Homo sapiens 
HSP90AA1 785761 heat shock protein 90kDa alpha (cytosolic), class A member 2; heat 
shock protein 90kDa alpha (cytosolic), class A member 1      Homo 
sapiens 
HSPA1A 775531 heat shock 70kDa protein 1A; heat shock 70kDa protein 1B        Homo 
sapiens 
IFI16 824993 interferon, gamma-inducible protein 16  Homo sapiens 
IGHA1 824622 immunoglobulin heavy constant alpha 1   Homo sapiens 
IMMT 772458 inner membrane protein, mitochondrial (mitofilin)       Homo sapiens 
KARS 785252 lysyl-tRNA synthetase   Homo sapiens 
KCTD10 790367 potassium channel tetramerisation domain containing 10  Homo sapiens 
KIAA0090 825863 KIAA0090        Homo sapiens 
KRT13 772288 keratin 13      Homo sapiens 
KRT16 799223 keratin 16; keratin type 16-like        Homo sapiens 
KRT17 813039 keratin 17; keratin 17 pseudogene 3     Homo sapiens 
KRT24 783507 keratin 24      Homo sapiens 
KRT4 783234 keratin 4       Homo sapiens 
KRT5 808801 keratin 5       Homo sapiens 
KRT78 784148 keratin 78      Homo sapiens 
KRT9 811716 keratin 9       Homo sapiens 
KTN1 811040 kinectin 1 (kinesin receptor)   Homo sapiens 
LACRT 774749 lacritin        Homo sapiens 
LARS2 787847 leucyl-tRNA synthetase 2, mitochondrial Homo sapiens 
LIMS1 786366 LIM and senescent cell antigen-like domains 1   Homo sapiens 
LOC390714 790711 similar to Ig heavy chain V-III region VH26 precursor   Homo sapiens 
LOC391405 789246 similar to Ig kappa chain V-I region Walker precursor   Homo sapiens 
LTF 817740 lactotransferrin        Homo sapiens 
LYZ 799441 lysozyme (renal amyloidosis)    Homo sapiens 
MAP1B 785288 microtubule-associated protein 1B       Homo sapiens 
MARS 818141 methionyl-tRNA synthetase       Homo sapiens 
MAST2 798950 microtubule associated serine/threonine kinase 2        Homo sapiens 
MCM3 815420 minichromosome maintenance complex component 3  Homo sapiens 
MCM5 807548 minichromosome maintenance complex component 5  Homo sapiens 
MLL 800385 myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, 
Drosophila)      Homo sapiens 
MPO 807542 myeloperoxidase Homo sapiens 
MRPS22 817976 mitochondrial ribosomal protein S22     Homo sapiens 
MRPS26 780064 mitochondrial ribosomal protein S26     Homo sapiens 
MTHFD1 784198 methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1, 
methenyltetrahydrofolate cyclohydrolase, formyltetrahydrofolate 
synthetase Homo sapiens 
MYBBP1A 805661 MYB binding protein (P160) 1a   Homo sapiens 
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NCL 792174 nucleolin       Homo sapiens 
NOL6 779120 nucleolar protein family 6 (RNA-associated)     Homo sapiens 
NOP2 821241 NOP2 nucleolar protein homolog (yeast)  Homo sapiens 
NPM1 810988 nucleophosmin 1 (nucleolar phosphoprotein B23, numatrin) pseudogene 
21; hypothetical LOC100131044; similar to nucleophosmin 1; 
nucleophosmin (nucleolar phosphoprotein B23, numatrin)   Homo 
sapiens 
PABPC1 788561 poly(A) binding protein, cytoplasmic pseudogene 5; poly(A) binding 
protein, cytoplasmic 1       Homo sapiens 
PAIP1 783127 poly(A) binding protein interacting protein 1; similar to poly(A) binding 
protein interacting protein 1 Homo sapiens 
PARP1 806958 poly (ADP-ribose) polymerase 1  Homo sapiens 
PCBP2 782567 poly(rC) binding protein 2      Homo sapiens 
PDIA5 795227 protein disulfide isomerase family A, member 5  Homo sapiens 
PGAM5 804781 phosphoglycerate mutase family member 5 Homo sapiens 
PHB2 775357 prohibitin 2    Homo sapiens 
PKLR 793730 pyruvate kinase, liver and RBC  Homo sapiens 
PRKDC 791583 similar to protein kinase, DNA-activated, catalytic polypeptide; protein 
kinase, DNA-activated, catalytic polypeptide   Homo sapiens 
PRPF19 817432 PRP19/PSO4 pre-mRNA processing factor 19 homolog (S. cerevisiae)        
Homo sapiens 
PRSS1 773661 protease, serine, 1 (trypsin 1); trypsinogen C  Homo sapiens 
PTRF 775001 polymerase I and transcript release factor      Homo sapiens 
QARS 795667 glutaminyl-tRNA synthetase      Homo sapiens 
RANBP2 823753 RAN binding protein 2   Homo sapiens 
RECQL 784519 RecQ protein-like (DNA helicase Q1-like)        Homo sapiens 
RND3 789205 Rho family GTPase 3     Homo sapiens 
RPL11 810885 ribosomal protein L11   Homo sapiens 
RPL13 822027 ribosomal protein L13 pseudogene 12; ribosomal protein L13      Homo 
sapiens 
RPL13A 791016 ribosomal protein L13a pseudogene 7; ribosomal protein L13a 
pseudogene 5; ribosomal protein L13a pseudogene 16; ribosomal protein 
L13a; ribosomal protein L13a pseudogene 18    Homo sapiens 
RPL15 779090 ribosomal protein L15 pseudogene 22; ribosomal protein L15 
pseudogene 18; ribosomal protein L15 pseudogene 17; ribosomal protein 
L15 pseudogene 3; ribosomal protein L15 pseudogene 7; ribosomal 
protein L15    Homo sapiens 
RPL17 783997 ribosomal protein L17 pseudogene 22; ribosomal protein L17 
pseudogene 36; ribosomal protein L17 pseudogene 20; similar to 
ribosomal protein L17; ribosomal protein L17 pseudogene 33; ribosomal 
protein L17 pseudogene 34; ribosomal protein L17 pseudogene 9; 
ribosomal protein L17; ribosomal protein L17 pseudogene 18; ribosomal 
protein L17 pseudogene 7; ribosomal protein L17 pseudogene 39      
Homo sapiens 
RPL18A 778688 ribosomal protein L18a pseudogene 6; ribosomal protein L18a     Homo 
sapiens 
RPL19 786531 ribosomal protein L19; ribosomal protein L19 pseudogene 12      Homo 
sapiens 
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RPL21 793235 ribosomal protein L21 pseudogene 134; ribosomal protein L21 
pseudogene 80; ribosomal protein L21 pseudogene 20; ribosomal protein 
L21 pseudogene 46; ribosomal protein L21 pseudogene 45; ribosomal 
protein L21 pseudogene 131; ribosomal protein L21 pseudogene 16; 
ribosomal protein L21 pseudogene 53; ribosomal protein L21 
pseudogene 120; ribosomal protein L21 pseudogene 37; ribosomal 
protein L21 pseudogene 93; ribosomal protein L21 pseudogene 39; 
ribosomal protein L21 pseudogene 29; ribosomal protein L21 
pseudogene 28; ribosomal protein L21 pseudogene 14; ribosomal protein 
L21 pseudogene 98; ribosomal protein L21 pseudogene 105; ribosomal 
protein L21 pseudogene 87; ribosomal protein L21 pseudogene 128; 
ribosomal protein L21 pseudogene 69; ribosomal protein L21 
pseudogene 97; ribosomal protein L21; ribosomal protein L21 
pseudogene 119; ribosomal protein L21 pseudogene 125 Homo sapiens 
RPL23 780689 ribosomal protein L23 pseudogene 6; ribosomal protein L23       Homo 
sapiens 
RPL24 800698 ribosomal protein L24; ribosomal protein L24 pseudogene 6       Homo 
sapiens 
RPL27 784332 ribosomal protein L27   Homo sapiens 
RPL3 802424 ribosomal protein L3; similar to 60S ribosomal protein L3 (L4)  Homo 
sapiens 
RPL34 803929 ribosomal protein L34   Homo sapiens 
RPL5 804383 ribosomal protein L5 pseudogene 34; ribosomal protein L5 pseudogene 
1; ribosomal protein L5     Homo sapiens 
RPL6 795791 ribosomal protein L6 pseudogene 27; ribosomal protein L6 pseudogene 
19; ribosomal protein L6; ribosomal protein L6 pseudogene 10        
Homo sapiens 
RPL7A 823404 ribosomal protein L7a pseudogene 70; ribosomal protein L7a; ribosomal 
protein L7a pseudogene 30; ribosomal protein L7a pseudogene 66; 
ribosomal protein L7a pseudogene 27; ribosomal protein L7a 
pseudogene 11; ribosomal protein L7a pseudogene 62     Homo sapiens 
RPL8 801125 ribosomal protein L8; ribosomal protein L8 pseudogene 2 Homo sapiens 
RPL9 778568 ribosomal protein L9; ribosomal protein L9 pseudogene 25        Homo 
sapiens 
RPN1 773182 ribophorin I    Homo sapiens 
RPN2 791634 ribophorin II   Homo sapiens 
RPS12 800729 ribosomal protein S12; ribosomal protein S12 pseudogene 4; ribosomal 
protein S12 pseudogene 11; ribosomal protein S12 pseudogene 9      
Homo sapiens 
RPS14 817032 ribosomal protein S14   Homo sapiens 
RPS2 776216 ribosomal protein S2 pseudogene 8; ribosomal protein S2 pseudogene 
11; ribosomal protein S2 pseudogene 5; ribosomal protein S2 
pseudogene 12; ribosomal protein S2 pseudogene 51; ribosomal protein 
S2 pseudogene 17; ribosomal protein S2 pseudogene 55; ribosomal 
protein S2 pseudogene 20; ribosomal protein S2      Homo sapiens 
RPS23 801872 ribosomal protein S23   Homo sapiens 
RPS24 816407 ribosomal protein S24   Homo sapiens 
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RPS26 772335 ribosomal protein S26 pseudogene 38; ribosomal protein S26 
pseudogene 39; ribosomal protein S26 pseudogene 35; ribosomal protein 
S26 pseudogene 31; ribosomal protein S26 pseudogene 20; ribosomal 
protein S26 pseudogene 54; ribosomal protein S26 pseudogene 2; 
ribosomal protein S26 pseudogene 53; ribosomal protein S26 
pseudogene 25; ribosomal protein S26 pseudogene 50; ribosomal protein 
S26 pseudogene 6; ribosomal protein S26 pseudogene 8; ribosomal 
protein S26  Homo sapiens 
RPS27 789083 ribosomal protein S27 pseudogene 29; ribosomal protein S27 
pseudogene 9; ribosomal protein S27 pseudogene 23; ribosomal protein 
S27 pseudogene 13; ribosomal protein S27; ribosomal protein S27 
pseudogene 21; ribosomal protein S27 pseudogene 7; ribosomal protein 
S27 pseudogene 6; ribosomal protein S27 pseudogene 19      Homo 
sapiens 
RPS3 816191 ribosomal protein S3 pseudogene 3; ribosomal protein S3 Homo sapiens 
RPS3A 789968 ribosomal protein S3A pseudogene 5; ribosomal protein S3a pseudogene 
47; ribosomal protein S3a pseudogene 49; ribosomal protein S3A; 
hypothetical LOC100131699; hypothetical LOC100130107       Homo 
sapiens 
RPS4X 791681 ribosomal protein S4X pseudogene 6; ribosomal protein S4X 
pseudogene 13; ribosomal protein S4, X-linked Homo sapiens 
RPS6 808508 ribosomal protein S6 pseudogene 25; ribosomal protein S6; ribosomal 
protein S6 pseudogene 1     Homo sapiens 
RPS7 773042 ribosomal protein S7; ribosomal protein S7 pseudogene 11; ribosomal 
protein S7 pseudogene 4; ribosomal protein S7 pseudogene 10 Homo 
sapiens 
RPS8 821732 ribosomal protein S8; ribosomal protein S8 pseudogene 8; ribosomal 
protein S8 pseudogene 10     Homo sapiens 
RPS9 798227 ribosomal protein S9; ribosomal protein S9 pseudogene 4 Homo sapiens 
RRBP1 822623 ribosome binding protein 1 homolog 180kDa (dog) Homo sapiens 
RSL1D1 781114 ribosomal L1 domain containing 1        Homo sapiens 
S100A8 783621 S100 calcium binding protein A8 Homo sapiens 
SART3 795024 squamous cell carcinoma antigen recognized by T cells 3 Homo sapiens 
SEC62 793015 SEC62 homolog (S. cerevisiae)   Homo sapiens 
SF3B1 819770 splicing factor 3b, subunit 1, 155kDa   Homo sapiens 
SF3B3 792435 splicing factor 3b, subunit 3, 130kDa   Homo sapiens 
SFRS2B 784941 splicing factor, arginine/serine-rich 2B        Homo sapiens 
SGPL1 789498 sphingosine-1-phosphate lyase 1 Homo sapiens 
SLC25A1 797071 solute carrier family 25 (mitochondrial carrier; citrate transporter), 
member 1 Homo sapiens 
SLC25A10 796046 solute carrier family 25 (mitochondrial carrier; dicarboxylate 
transporter), member 10  Homo sapiens 
SLC25A3 791524 solute carrier family 25 (mitochondrial carrier; phosphate carrier), 
member 3   Homo sapiens 
SLC25A6 823629 solute carrier family 25 (mitochondrial carrier; adenine nucleotide 
translocator), member 6     Homo sapiens 
SMC1A 794773 structural maintenance of chromosomes 1A        Homo sapiens 
SMC2 798960 structural maintenance of chromosomes 2 Homo sapiens 
SMC3 793277 structural maintenance of chromosomes 3 Homo sapiens 
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GENE CARDS  DAVID ID GENE / PROTEIN DESCRIPTION 
SMC4 781161 structural maintenance of chromosomes 4 Homo sapiens 
SND1 798687 staphylococcal nuclease and tudor domain containing 1   Homo sapiens 
SNRNP35 820447 ATP-binding cassette, sub-family B (MDR/TAP), member 5; small 
nuclear ribonucleoprotein 35kDa (U11/U12) Homo sapiens 
SRP54 787467 similar to signal recognition particle 54kDa; signal recognition particle 
54kDa Homo sapiens 
SRP72 816308 signal recognition particle 72kDa       Homo sapiens 
STAU1 822124 staufen, RNA binding protein, homolog 1 (Drosophila)    Homo sapiens 
STEAP3 799131 STEAP family member 3   Homo sapiens 
SYNCRIP 811579 synaptotagmin binding, cytoplasmic RNA interacting protein      Homo 
sapiens 
TBL2 798215 transducin (beta)-like 2        Homo sapiens 
TMEM109 822806 transmembrane protein 109       Homo sapiens 
TOP2B 783488 topoisomerase (DNA) II beta 180kDa      Homo sapiens 
TTN 795630 titin   Homo sapiens 
TUBA1A 811901 tubulin, alpha 1a       Homo sapiens 
TUBB2C 776899 tubulin, beta 2C        Homo sapiens 
TXLNA 801671 taxilin alpha   Homo sapiens 
UBE2B 805624 ubiquitin-conjugating enzyme E2B (RAD6 homolog) Homo sapiens 
VARS 785609 valyl-tRNA synthetase   Homo sapiens 
VDAC2 785721 voltage-dependent anion channel 2       Homo sapiens 
VIM 814359 vimentin        Homo sapiens 
YIPF5 778492 Yip1 domain family, member 5    Homo sapiens 
YWHAG 815903 tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation 
protein, gamma polypeptide       Homo sapiens 
YWHAH 817322 tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation 
protein, eta polypeptide Homo sapiens 
YWHAQ 820893 tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation 
protein, theta polypeptide       Homo sapiens 
 
Note: Total of 195 genes recognised by DAVID 
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